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Chapter 1
Introduction
Clinical relevance of ischemia/reperfusion induced myocardial injury
Coronary heart disease is a wide-spread disorder in the western industrialized
world. Although a downward trend is observed in mortality rates due to coronary
heart disease, it remains the most important cause of death (O Rourke er a/.
1993, Uemura er a/., 1988, Widdershoven er a/., 1997). The most common
clinical manifestations of the disorder include myocardial ischemia, unstable
angina pectoris, cardiac arrhythmias and sudden cardiac arrest. Myocardial
ischemia is often caused by an atherosclerotic stenosis of coronary arteries,
while sudden cardiac syndromes such as acute myocardial infarction generally
results from a thrombotic occlusion of the coronary vessel. Prolonging
myocardial ischemia will eventually result in myocardial cell death by necrotic
and apoptotic processes or a combination thereof (Schaper er a/., 1988,
MacLellan er a/., 1997). Currently, clinical treatment mainly consists of
techniques to re-open the thrombotic occlusion of a coronary vessel
(reperfusion) by intracoronary thrombolysis and percutaneous transluminal
coronary angioplasty. Although reperfusion is a prerequisite to prevent
inevitable death of the flow-deprived cardiac muscle cells, indications exist that
reperfusion itself may induce additional myocardial cell damage (Piper er a/.,
1990, Fox er a/., 1992). In spite of intensive research over the past 3 decades,
knowledge of the mechanisms of ischemia and reperfusion-induced cardiac cell
injury is still limited and an expansion of our understanding of the causal events
behind this particular disorder may have substantial therapeutic potentials.
Ischemia and reperfusion-induced cell damage
Impaired blood supply to cardiac tissue leads to a range of functional,
biochemical and ultrastructural changes in cardiomyocytes (Jennings er a/.,
1978, Schaper er a/., 1979, Reimer er a/., 1983, Post er a/., 1985, Van der Vusse
er a/., 1992). Interruption of blood flow will immediately result in a lack of
oxygen supply to the cardiac muscle cell. As a result mitochondrial respiration
ceases and ATP generation by oxidative phosphorylation is hampered.
Glycolysis, the conversion of glucose to lactate, will subsequently become the
major process by which the cardiac cell can generate ATP. A negative side-
effect of acceleration of anaerobic glycolysis is acidification of the oxygen
deprived cells. Since ATP generation through glycolysis is insufficient to cover
myocardial energy demand (Jennings er a/., 1978), the tissue content of
phosphocreatine and ATP will decline, despite the fact that contractile activity
is slowed or even stopped (Ganote er a/., 1975).
Cellular energy depletion will manifest itself in impaired cellular ion
homeostasis, which leads to a rise in intracellular Na*, through activation of the
Na*/H* exchanger. To compensate for the intracellular increase in Na*, the
Na7Ca** exchanger is then activated, resulting in intracellular Ca** accumulation
(Peng er a/,. 1980, Li er a/., 1988, Allshire er a/., 1989). The increase in
intracellular Ca^* most likely results in activation of Ca^-dependent proteases
that degrade the cytoskeleton and cytoskeletal membrane connections
(Schwartz er a/., 1984). Furthermore, activation of Ca~*-dependent
phospholipases might result in accumulation of membrane-destabilizing factors
like lysophospholipids and fatty acids. Collectively, these processes will weaken
the (intracellular) membranes of the sarcolemma, sarcoplasmatic reticulum and
mitochondria (Van der Vusse er a/., 1982, Chien er a/., 1984, Van Bilsen er a/.,
1989). Loss of lysosomal integrity during ischemia will result in the release of
lysosomal proteases and phospholipases, which will also contribute to the
degradation of cellular structures (Decker er a/., 1990).
Prolongation of the ischemic duration eventually leads to cardiac cell
death by a combination of the above mentioned processes. If restoration of
blood flow takes place soon after oxygen deprivation, complete structural and
functional recovery of the cardiac muscle cell is possible. If the duration of the
ischemic episode is extended beyond a certain point, ischemic injury becomes
irreversible and will lead to cell death (Schaper er a/., 1988, MacLellan er a/.,
1997). Although restoration of flow to the weakened myocardium is necessary
to alleviate the detrimental impact of ischemia, reperfusion itself may induce
additional microvascular and cellular damage (the so-called reperfusion-injury;
Piper er a/., 1990, Fox el a/., 1992). Whether reperfusion per se inflicts cellular
damage or that the reperfusion phenomenon is merely a manifestation of
ongoing destruction of the cardiac muscle cell already started during the
preceding ischemic interval, is still matter of continuous debate (Miura er a/.,
1990, Fox era/., 1992).
Restoration of blood flow to the ischemic region of the heart results in
enhanced supply of, among others, water, oxygen calcium ions and oxidizable
substrates to the previously weakened cardiomyocytes. Due to the accumulation
of low-molecular weight substanses, such as lactate, degradation products of
adenine nucleotides and inorganic phosphate, reperfused cells readily take up
water from the microvascular compartment during the initial reperfusion phase,
which imposes an osmotic load on the affected cardiac muscle cell (Steenbergen
er a/., 1985). Moreover, the continuing increase in intracellular Ca^* may result
in substantial accumulation of these ions in cardiac muscle cells (Peng er a/.,
1980, Schwartz er a/., 1984, Allshire er a/., 1989). The increase in supply of Oj
and oxidizable substrates will result in enhanced production of oxygen free
radicals by mitochondria, which may be partially damaged during the preceding
period of flow deprivation (Ceconi er a/., 1982). Moreover, the decline in
activity of a set of enzymes involved in oxygen free radical scavaging may add
to the damaging effect of oxygen free radicals (Ferrari er a/., 1988).
The nature of the relationship between increased osmotic load, elevated
intracellular Ca~* levels and enhanced production of oxygen free radicals on the
one hand, and loss of cellular viability on the other, is most likely complex. For
example, the weakening of membranes by physical forces and the hydrolytic
activity of Ca^-dependent proteases and Ca^-dependent phospholipases
(membrane phospholipids damaged by oxygen free radicals are more vulnerable
for hydrolysis; Weglicki era/., 1973, Dan era/., 1996) may contribute to the
loss of cardiac cell integrity during the initial reperfusion phase.
Role of phospholipase Aj in phospholipid degradation during ischemia
and reperfusion
A variety of studies suggest that membrane phospholipid degradation is a critical
event in the development of irreversible myocyte injury in flow-deprived
cardiac tissue (Van der Vusse er a/., 1982, Chien er a/., 1984, Van Bilsen er a/.,
1989, Van der Vusse er a/., 1992). Net degradation of phospholipids under
/
pathophysiological conditions is thought to destabilize cardiac membranes and
to result in loss of function of the semi-permeable barrier as evidenced by the
release of macromolecules into the extracellular environment (Van Bilsen e/ a/.,
1989). The mechanism behind ischemia-induced phospholipid degradation is
unclear, but may be due to the enhanced activity of endogenous phospholipase
AT in the heart (Van der Vusse ef a/., 1989, Van Bilsen ef a/., 1995), alone or in
combination with impaired resynthesis of phospholipid molecules (Van Bilsen ef
a/., 1989). The observation that arachidonic acid, which under normoxic
conditions is predominantly esterified in the cardiac phospholipid pool (Van der
Vusse e/ o/., 1992), readily accumulates during ischemia suggest degradation of
membrane phospholipids (Van der Vusse e/ a/., 1982, Chien ef a/., 1984, Van
Bilsen ef a/., 1989). Interestingly, accumulation of arachidonic acid proceeds
even faster following restoration of flow to the previously ischemic myocardium
(Van Bilsen e/a/., 1989).
Experimental data suggest that especially cardiac type IIA phospholipase
A2, a low molecular mass member of the phospholipase A2 family, is a likely
candidate to be involved in ischemia-induced degradation of membrane
phospholipids and subsequent cellular damage (Van der Vusse e/ a/., 1989, Van
Bilsen e/ a/., 1995). The observation that in addition to arachidonic acid a whole
set of long-chain fatty acids accumulate during prolonged myocardial ischemia
and reperfusion of the isolated rat heart strongly suggests a predominant role of
the aspecific type IIA phospholipase A2 (Van Bilsen er a/., 1995). The notion
that reperfusion is accompanied by a calcium overload of the ischemic cardiac
muscle cell supports a predominant role of the calcium-dependent type IIA
phospholipase A 2 (Van der Vusse ef a/., 1992, Van Bilsen e/ a/., 1995). Finally,
in a number of ischemia/reperfusion and anoxia/reoxygenation studies membrane
phospholipid degradation and release of cytoplasmic proteins into the
extracellular milieu could be efficiently blocked by pharmacological inhibition
phospholipase A2 and by antibodies raised against type IIA related
phospholipases A, (Van Bilsen e/ a/., 1990, Prasad e/ a/., 1991, Kikuchi-
Yanoshita e/a/., 1993).
Aims of the present study
The present study specifically focusses on the hypothesis that hydrolytic
activity of type IIA secretory phospholipase A2 is involved in
ischemia/reperfusion-induced phospholipid degradation. Testing of this
hypothesis required an integration of molecular biological, biochemical and
physiological techniques. Accordingly, the first aim was to establish the
presence, abundance and cellular localization of type IIA secretory
phospholipase A2 in cardiac muscle by means of molecular biological and
immunochemical techniques. The second aim was to develop and characterize an
ex vivo, antegradely perfused mouse heart model, which allows detailed analysis
of the functional and metabolic changes, with special emphasis on changes in
phospholipid metabolism, during cardiac ischemia and reperfusion. Such an ex
vivo model system would be helpful for the evaluation of cardiac function in
genetically modified mice. The third and final aim of this thesis was to
determine the role of type IIA secretory phospholipase A2 in
ischemia/reperfusion induced cellular damage by means of mutant inbred mouse
strains that lack functional type IIA secretory phospholipase A2 and by creating
transgenic mice that overexpress this phospholipase isoform in a cardiac-
specific manner.
General outline of the thesis ; i» t
The theoretical aspects of cardiac phospholipid homeostasis under
(patho)physiological conditions are described in CAapter 2. In addition, an
overview is given of the currently described mammalian phospholipase A2 types
that may play a role in myocardial ischemia and reperfusion-induced cellular
injury. CAapter 5 describes the cloning of the full length cDNA and molecular
characterization of rat heart type IIA secretory phospholipase A2. In CAapter 4
the expression and purification of recombinant rat heart type IIA phospholipase
A2 is described. In addition, the ability of a polyclonal antisera raised in the
rabbit against this purified recombinant enzyme was compared with several anti-
type IIA secretory phospholipase A2 antibodies to detect type IIA secretory
phospholipase A2 at the protein level. In CAapte/- 5, the development and
characterization of the isolated, left ventricular ejecting mouse heart model is
described. The stability of the mouse heart in this experimental model under
normoxic conditions was characterized in terms of functional and metabolic
performance. In CAap/er 6 the ischemia tolerance of the antegradely perfused
wildtype mouse heart was determined by investigating functional and metabolic
recovery following various periods of ischemia and subsequent reperfusion. In
CAapter 7 the ischemia tolerance of hearts derived from heterozygous IGF-1
knockout mice is compared to their wildtype littermates. In addition, the
functional recovery and extent of irreversible cell injury following global
ischemia and reperfusion is related to the tissue content of arachidonic acid in
the reperfused ventricles. The study on heterozygous IGF-1 knockout mice was
included to test the sensitivity of the isolated working mouse heart preparation
to detect small differences in ischemia/reperfusion-induced cardiac injury. In
CAap/er 5 this isolated murine heart model is applied to determine the role of
type IIA secretory phospholipase A2 in ischemia/reperfusion damage in more
detail by making use of genetically closely related inbred mouse strains, one of
which is wildtype and the other contains two mutated type IIA secretory
phospholipase A2 alleles, resulting in a non-functional protein product. In
CAap/er 9, prelimenary results are given about generation of transgenic mice
with a cardiac-specific overexpression of type IIA secretory phospholipase A2.
In the general discussion (CAapter 70) the data obtained in this thesis are
discussed in a broader spectrum and future directions for research are delineated.
The thesis is preceded by an
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Chapter 2
Phospholipase A2-mediated hydrolysis
of cardiac phospholipids:
a review of literature.
LJ De Windt, RS Reneman, GJ Van der Vusse, M Van Bilsen. Phospholipase
A2-mediated hydrolysis of cardiac phospholipids: the use of molecular and
transgenic techniques. A/o/ CW/ Ä/oc/ie/w 1998; 180:65-73.
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Abstract
Under pathophysiological conditions, like myocardial ischemia
and reperfusion, cardiac phospholipid homeostasis is severely
disturbed, resulting in a net degradation of phospholipids and the
accumulation of degradation products, such as
lysophospholipids and (non-esterified) fatty acids. The
derangements in phospholipid metabolism are thought to be
involved in the sequence of events leading to irreversible
myocardial injury. The net degradation of phospholipids as
observed during myocardial ischemia may result from increased
hydrolysis and/or reduced resynthesis, while during reperfusion
hydrolysis is likely to prevail in this net degradation. Several
studies indicate that the activation of phospholipases A2 plays an
important role in the hydrolysis of phospholipids. In this review
current knowledge regarding the potential role of the different
types of phospholipases A2 in ischemia and reperfusion-induced
damage is being evaluated. Furthermore, it is indicated how
recent advances in molecular biological techniques could be
helpful in determining whether disturbances in phospholipid
metabolism indeed play a crucial role in the transition from
reversible to irreversible myocardial ischemia and reperfusion-
induced injury, the knowledge of which could be of great
therapeutic relevance.
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Introduction
All living cells are surrounded by membranes, consisting of phospholipids,
cholesterol and proteins. The cell membrane (plasmalemma) serves as a selective
barrier to create and maintain an internal environment to allow the cell to fulfil its
specific functions. In addition to its function as physical barrier, the plasmalemma is
also an important source of phospholipid-derived bioactive lipids, like
lysophospholipids and fatty acids, such as arachidonic acid (Van der Vusse er a/.,
1992). Arachidonic acid can subsequently serve as a substrate for the production of
auto/paracrine factors, including prostaglandins and thromboxanes (Karmazyn ef
a/., 1989, Engels e/ a/., 1990).
The integrity of the membrane is a prerequisite for proper functioning of the
cell. Therefore, the major constituents of the plasmalemma, the phospholipids, are
subjected to a continuous turnover process to enable the cell to synthesize any
required phospholipid and to regulate the fatty acyl composition of the
phospholipids (Van der Vusse er a/., 1992). In this way, the cellular membrane
adjusts its physico-chemical properties in response to changes in the extracellular
environment. The turnover of phospholipids requires the liberation of fatty acids
from phospholipids (deacylation), as well as the reincorporation of fatty acyl
moieties into the phospholipid pool (reacylation). These phospholipid turnover
cycles are also operative in cardiomyocytes (Van der Vusse er a/., 1992).
During myocardial ischemia/reperfusion a net phospholipid degradation has
been observed, either caused by increased activity of phospholipid hydrolyzing
enzymes, such as phospholipase A2, or caused by an impairment of the resynthesis
of phospholipids (Van Bilsen er a/., 1989, Van der Vusse er a/., 1990, Van der
Vusse er a/., 1992, Van Bilsen er a/., 1995). Therefore, detailed knowledge of
cardiac phospholipid homeostasis and derangements therein under
pathophysiological conditions can be of great therapeutic value, as ischemic heart
diseases as a result of the occlusion of a coronary artery are still by far the most
common cause of death in western industrialized countries.
In this review we will focus on cardiac phospholipase A2-mediated
phospholipid hydrolysis and its possible role in the derangements in phospholipid
homeostasis as a crucial event in the transition from reversible to irreversible cell
damage as a result of myocardial ischemia and reperfusion. Although not the
subject of this review, it is important to note that derangements in the resynthesis of
phospholipids may also be involved, especially under energy-deprived conditions
like ischemia. In addition, the usefulness of sophisticated molecular biological
techniques in combination with an appropriate murine heart model in the
assessment of the role of phospholipases A2 during myocardial ischemia and
reperfusion will be discussed.
Myocardial membranes consist of a variety of phospholipid species, differing in
chemical composition of the hydrophylic alcoholic headgroup, or of the
hydrophobic tail that is composed of two long-chain fatty acyl residues connected to
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the glycerol backbone. The phospholipid subtypes are classified by their
hydrophylic alcohol headgroup. The hydrophylic alcohol is attached to the third (SH-
3) carbon atom of the glycerol moiety via an inorganic phosphate (Figure 1). The
hydrophobic part of phospholipids is formed by the fatty acyl chains bound to the
first (5/1-/) and second (J/J-2) carbon atom of the glycerol backbone (Figure 1). The
.?«-/ and 5/7-2 fatty acyl residues are generally a saturated and (poly-)unsatured fatty
acid, respectively. The number of carbon atoms of the long-chain fatty acyl residues
commonly ranges from 14 to 24. The number of unsaturated bonds of the SM-2 fatty
acyl chain may vary between zero and six (Van der Vusse e/ a/., 1992).
CH2—o-T- p—O—CH<—CHj—NH,
Figure 1. Chemical structure of 1-palmitoyl, 2-arachidonoyl
phosphatidylethanolamine and the cleavage site of different phospholipases. The
arrows point to the covalent bond hydrolyzed by phospholipase Aj (PLA|),
phospholipase A2 (PLA2), phospholipase C (PLC) and phospholipase D (PLD).
The fatty acyl residues at the .vn-/ andsw-2 position are generally O-acyl-residues,
i.e., they are connected to the glycerol backbone via an ester linkage. In membrane
phospholipids, however, a certain proportion of the fatty acyl residues at the .vn-/
position is connected to the 5/1-/ carbon atom of glycerol via a vinyl ether linkage
(O-[l-alkenyl]-residues). These phospholipids are commonly referred to as
plasmalogens. The plasmalogen content in membranes is tissue-dependent and
varies between cardiac membranes of different animal species, ranging from ~ 5%
in the rat heart to ~ 40% in the rabbit heart (Hatch e/ a/., 1989).
Because of their shape and amphipathic nature, phospholipids readily form
lipid bilayers in an aqueous environment. In case of the sarcolemma, the
hydrophilic headgroups of the inner leaflet point towards the intracellular space and
those of the outer leaflet towards the extracellular space. The fatty acids tails are
burned in the inner part of the bilayer.
The various phospholipid classes in the sarcolemmal bilayer are
asymmetrically distributed. The outer leaflet is relatively enriched with
phosphatidylcholine and sphingomyelin, while the negatively charged
12
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phosphatidylserine, phosphatidylethanolamine and phosphatidylinositol are located
almost exclusively in the cytoplasmic leaflet. This phenomenon results in a more
negatively charged inner leaflet as compared to the outer sarcolemmal leaflet. To
compensate for differences in fluidity between the leaflets, the
cholesterol/phospholipid ratio is higher in the outer leaflet of the sarcolemma (Post
e/a/., 1988).
Under normoxic conditions the amount of intracellular (non-esterified) fatty acids is
very small, indicating that the pool size of these fatty acids is well controlled (Van
der Vusse e/ a/., 1992). Apparently a strict balance exists between the activity of
enzymes that control the liberation of fatty acyl moieties from phospholipid
molecules and that of enzymes that control the rate of incorporation of fatty acyl
residues into the phospholipid pool.
The cardiomyocyte is equipped with a set of enzymes required for the
resynthesizing part of phospholipid turnover as well as for the hydrolytic part of the
phospholipid turnover cycle. De «ovo synthesis of phospholipids takes place in the
sarcoplasmic reticulum. Newly synthesized phospholipids are transported to the
sarcolemma through the cytosol (Van der Vusse e/ a/., 1992). For cfe MOVO synthesis
of phoshatidylcholine the condensation of 1,2-diacylglycerol and CDP-choline is
achieved by the action of choline-phosphotransferase. When the substrate is a
lysophoshatidylcholine, the incorporation of the second fatty acyl moiety is
dependent on the activity of the enzymes acyl-CoA synthetase and
lysophosphatidylcholine acyltransferase (Figure 2).
Among the enzymes involved in the hydrolytic part of the phospholipid
turnover process are phospholipase A, (PLA,) and phospholipase A2 (PLA2), which
hydrolyze the ester bond between the fatty acyl unit at the 5/1-/ and .vn-2 carbon
atom of glycerol, respectively. In case of a plasmalogen, a plasmalogen-specific
type PLA2 is present in the cardiomyocyte to remove fatty acyl chains from the ,v«-2
position (Hazen e/ a/., 1991). The vinyl ether bond at the .vw-/ position is
hydrolyzed by a specific plasmalogenase (Arthur e/ a/., 1985). Phospholipase C
(PLC) breaks the covalent bond between the polar headgroup and the carbon atom
at the s/7-5 position of glycerol and phospholipase D (PLD) the bond between
phosphate and the alcohol unit that together form the polar headgroup (Figure 1).
The final products of phospholipase A| and A2 activity are lysophospholipids and
fatty acids. In turn, the remaining fatty acyl chain of lysophospholipids can be
removed by lysophospholipase. It has been hypothesized that in cardiac cells the
balance between the activities of lysophospholipid acyltransferase and
phospholipase A2 determines the actual level of unesterified arachidonic acid
(Irvine, 1982, Van der Vusse er a/., 1992).
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Figure 2: Synthesis and degradation of 1-palmitoyl, 2-arachidonoyl
phosphatidylcholine. Pa»/iwa>' / (upper panel) describes the deacylation-reacylation
pathway for this phospholipid. PafWav // depicts the turnover of the hydrophylic
headgroup of phsphatidylcholine. Numbers refer to the enzymes involved in the
pathways: (1) phospholipase Aj, (2) fatty acyl-CoA synthetase, (3)
lysophosphatidylcholine acyltransferase, (4) lysophospholipase, (5) phospholipase C,
(6) CTP:phosphocholine cytidyltransferase, (7) phosphocholine transferase, (8)
diacylglycerol + monoacylglycerol lipases. [Reprinted with permission from Van der
Studies with radiolabeled substrates show that the cardiomyocyte is able to
change the polar headgroup as well as the fatty acyl units of the membrane
phospholipids (Van der Vusse er a/., 1992). Detailed knowledge about phospholipid
turnover rate in cardiomyocytes, however, is still lacking, /M v/7ro measurements
revealed a maximal myocardial total phospholipase activity of about 3 (imol
phosholipid . h ' . g"' tissue in rat heart (Termin e/ a/., 1987). Based on the presence
of approximately 30 (imol total phospholipid . g"' tissue and assuming that
degradation of phospholipids keeps pace with resynthesis, complete turnover of all
sarcolemmal phospholipids could be accomplished in about 10 hours. However, it
cannot be excluded that phospholipid species in different subcellular compartments
are subjected to different turnover rates (Miyazaki e/ a/., 1987, Miyazaki er a/.,
1990).
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The heart contains at least three different types of phospholipases A2.
Recently, a member of type IIA secretory PLA2 (type IIA sPLAi) was cloned in our
laboratory (De Windt er a/., 1996). All mammalian type II PLA2S are small
molecular weight acylhydrolases of about 14 kD with a slight preference for
phosphatidylserine and phosphatidylethanolamine over phosphatidylcholine, but
they have no specificity for the type of fatty acyl moiety at the s«-2 position. Type
IIA SPLA2S have been found to be associated with membranes like the
plasmalemma of guinea pig spermatozoa (Garcia er a/., 1991), the outer contact
sites and the inner membrane of mitochondria (Levrat ef a/., 1992), or the matrix of
a-granules in platelets (Aarsman er a/., 1989). Furthermore, type IIA SPLA2 can be
secreted from rat platelets upon stimulation, due to the presence of a putative
eukaryotic signal sequence for secretion at the N-teiminal end of the enzyme
(Horigome er a/., 1987). Whether in cardiomyocytes type IIA SPLA2 is present in a
membrane-associated form or can be secreted remains to be elucidated.
Circumstantial evidence for a membrane-associated localization of type IIA SPLA2
in cardiomyocytes was provided by a cytochemical study by Kriegsmann and
coworkers, in which they showed that a monoclonal antibody against bee venom
type II SPLA2 bound to antigens at the level of the sarcolemma (Kriegsman er a/.,
1993).
The knowledge of mechanisms involved in the regulation of type IIA SPLA2
activity is gradually increasing; mechanisms of short-term regulation of the enzyme
activity and those involved in long-term regulation of enzyme content can be
distinguished (Van Bilsen er a/., 1995). Short-term regulation is based on the
requirement of (sub)millimolar calcium concentrations for maximal activity of the
enzyme. This raises questions about the probability of its intracellular activity under
normoxic conditions, as in the cardiomyocyte the overall intracellular calcium
concentration oscillates from 0.15 UM during diastole to 2.0 ^M during systole.
However, Langer and colleagues have demonstrated that in specific regions close to
the sarcolemma calcium concentrations up to 600 (J.M may be reached during
systole, postulating the existence of multiple compartments with different calcium
concentrations within the cytosol (Langer, 1994). Accordingly, the calcium
concentration in the subsarcolemmal space might be sufficient to allow intracellular
activity of type IIA SPLA2 under physiological conditions.
As far as the short-term regulation of extracellular activity is concerned
evidence has been provided that type IIA SPLA2 activity can be modulated by the
association of the enzyme via its putative C-terminal heparin-binding domain to the
proteoglycans of the extracellular matrix. The association of type IIA SPLA2 with
the sulfated polysaccharides results in changes of enzyme activity on membrane
phospholipids (Sartipy er a/., 1996). This mechanism of regulation could be of
importance for the heart, if cardiac type IIA SPLA2 is associated to the extracellular
part of the sarcolemma, where calcium concentrations are no longer a limiting
factor for the activity of the enzyme. Finally, it appears that type IIA SPLA2 activity
can be modulated by accessory proteins, like phospholipase A2-activating protein
(PLAP) which has a stimulatory effect, or uteroglobins and annexins which are
putative inhibitors of type IIA SPLA2 activity. The exact mechanism of action and
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the physiological significance of these accessory proteins on type IIA SPLA2
activity are still a matter of debate (Van Bilsen er a/., 1995, Jans er a/., 1995).
Long-term regulation of type IIA SPLA2 activity is accomplished by
adjusting the level of gene transcription. In several cell types type IIA SPLA2
expression is induced by inflammatory cytokines like interleukin-1 (IL-1),
interleukin-6 (IL-6), and tumor necrosis factor a (TNFa), or by cAMP-elevating
substances like forskolin (Schalkwijk er a/., 1992, Pfeilschifter er a/., 1993,
Konieczkowski er a/., 1993). These observations were substantiated by the
demonstration of the presence of cAMP and cytokine responsive elements in the 5 -
flanking region of the type IIA SPLA2 gene (Ohara er a/., 1990). In contrast, the
expression of this enzyme is downregulated by a variety of substances like
glucocorticoids, transforming growth factor ß (TGFß), aspirin, and tetranactin
(Schalkwijk er a/., 1992, Van den Bosch er a/., 1992, Vervooldeldonk er a/., 1996,
Walker er a/., 1996). Recently it was shown that activation of the nuclear
transcription factor NF-KB is an essential component of the cytokine signalling
pathway responsible for type IIA SPLA2 gene regulation (Vervoordeldonk er a/.,
1996). That this mechanism of regulation is also operative in cardiac cells is
supported by the observation that type IIA SPLA2 mRNA levels increase in cultured
rat neonatal cardiomyocytes upon stimulation with TNFa (De Windt er a/., 1996).
The recent discovery of a high-molecular mass phospholipase A2 (85-110
kD) or type IV cytosolic PLA2 (type IV CPLA2) led to a different view of the
activation of SAJ-2 acylhydrolysis through receptor mediated signal transduction
(Scharp er a/., 1993). This enzyme selectively cleaves arachidonoyl residues at the
5/1-2 position of membrane phospholipids. Type IV CPLAT is equally active against
ethanolamine- and choline containing phospholipids, and hydrolyzes both l-acyl-2-
arachidonoyl phospholipids, and l-alkenyl-2-arachidonoyl phospholipids. Type IV
CPLA2 has a predominantly cytosolic localization and requires Ca^* in the
micromolar range for translocation to its site of action, the phospholipid bilayer.
Because of these features, the high molecular mass cytosolic phospholipase A2 is a
likely candidate for the acute liberation of arachidonic acid from membrane
phospholipids in cardiac cells under physiological conditions, e.g. by alterations in
the cellular Ca~* concentration as a result of ligand-receptor interactions. This
notion is substantiated by the observation that type IV CPLA2 itself is a substrate for
mitogen-activated protein kinases (MAPK), which serve as important mediators for
a variety of receptor-mediated signal transduction pathways (Lin er a/., 1993).
The third type of phospholipase A2 present in the myocardium was first
reported in 1985 by Gross and coworkers (Wolf er a/., 1985). It has a molecular
mass of ~ 40 kD and was shown to be Ca"*-independent for its activity. Although it
has a preference for srt-2-arachidonoyl plasmalogens, it is also capable of
hydrolyzing diacyl-phospholipids or plasmalogens with other fatty acids at the sn-2
position, albeit at lower rate (Diez er a/., 1994). Ca^-independent, plasmalogen
specific type V phospholipase A2 (type V iPLA2) is localized in the cytosol and can
translocate to the cell membrane by interacting with the glycolytic enzyme
phosphofructokinase (PFK), forming a large 400 kD protein complex, indirectly
regulating the activity of type V iPLA2 via allosteric modulation of PFK by
cytosolic ATP levels (Hazen er a/., 1993). Recently a novel regulatory mechanism
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was identified whereby the Ca^-independent type V iPLA2 is modulated indirectly
by calcium ions, i.e., through alterations in the interaction of the phospholipase
complex with calmodulin (Wolfe/ a/., 1996).
To summarize, at least three different types of phospholipase A2 activities
have been identified in the heart: a 14 kD Ca^-dependent type IIA SPLA2, type V
iPLA2 and type IV CPLA2. Recently, Chen and colleagues cloned another low
molecular mass Ca^-dependent phospholipase A2 from rat heart that showed only
limited homology to type IIA SPLA2 (Chen ef a/., 1994). Dennis and coworkers
demonstrated that type HA SPLA2, type IV CPLA2 and type V iPLA2 were involved
in the release of arachidonic acid following stimulation of P388Di macrophages
(Balsinde e/ a/., 1996). Interestingly, type IIA SPLA2 was accountable for 60-70 %
of the AA release in this particular model system. As far as cardiomyocytes are
concerned the contribution of the different phospholipase A2 types in the ligand-
receptor-induced hydrolysis of phospholipids remains to be established.
c/ o/7.sc/»em/"a a«J reper/ws/o« o«
Ischemic heart diseases are predominantly caused by impaired coronary perfusion.
If the ischemic period has a limited duration, structural and functional recovery of
the myocardium is possible by timely restoration of blood flow. If the ischemic
period is prolonged, however, injury becomes irreversible, eventually leading to cell
death and cardiac dysfunction. During myocardial ischemia phospholipid
homeostasis is disturbed. The net degradation of phospholipids results in an
increase of their degradation products, mainly fatty acids and lysophospholipids
(Weglicki er a/., 1973, Van der Vusse e/ a/., 1982, Chien er a/., 1984, Van Bilsen er
er/., 1989). The sarcolemma appears to be the primary target for accelerated
phospholipid degradation in oxygen and energy-depleted cardiomyocytes (Van der
Vusse er a/., 1992). Although timely restoration of blood flow is required to save
the myocardium from irreversible damage, an even more dramatic rise in the tissue
levels of lysophospholipids and fatty acids has been observed during the reperfusion
phase. Whether this reperfusion-induced injury is a manifestation of cell damage
which was already present during ischemia or is a caused by the re-introduction of
blood flow per se to the previously ischemic myocardium, is still a matter of debate
(Van der Vusse er a/., 1989, Van der Vusse er a/., 1994).
Currently there are two hypotheses concerning the mechanism involved in
the increased phospholipid degradation of the sarcolemma during ischemia and
reperfusion (Van der Vusse e/ a/., 1989, Van der Vusse er a/., 1994). The first
hypothesis implies that the integrity of the sarcolemma is lost due to physical
forces, before the phospholipids are hydrolysed. Mechanical stress will be imposed
on the sarcolemma of energy-deprived cells by adjacent non-ischemic, contracting
myocytes or by hypercontracture of the ischemic cells themselves. In addition, low-
molecular weight substances such as lactate, protons and inorganic phosphate, will
accumulate inside ischemic myocytes. This will lead to a shift of water from the
extracellular to the intracellular space, imposing an increased osmotic force on the
cell membrane. Together with weakening of the anchoring of the cytoskeleton to
the sarcolemma, this might result in enhanced membrane fragility. When the
17
Cftap/er 2
sarcolemma is unable to withstand the physical forces anymore the sarcolemma will
rupture, after which intracellular structures will become accessible to the
extracellular fluid. This will lead to the activation of, amongst others, Ca^-
dependent proteases and phospholipases, which will start to digest cellullar
components. According to the physical forces hypothesis, degradation of
phospholipids is merely an epiphenomenon, reflecting post-mortem autolysis of
cardiac cells (Van der Vusse e/ a/., 1989, Buja ef a/., 1991).
In the second hypothesis, the loss of integrity is explained, among others,
by a imbalance between hydrolysis and resynthesis of the membrane phospholipids.
As indicated before, this may result from increased activity of hydrolyzing
enzymes, like phospholipases, or impaired resynthesis due to loss of catalytic
activity of the enzymes involved. Acyl-CoA synthetase, an enzyme involved in
phospholipid resynthesis, requires ATP as cofactor and is inhibited by AMP and
adenosine. Therefore, the ischemia-induced decrease in cellular ATP and elevated
levels of AMP and adenosine might lead to impairment of resynthesis (Van Bilsen
ef a/., 1989). In this light it is also of interest to note that the activity of
lysophosphatidyl acyltransferase was found to be compromized in the ischemic pig
heart (Das e/ a/., 1986) while in several studies PLA2 activity was found to be
increased in the ischemic and reperfused heart (Van der Vusse e/ a/., 1992). The
latter hypothesis implies that the increased degradation of membrane phospholipids
plays a pivotal role in the transition to irreversible injury of cardiomyocytes during
myocardial ischemia (Buja e/ a/., 1991, Van der Vusse ef a/., 1992).
Several studies indicate that the activation of especially PLA2 plays an important
role in the transition from reversible to irreversible ischemic myocardial injury.
First, in ischemic myocardium various phospholipid degradation products
accumulate, including arachidonic acid and lysophospholipids. As arachidonic acid
is predominantly (99 %) located in the esterified form at the .vn-2 position in
phospholipids, its liberation is conceivably due to PLA2 activity (Van der Vusse e/
a/., 1992). Second, chemical inhibitors of PLA2 have been reported to protect the
cardiomyocytes against ischemia, anoxia, or energy-deprivation (Van Bilsen e/ a/.,
1990, Atsma, 1996).
Earlier attempts to identify the PLA2 type involved in the enhanced
phospholipid hydrolysis during myocardial ischemia and reperfusion have focussed
on the plasmalogen-specific, Ca^-independent type V iPLA2. Hazen and coworkers
reported that in the rabbit heart the activity of type V iPLA2 is greatly enhanced
already 2 min after the onset of ischemia (Hazen ef a/., 1991). Moreover, halo-enol-
lactone suicide substrate (HELSS), a specific inhibitor of type V iPLA2 was found
to reduce cell death in cultured neonatal cardiomyocytes exposed to chemical
anoxia (Atsma er a/., 1996). However, several other observations raise questions as
to whether cardiac type V iPLA2 plays an important role in the
ischemia/reperfusion-induced phospholipid degradation. First, in cardiac
homogenates the diacyl-form of phosphatidylethanolamine is hydrolyzed rather
than the plasmalogen-form of phosphatidylethanolamine (Kikuchi-Yanoshita e/ a/.,
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1993). In line with the latter finding Davies and coworkers observed that the levels
of lysoplasmenylcholine and lysoplasmenylethanolamine did not significantly
increase in isolated rat hearts subjected to ischemia (Davies er a/., 1992). Secondly,
the time course of arachidonic acid accumulation during reperfusion does not
coincide with that of type V iPLA2 activation. The enzyme activity quickly goes
down to normal levels after ischemia, whereas arachidonic acid continues to
accumulate (Hazen er a/., 1991, Van der Vusse er a/., 1992). Thirdly, Vesterqvist
and colleagues reported a marked decrease in the activity of type V iPLA2 in
isolated rabbit hearts subjected to a prolonged period of global ischemia
(Vesterqvist er a/., 1996). In their study they used intact isolated sarcolemmal
membranes as substrate to measure enzyme activity, while Hazen and colleagues
used exogenously added phospholipid substrates (Hazen er a/., 1991).
In our opinion type IIA SPLA2 is a likely candidate to be involved in
ischemia/reperfusion-induced degradation of membrane phospholipids, because not
only arachidonic acid, but also other (un)satured fatty acids accumulate during
prolonged myocardial ischemia (Figure 3). This argues in favor of the involvement
of an aspecific PLA2 rather than an arachidonoyl-, plasmalogen-specific PLA2
(Buja, 1991, Van der Vusse er a/., 1994). Secondly, the observation that cardiac
fatty acid levels, including arachidonic acid, continue to rise in the reperfusion
phase points toward a role for type IIA SPLA2 in the process. Reperfusion is known
to be accompanied by a substantial increase in intracellular calcium concentration,
so that the activation of calcium-dependent phospholipases can be anticipated.
Furthermore, during reperfusion peroxidation of membrane phospholipids, as a
result of enhanced oxygen free radical production, has been demonstrated (Van der
Vusse er a/., 1992). It is of interest to note that peroxidation-damaged phospholipids
are more vulnerable for type IIA SPLA2 attack (Dan er a/., 1996). Furthermore, in a
study by Prasad and colleagues it was shown that pretreatment of isolated hearts
with antibodies raised against a snake venom type II SPLA2 effectively blocked the
degradation of membrane phospholipids and mitigated the release of cytoplasmic
proteins in the acute reperfusion phase (Prasad er a/., 1991). Anti-type IIA SPLA2
antibodies were also found to decrease the phospholipid degradation in
homogenates of rat hearts that had been previously subjected to a period of hypoxia
and reoxygenation (Kikuchi-Yanoshita er a/., 1993). Finally, increased expression
levels of type IIA SPLA2 have been found in rat brain after severe forebrain
ischemia (Lauritzen er a/., 1994) and in rat small intestinal mucosa after ischemia
and revascularization (Otamiri er a/., 1987). On the basis of the above, it is tempting
to speculate that cardiac type IIA SPLA2 expression levels will also increase during
myocardial ischemia and/or reperfusion.
Alternatively, the observation that type II PLA2 activity can be greatly
enhanced by members of the inflammatory cytokine family, might be of relevance
to the process of ischemic injury. First of all it has been shown that serum levels of
inflammatory cytokines, like IL-1, IL-6 and TNFa, are increased in various
pathophysiological conditions, including myocardial ischemia (Maury era/., 1989,
Guillnera/., 1995).
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Figure 3: Effects of ischemia and reperfusion of isolated rat hearts on the tissue
content of individual fatty acid species. Values are give in nmol.g"' dry weight and
represent the mean of 6-10 experiments. 16:0 refers to palmitic acid, 18:0 to
stearic acid, 18:1 to oleic acid, 18:2 to linoleic acid, 20:4 to arachidonic acid, and
22:6 to docosahexaenoic acid. [Adapted from Van Bilsen, thesis 1989].
Moreover, for other cell types it has been shown that cytokine stimulation caused a
very rapid (within 5 minutes) increase of type IIA SPLA2 activity (Bomalski e/ a/.,
1992). Finally, it has been demonstrated that cardiomyocytes can produce TNFa
under hypoxic stress (Yamauchi-Takihara e/ a/., 1995), and that stimulation of
cultured rat neonatal cardiomyocytes with TNFa resulted in increased type IIA
SPLA2 mRNA levels (De Windt er a/., 1996). Therefore, it can be hypothesized that
cytokines secreted by cardiomyocytes could indirectly influence sarcolemmal
stability, by increasing the cellular level of type HA SPLA2 in an autocrine manner.
Fu/wre <flrec//ons: /Ae use o/
As indicated above, no definitive proof has been provided that enhanced
phospholipid hydrolysis and the induction of irreversible cell damage are causally
related. It is also uncertain which type of PLA2 would be accountable for the
ischemia and reperfusion-induced hydrolysis of membrane phospholipids. Studies
performed with phospholipase inhibitors lack specificity, which hampers an
unequivocal interpretation of the results obtained. For example, in an isolated rat
heart preparation subjected to a period of global ischemia followed by reperfusion,
the phospholipase inhibitor mepacrine was able to reduce the phospholipid
degradation, but also was shown to exert a negative inotropic effect (Van Bilsen e/
a/., 1989) and to interfere with transsarcolemmal calcium fluxes (Philpson e/ a/.,
1985). Accordingly, current conventional pharmacological and/or physiological
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approaches do not provide conclusive answers as to the role of PLA2 in
ischemia/reperfusion injury.
The advent of molecular biological techniques and transgenic technology
allows the generation of mice with either an overexpression ( gain of function ) or
the absence (loss of function ) of specific genes. By using transgene technology it
has been possible to study the role of a specific gene of interest and to dissect
complex cardiovascular phenotypes involving several gene products. This approach
has been demonstrated to be effective in creating murine models resembling human
myocardial diseases, such as cardiac hypertrophy/failure, congenital heart diseases,
and hypertension, just to mention a few (see reviews by Field, 1993 and Chien,
1994). The transgene technology has also been successfully applied in studies
related to ischemia and reperfusion damage. For example, the contribution of
oxygen free radical to ischemia/reperfusion damage was confirmed by the
subjecting the hearts of transgenic mice overexpressing Superoxide dismutase to
transient ischemia (Chen ef a/., 1996). In addition, transgenic mice overexpressing
HSP70 were found to be less vulnerable against ischemic injury, clearly indicating
the protective effect of HSP70 in this setting (Plumier e/ a/., 1995, Marber er a/.,
1995).
In our laboratories we are currently applying transgene technology in order
to modulate type IIA SPLA2 activity in the heart. With this approach mechanisms
underlying disturbances in phospholipid homeostasis as a result of cardiac ischemia
and reperfusion will be studied. To achieve this, transgenic mice have been
generated that harbor the recently cloned cDNA of rat heart type IIA SPLA2
downstream to the proximal fragment (250 bp) of the promoter of the myosin light
chain-2 (MLC-2) gene. Recent studies indicate that this part of the promoter is
sufficient to mediate cardiac-specific expression (Lee e/ a/., 1992). In this way,
several lines of transgenic mice, differing in copy number and, hence, in the level of
cardiac type IIA SPLAT activity, will become available for analysis.
The hearts of transgenic and control mice will be subjected to ischemia and
reperfusion ex v/vo to assess the causal relationship, if any, between the level of
type IIA SPLA2 and the extent of phospholipid hydrolysis on the one hand and
cellular damage and functional recovery on the other. We are currently scaling
down the technique of isolated rat heart perfusion (Neely ef a/., 1967), according to
"the assisted mode perfusion", to the level of the mouse. This model will allows us
to study functional recovery by parameters like the recovery of left ventricular
developed pressure and cardiac output. The development of this isolated left
ventricular ejecting mouse heart model will not only be of interest for this particular
problem, but will be of great value for future studies to evaluate cardiac function of
transgenic mice, whatever the transgene they are harboring.
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Chapter 3
Cloning and cellular distribution of
type IIA secretory phospholipase A2
expressed in the heart.
LJ de Windt, PHM Willemsen, S P pping, GJ Van der Vusse, RS Reneman, M
Van Bilsen. Cloning and cellular distrubution of a group II phospholipase A2
expressed in the heart. 7 M>/ G?// Car^/o/1997;29:2093-2106.
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Abstract
Phospholipase A2 has been considered to play a role in physiological
membrane turnover in cardiac tissue and in the degradation of membrane
lipids under pathophysiological conditions, such as ischemia and
reperfiision. We report the cloning of a cDNA encoding a member of the
Ca^-dependent, low molecular mass type ILA secretory phospholipase A2
(type ILA SPLA2) present in rat heart. The cDNA predicts a mature
protein of 146 amino acid residues including a 21 amino acid sequence at
the N-terminal end, which has the features characteristic of eukaryotic
secretory signal peptides. The deduced amino acid sequence constitutes
an enzyme of the type II class of SPLA2S, and resembles type ILA SPLA2S
from other mammalian sources. A Northern blot analysis performed to
determine the tissue distribution showed that rat ileum contains the
largest amount of the type ILA sPLA: transcript among the tissues
examined, a weaker signal was present in heart, spleen, and soleus
muscle, and no signal could be detected in EDL muscle, stomach, liver,
kidney, brain, and lung. Northern blot analysis and RT-PCR techniques
indicate the presence of this enzyme in neonatal and adult rat
cardiomyocytes and in a cultured rat cardiac fibroblast-like cell line, but
not in rat cardiac-derived endothelial cell lines. Transcription levels of rat
heart type ILA SPLA2 in isolated neonatal rat cardiomyocytes were found
to increase after stimulating the cells with tumor necrosis factor-cc or the
(X|-adrenergic agonist phenylephrine.
26
C/omng (ype ///I
Introduction •' • ' • '*
Phospholipases A2 (PLA2S) (phosphatide 2-acylhydrolase; EC 3.1.1.4) hydrolize the
sn-2 fatty acyl ester bond of phospholipids giving yield to fatty acids and
lysophospholipids. PLA2S have been implicated in such diverse activities as
membrane turnover, signal transduction, and inflammation (Van Bilsen and Van der
Vusse, 1995). Furthermore, myocardial ischemia and reperfusion are associated
with disturbances in phospholipid homeostasis. The net loss of membrane
phospholipids and the concomitant accumulation of lysophospholipids and fatty
acids are likely to compromise cellular integrity (Van der Vusse e/a/., 1992).
Several lines of evidence support the notion that the degradation of phospholipids
during ischemia/reperfusion is due to the activation of myocardial PLA2.
In mammalian cells three types of PLA2S have been distinguished, i.e., an
ubiquitously expressed high molecular mass (85 kDa) PLA2 with a high specificity
for arachidonic acid-containing phospholipids (Sharp er a/., 1991), a 40 kDa Ca**-
independent enzyme that prefers sw-2 arachidonoyl plasmalogens as substrate
(Hazen er a/., 1990, Clark er a/., 1991), and the low molecular mass (13-15 kDa),
Ca^-dependent PLA2S (Van Schaick er a/., 1993, Komada er a/., 1989, Ishizaki er
a/., 1989).
At present, it is unclear which type(s) of PLA2 is (are) involved in the
degradation of phospholipids during ischemia and reperfusion. The findings in a
number of studies indicate that a calcium-dependent non-specific PLA2 may play an
essential role in the hydrolysis of myocardial phospholipids under these conditions.
This notion is substantiated by the finding that antibodies raised against a snake
venom type II SPLA2 were able to inhibit phospholipase activities in the isolated rat
heart after an ischemic insult (Prasad er a/., 1991). Further indications for the
presence of a membrane-associated type IIA SPLA2 in rat heart myocytes were
provided by a histochemical study of Kriegsmann and colleagues (1993) using a
monoclonal antibody against bee venom PLA2.
To allow a more specific analysis of the (patho)physiological role of type IIA
SPLA2 within the heart, the availability of its cDNA would be very helpful. Because
of the presence of marked differences in subcellular localization and subtle
differences in DNA sequence between type IIA SPLA2S that were cloned from
various rat tissues (Van Schaick er a/., 1991, Komada er a/., 1989, Ishizaki er o/.,
1989), we have chosen for a strategy with conventional cloning techniques to
identify the cDNA of type IIA SPLA2 that might be present in the heart. In addition,
we wanted to determine the tissue distribution of this PLA2 and its cellular distribution
within the heart. Furthermore, it was investigated whether in cardiomyocytes the
transcription level of this PLA2 is subject to regulation by cytokines similar to what has
been found in other cell types, like rat vascular smooth cells (Nakano er a/., 1990), rat
hepatoma cells (Crowl er a/., 1991), and rat mesangial cells (Pfeilschifter er a/., 1989).
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Materials and Methods
O/"CK/M// awe/ neowata/ car^/'omyocy/es
Adult cardiomyocytes (CMC) were isolated from the ventricles of rats (Wistar-Kyoto)
as described previously by Linssen er a/. (1993). Briefly, after perfusion of the isolated
heart with a collagenase solution, the ventricles were chopped and incubated in
Modified Krebs Ringer buffer containing 2.5 mM CaCb, 0.06% collagenase type I
(Gibco BRL, Breda, the Netherlands) and 1% bovine serum albumin (BSA). Cells
were centrifuged at 25xg for 90 s. The cells were plated on tissue culture dishes in
CMC culture medium (i.e., Ml99, 2 mM L-glutamine, 13 mM NaHCCh, 10 mM
HEPES, 100 U/ml penicillin, 100 ug/ml streptomycin, 4% fetal calf serum). The
immortal cardiac-derived endothelial cell lines RHEC-50 and RHEC-116, and the
cardiac-derived fibroblast-like cell line CFLC-122 (cell lines described by Linssen ef
a/., 1990 and 1993) were cultured in DMEM (Gibco 42430) supplemented with 10%
fetal calf serum (Gibco BRL).
Neonatal ventricular myocytes were isolated as described by Iwaki ef a/. (1990)
with slight modifications. Briefly, hearts were removed from decapitated 1 to 3 days
old Wistar-Kyoto rats. Atria were trimmed off and ventricular tissue was cut into
pieces, transferred to a spinner flask and digested to single cells with collagenase type I
(Gibco BRL) and pancreatin (Gibco BRL) in Ads-buffer (pH 7.35), consisting of 116
mM NaCl, 20 mM HEPES, 0.9 mM NaP^PO.,, 5 mM glucose, 5.4 mM MgSCv The
cell suspension was loaded on a discontinuous gradient of Percoll (Sigma Chemical
Co., St. Louis, USA) with two different densities (1.059 and 1.082 g/ml, respectively)
to separate the cardiomyocytes from non-myocytes, mainly fibroblasts and endothelial
cells. The cardiomyocytes were allowed to adhere to tissue culture dishes coated with
1% gelatin type B (Sigma G-9382) in a 4:1 mixture of DMEM (Gibco 42430) and
Ml99 (Gibco 31153), supplemented with 10% horse serum (Gibco 16050), 5%
newborn calf serum (Sera-Lab, Sussex, UK), and antibiotics (pennicilin 100 U/ml,
streptomycin 100 ug/ml, P/S, Gibco BRL).
Total RNA from adult rat heart (Lewis strain), isolated myocytes, and the above
described cardiac-derived cell lines, was prepared using TRIzol Reagent (Gibco BRL).
Reverse transcription (RT) was performed with Superscript™-II RNAse H" reverse
transcriptase (Gibco BRL) according to the instructions of the supplier. Polymerase
chain reaction (PCR) was performed on a DNA thermal cycler (Perkin Elmer Co.,
Norwark, USA) using Thermus Aquaticus (Taq) polymerase (Gibco BRL). After an
initial incubation of 5 min at 95 °C, the reactions were cycled 30 times between 55 °C,
72 °C, and 95 °C, all for 1 min. An additional extension reaction at 72 °C for 10 min
was included after cycle 30. Samples were size-fractionated by agarose gel
electrophoresis and visualized after staining with ethidium bromide. RT-PCR and PCR
reactions were performed with combinations of primers designated PLA-F1 [5-
GAGTTTGGGCAAATGATTC-3], PLA-Rl [5-CAGCTTTATCGCACTGGCA-31,
and PLA-R2 [5-AGTCCTGGTTTGTAGAGCAG-31 (all purchased from Pharmacia,
Uppsala, Sweden). PLA-F1 and PLA-Rl correspond to bp 73-91 and bp 328-346 of
the sequence of rat spleen type ILA SPLA2 (Ishizaki er a/., 1989). PLA-R2 is a nested
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primer in the rat heart PLA2 cDNA sequence corresponding to bp 291-311 in Figure 2.
The subsequently found 273 bp RT-PCR product was subcloned in a pBluescript
vector. The fragment was excised as a Xho I/Pst 1 fragment and radioactively labeled
using [^P]-dCTP (3000 Ci/mmol, NEN DuPont, Dordrecht, the Netherlands) by
random priming using a commercial kit (rediprime™, Amersham, Buckinghamshire,
UK). The probe was designated PLA-probe.
Figure 1
PCR amplification of RT-RNA
from adult rat myocytes. The PCR
products generated with primers
PLA-F1 and PLA-R1 on RT-RNA
from adult rat cardiomyocytes were
resolved by gel electrophoresis and
stained with ethidium bromide.
Control refers to PCR reaction to
which H2O was added instead of
template (negative control). An 1
kb ladder (Gibco BRL) was used as
molecular weight marker.
500 bp -
298 bp -
275 bp
5-RACE-RT-PCR (rapid amplification of cDNA-ends-reverse transcription
polymerase chain reaction) was applied to generate the full length cDNA from adult rat
cardiomyocyte total RNA, using a kit from Gibco BRL. Primer PLA-R1 was used for
first round amplification, while the supplied anchor primer and the nested primer PLA-
R2 were used for the second round of amplification, according to the supplier's
instructions.
1.2x10* clones from an adult rat heart UNI-ZAP™ XR-cDNA library (Stratagene, La
Jolla, California, USA) were lifted in duplicate onto nylon filters. The filters were
denatured, baked at 80 °C for 1 h, prehybridized for 2 h in 6x SSPE, lxDenhardt's
solution, 0.5% sodium dodecyl sulfate (SDS), 100 fig/ml salmon sperm DNA at 58 °C,
and hybridized overnight in the same solution with 10* cpm/ml of ^P-labeled PLA-
probe. Final washing conditions were 0. lxSSC at 60 °C for 15 min.
Filters were exposed to X-ray film for 24 h. After three subsequent rounds of
duplicate filter lifting in order to obtain a purified clone, 12 potential positive clones
were found and subjected to an In Vivo Excision reaction of the insert, using the
ExAssist/SolR system (Stratagene), thereby directly cloning the insert into a
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pBluescript vector. Candidate clones were subjected to restriction enzyme digest
analysis and sequence reactions using the T7 sequence kit (Pharmacia).
Total RNA from various rat tissues and cells was isolated using TRIzol Reagent
(Gibco BRL) and the RNA (10 jig) was size-fractionated on a 1% agarose, 18%
formaldehyde gel according to the method described in Sambrook e/ a/. (1989). The
RNA was transferred to a nylon filter (Hybond-N, Amersham) by capillary transfer
overnight. After UV crosslinking and baking at 80 °C for 2 h, the filters were
prehybridized for 2 h in 6xSSPE, lxDenhardt s solution, 0.5% sodium dodecyl sulfate
(SDS), 100 u,g/ml salmon sperm DNA at 58 °C and hybridized in the same solution
with 10* cpm/ml of "P-labeled PLA- probe. Final washing conditions were lxSSC
with 0.1% SDS at 50 °C for 30 min. To correct for possible differences in loading and
transfer, the filters were also hybridized with an "P-labeled 18S probe. Filters were
exposed to X-ray film with two intensifying screens.
For these experiments, after isolation from the hearts, 2x10* neonatal rat
cardiomyocytes were allowed to adhere to 10 cm tissue culture dishes coated with 1 %
gelatin type B in a 4:1 mixture of DMEM (Gibco 42430) and Ml99 (Gibco 31153),
supplemented with 10% horse serum (Gibco 16150), 5% newborn calf serum, and P/S.
After 24 h the cells were rinsed twice with sterile PBS and serum free medium was
added (a 4:1 mixture of DMEM and Ml 99 with P/S). After 24 h tumor necrosis factor-
ex (TNF-ot, final concentration 1 nM) or phenylephrine (PE, final concentration 10
|iM) were added to the cells. After a 16 h incubation unstimulated cells, TNF-a-
stimulated, and PE-stimulated cells were harvested for RNA isolation using TRIzol
reagent (Gibco). The RNA was subjected to Northern blot analysis according to the
method described above. The Northern blots were exposed to storage phosphor screens
and subsequently scanned and quantified using a Phosphorlmager and the ImageQuant
software (Molecular Dynamics, Sunnyvale, CA, USA).
Results
/?r-PC7? on wo/ata/ myocy/es
In order to investigate the presence of type IIA SPLA2 in cardiac myocytes, two
primers, designated PLA-F1 and PLA-R1, were generated corresponding to bp 73-91
and bp 328-346 of the sequence of rat spleen type IIA SPLA2 (Ishizaki e/ a/., 1989).
PCR amplification using these primers on reverse transcribed (RT) RNA from isolated
adult rat heart myocytes, produced several bands among which one prominent band of
the expected size of 273 bp (Figure 1). These fragments were subcloned into the
pBluescript vector and sequenced in both directions. Sequence comparison was
performed using the GenBank data base. This confirmed only the 273 bp PCR-product
to be part of a type IIA sPLA2 cDNA. The 273 bp fragment was found to be nearly
identical to the corresponding part of rat spleen and platelet type IIA sPLA2- Only at
one position (bp 126 in Figure 2/Figure 3, Panel A) a thymidine residue in the
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spleen/platelet type was found to be be replaced by a cytidine residue in the heart
cDNA.
The 273 bp PCR-product was subcloned in the pBluescript vector and isolated
as a Xho I/Pst I fragment and labeled with [^P]-dCTP. The fragment was designated
PLA-probe and used as a probe for the screening of a cDNA library and in RNA blot
analysis.
Screew/wg q/Va/ Aear/ cDM4 //Z?rary.
In order to obtain the full length cDNA of the PLA2, 1.2x10* clones of an adult rat
heart cDNA library were screened, using the radioactively labeled PCR-fragment as a
probe. Twelve potential candidates were identified after three sequential rounds of
plaque purification. After using the ExAssist/SolR system supplied with the cDNA
library to allow efficient excision of the pBluescript phagemid, the candidates were
subjected to restriction analysis and Southern blot analysis. Based on these analyses,
only one of the twelve candidates proved to contain a part of a type IIA SPLA2 cDNA.
This was affirmed after sequencing the pBluescript plasmid containing the fragment of
approximately 600 bp. This revealed that the clone contained a large part of the coding
region, starting from basepair 104, and the complete 3 untranslated region ending in a
poly(A) tail (Fig. 2). However, the 5 end of the coding region was missing.
5 -/
In order to procure the missing part of the coding region, the 5-rapid amplification of
cDNA ends-PCR technique was applied. Total RNA from adult rat heart myocytes
was isolated, and a first round PCR amplification was performed, using primer PLA-
Rl to produce a crude 5-rat heart PLA2-CDNA sample. This product was tailed with a
supplied anchor primer at its 5' end and amplified using a supplied complementary
anchor primer and the nested PLA2 primer, designated PLA-R2. The product obtained
was electrophorized on an agarose gel and visualized after staining with ethidium
bromide. A very faint PCR-fragment of approximately 400 bp was isolated from the
gel via the Qiaex gel extraction procedure (Qiagen GmbH, Hilden, Germany), and re-
amplified with the last set of primers that was applied in the 5-RACE-PCR reaction.
This product was cloned into a PCR-II vector of the TA cloning kit (InVitrogen Corp.,
San Diego, USA). Sequencing reactions using the primers PLA-F1 and PLA-R2
revealed the product as being a part of a type ILA SPLA2 cDNA and containing the
missing 5 end of the rat heart type IIA SPLA2 cDNA.
C/omng o/^ü// fe/jg//i
The first 404 basepairs of the PLA2 5-RACE-PCR fragment and the clone isolated by
screening the cDNA library were combined, using internal BamHI sites at bp 164 and
bp 610 in de cDNA sequence of type ILA SPLA2 and an EcoRI site in de anchor primer
used in the 5 RACE-PCR reaction, which resulted in the full length PLA2 cDNA in
pBluescript. In this sequence an open reading frame (438 basepairs) was found,
predicting a protein of 146 amino acids, containing a short sequence composed of 21
amino acid residues at the N-terminal end, which has the features characteristic of
eukaryotic secretory signal peptides. Furthermore, the enzyme contains a carboxyl-
terminal extension of six amino acids (KGKTPSC) and misses the elapid loop present
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in type I SPLA2, both features being characteristic for type II SPLA2 enzymes
(Davidson <?/ a/., 1990, Figure 2/Figure 3, Panel A).
.93 TCCTGGTTTGTAGA -79
-78 GCATTGGGAGTATAGGAAAAACAAGGCAGGCCCTrGAACAAGAAGCCATACCACCATCCCATCCAAGAGAGCTGACAGC 0
Mac Lys Val Lau Lau Lau Lau AI« Val Val Ila Met Val Phe Gly Sar II« Gin Val Gin
1 ATG AAG G7C CTC CTG TTG CTA GCA GTT GTG ATC ATG GCC TTT GGC TCA ATT CAG GTC CAG 60
I
Oly Ser Leu Leu Glu Phe Gly Gin Met lie Leu Phe Lys Thr Gly Lys Arg Ala Asp Val
61 GGG AGC CTT CTG GAG TTT OGC, CAA ATG ATT CTG TTT AAG ACA GGA AAG AGA GCT GAT GTT 120
Ser Tyr Gly Phe Tyr Gly Cys His Cys Gly Val Gly Gly Arg Gly Ser Pro Lys Asp Ala
121 AGC TAC GGC TTC TAC GGT TGC CAT TGT GGT GTG GGT GGC AGA GGA TCC CCC AAG GAT GCC 180
Thr Asp Trp Cys Cys Val Thr His Asp Cys Cys Tyr Asn Arg Leu Glu Lys Arg Gly Cys
181 ACA GAT TGG TGC TGT GTG ACT CAT GAC TGT TGT TAC AAC CGT CTG GAG AAA CGT GGA TGT 24 0
Gly Thr Lys Phe Leu Thr Tyr Lys Phe Ser Tyr Arg Gly Gly Gin H e Ser Cys Ser Thr
241 GGC ACA AAG TTT CTG ACC TAC AAG TTC TCC TAC CGA GGG GGC CAA ATC TCC TGC TCT ACA 300
Asn Gin Asp Ser Cys Arg Lys Gin Leu Cys Gin Cys Asp Lys Ala Ala Ala Glu Cys Phe
301 AAC CAG GAC TCC TGC CGG AAA CAG CTG TGC CAG TGC GAT AAA GCT GCC GCT GAA TGT TTT 360
Ala Arg Asr. Lys Lys Ser Tyr Ser Leu Lys Tyr Gin Phe Tyr Pro Asn Lys Phe Cys Lys
361 GCC CGG AAC AAG AAA AGC TAC AGT TTA AAG TAC CAG TTC TAC CCC AAC AAG TTT TGC AAA 420
Gly Lys Thr Pro Ser Cys
421 GGG AAG ACG CCC AGT TGC TGAAAGAGACATCTTCTGAAACATCCAGACATCCTCTAACACCTCTCCTAGCCCA 4 93
494 ACCAAGTTCCCCAGTGATCAAGAAAACACCCCTCTCCTAGAAGCAGGCGGGCCCTTCTGTCTTCACCCAGAAGGAGCCG 572
573 CTGAAGCCTG ATCTTTCCCCAACACTCCACAGCCTTGGATCCGCCCACTTTTCCCTTGGCATCCAACTTCCTGCTGCGT 651
6 52 AGTACCTAAGAGGGTCCTGAGAGCCTCTCGCAAGTAAAGCAATTCATCAACAAAAAAAAAAAAAAAAAA 75»
Figure 2
Nucleotide sequence of the cDNA of rat heart type HA secretory phospholipase A2 (type IIA
sPLA:).The cloned nucleotide sequence and deduced amino acid sequence of the largest found open
reading frame (ORF) of rat heart type HA SPLA2 is shown. The start codon (position +1) and
stopcodon are indicated in bold. The putative polyadenylation signal in the 3 -untranslated region is
indicated in bold. The first 21 amino acids residues that form the eukaryotic signal peptide for protein
secretion are indicated in bold. The respective position of the primers PLA-Fl, PLA-R1 and PLA-R1
are underlined, and the predicted cleavage site for signal peptidase (4-) is indicated.
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At the DNA level the differences with the sequence isolated from spleen by Ishizaki er
a/. (1989), and from platelets by Komada e/ a/. (1989) are minimal. Within the coding
region at bp 126 a thymidine residue in the spleen and platelet type has been replaced
by a cytidine residue in the heart cDNA. This replacement has no consequences for the
amino acid sequence. In the 3 untranslated region at bp 457 a guanidine residue is
present in the platelet type, while in the heart and spleen type a thymidine residue is
present. Furthermore, the platelet cDNA contains a short insertion of two adenine and
three cytidine residues at bp 531 and at bp 676 a guanidine residue in the spleen and
platelet type is substituted by a cytidine residue in the heart sequence. However, more
differences in the coding region can be observed between the PLA2 cDNAs cloned
from rat heart and rat liver (Van Schaick e/ a/., 1989). In addition to the basepair
difference in the coding region (bp 126), the rat liver cDNA shows a cytidine residue at
bp 344 and a guanidine residue at bp 345, resulting in an arginine at position 115 in the
amino acid sequence, whereas an alanine residue is found in the heart, spleen, and
platelet type ILA SPLA2 (Figure 3, Panel A and B).
Tissue a/J<i ce//u/ar c/ü/rtöuft'on
Northern blot analysis showed this PLA2 transcript to be present in a number of rat
tissues and to correspond to a 0.9 kb signal (Figure 4). In rat ileum a very strong signal
was found, and a relatively weaker signal in heart, spleen, and soleus muscle. No
signal could be detected in rat EDL muscle, stomach, kidney, brain and lung tissue
(Figure 4).
In addition it was investigated whether the type ILA SPLA2 was present in
isolated adult cardiomyocytes and several cardiac-derived cell lines (Figure 5). A
positive signal was observed in adult rat ventricular myocytes and in the cardiac-
derived fibroblast-like cell line CFLC-122. No hybridization signal was found in the
cardiac-derived endothelial cell lines RHEC-50 and RHEC-116 (Linssen er a/., 1993b),
not even after prolonged exposure of the film. Relative to the signal obtained in total
heart (100%) the signals in the cardiomyocytes and cardiac-derived fibroblast-like cell
line amounted to 105% and 130%, respectively (Figure 5).
To check whether type ILA SPLA2 was indeed absent in the endothelial cell
lines, RT-PCR was applied because of the greater sensitivity levels that are intrinsic to
this technique. RT-PCR was performed on total RNA isolated from rat ileum, total
heart, isolated adult cardiomyocytes and from the two cardiac-derived endothelial cell
lines and the cardiac-derived fibroblast-like cell line, using PLA-F1 and PLA-R1 as
primers (Figure 6). As expected, PCR-fragments of expected size (273 bp) were found
in ileum and total heart. Furthermore, a similar signal was obtained in isolated adult
cardiomyocytes and the cardiac-derived fibroblast-like cell line. In contrast, no signal
was detected in either one of the cardiac-derived endothelial cell lines, thereby
validating the Northern blot data shown above.
33
inl -«0 -60 «0 -JO 0
Rat spleen : AAGGCAGOCCCTTGAACAAGAAGCCATACCACCATCCCATCCAAaAQAGCTQACAOC
Rat platelet : - - - C
Rat liver : - - -
.1 20 40 (0 10 100 120
AISAAGGTCCTCCTGTTGCTAGCAGTrGTGATCATGGCOITTGGCTCAATTCAGGTCCAGGGGAGCCTTCTGGAGTTTGGGCAAATGArrCTGTTTAAGACAGGAAAGAGAGCTGATG^
&IGAAGGTCCTCCTGTTGCTAGCAGTTGTGATCATGGCCTTTGGCTCAATTCAGGTCCAGGGGAGCCTTC
AGCCTTCTGGAGTTTGGGCAAATGATTCTGTTTAAGACAGGAAAGAGAGCTGATGTT
140 160 180 200 220 :'4O
jtiu 400 420 440 460 4S0
GCCCGGAACAAGAAAAGCTACAGTTrAAAGTACCAGTTCTACCCCAACAAGTTTTGCAAAGGGAAGACGCCCAGTTGCIQ&AAGAGACATCTTCTGAAACATCCAGACATCCTCTAACAC
GCCCGGAACAAGAAAAGCTACAGTTTAAAGTACCAGTTCTACCCCAACAAGTTTTGCAAAGGGAAGACGCCCAGTTG<^GJW^GAGACATCTTCTGAAACATCCAGACATCCTCTAACAC
GCCCGGAACAAGAAAAGCTACAGTTTAAAGTACCAGTTCTACCCCAACAAGTTTTGCAAAGGGAAGACGCCCAGTTGCISA
500 520 MO 560 SBO
CCTCTCCTAGCCCAACCAAGTTCCCCAGTGATCAAGAAAACACCCCTCTCC TAGAAGCAGGCGGGCCCTTCTGTCTTCACCCAGAAGGAGCCGCTGAAGCCTGATCTTTCCCCAA
CCTCTCCTAGCCCAACCAAGTTCCCCAGTGATCAAGAAAACACCCCTCTCC TAGAAGCAGGCGGGCCCTTCTGTCTTCACCCAGAAGGAGCCGCTGAAGCCTGATCTTTCCCCAA
ATCTTTCCCCAA
600 620 640 660 680 100
CACTCCACAGCCTTGGATCCGCCCACTTTTCCCTTGGCATCCAACTTCCTGCTGCGTAGTACCTAAGAGGGTCCTGAGAGOCTCTCGCAAGTAAAGCAATTCATCAA
CACTCCACAGCCTTGGATCCGCCCACTTTTCCCTTGGCATCCAACTTCCTGCTGC<n'AGTACCTAAGAGGGTCCrGAaAGOCTCTCGCAAGTAAAGCAATTCATCAAC- (A)
C/om'ng Type 7L4
(b)
+1 10 20 30 40 50
Heart MKVLLLLAWIMAFGSIQVQGSLLEFGQMILFKTGKRADVSYGFYGCHCG
Spleen MKVLLLLAWIMAFGSIQVQGSLLEFGQMILFKTGKRADVSYGFYGCHCG
Platelet MKVLLLLAWIMAFGSIQVQGSLLEFGQMILFKTGKRADVSYGFYGCHCG
Liver SLLEFGQMILFKTGKRADVSYGFYGCHCG
60 70 80 90 100
VGGRGSPKDATDWCCVTHDCCYNRLEKRGCGTKFLTYKFSYRGGQISCST
VGGRGSPKDATDWCCVTHDCCYNRLEKRGCGTKFLTYKFSYRGGQISCST
VGGRGSPKDATDWCCVTHDCCYNRLEKRGCGTKFLTYKFSYRGGQISCST
VGGRGSPKDATDWCCVTHDCCYNRLEKRGCGTKFLTYKFSYRGGQISCST
110 120 130 140
NQDSCRKQLCQCDKAAAECFARNKKSYSLKYQFYPNKFCKGKTPSC
NQDSCRKQLCQCDKAAAECFARNKKSYSLKYQFYPNKFCKGKTPSC
NQDSCRKQLCQCDKAAAECFARNKKSYSLKYQFYPNKFCKGKTPSC
NQDSCRKQLCQCDKRAAECFARNKKSYSLKYQFYPNKFCKGKTPSC
Figure 3
Comparison of type IIA SPLA2 primary structures. .4, The cDNA sequences of type IIA SPLA2 from
rat heart, spleen, platelet and liver are depicted. Alignment is based on maximizing homology using
Clustal W 1.60 Multiple sequence alignment software. The start codon (position +1) and stop codon
are underlined. Differences between the cDNA sequences are given in bold and are depicted within
boxes. Ä, the amino acid sequences of rat heart, spleen, platelet and liver type IIA SPLA2 are depicted
in one letter code. Alignment is based on maximizing homology using Clustal W 1.60 software. The
first amino acid residue in the rat heart enzyme (position +1) is indicated. Differences between the
sequences are given in bold and are depicted whithin boxes. The putative secretory signal peptide is
also given in bold.
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Figure 4
Northern blot analysis of different rat tissues. Total RNA (10 |ig) isolated
from heart, spleen, ileum, extensor digitorum longus (EDL) muscle, soleus
muscle, stomach, liver, kidney, brain and lung was analyzed. A 273 bp ^P-
labeled fragment of rat heart type IIA sPLAj cDNA was used as a probe.
The blot was stripped and reprobed for 18S ribosomal RNA to check
whether comparable amounts of RNA had been loaded.
PLA,
18 S
Figure 5
Northern blot analysis of different rat cardiac cell types. Total RNA (10
ug) isolated from total heart, adult myocytes, the cardiac-derived
fibroblast-like cell line CFLC-122 and two cardiac-derived stable
endothelial cell lines RHEC-50 and RHEC-116 was analyzed. As probe,
the "P-labeled fragment of rat heart type IIA sPLAj cDNA was used. The
blot was stripped and reprobed for 18S ribosomal RNA to correct for
differences in RNA loading. Picture depicts one of two independent
Northern blot analyses with similar findings.
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To monitor whether type IIA SPLA2 transcription can be induced by cytokines in
cardiomyocytes, similar as to what has been shown for several other cell types
(Pfeilschifter e/ a/., 1989, Nakano ef a/., 1990, Crowl e/ a/., 1991), primary cultures of
neonatal ventricular myocytes were stimulated with TNF-a (1 nM). In addition, the
myocytes were stimulated with the (X|-adrenergic agonist phenylephrine (10 u,M). The
results show a five fold upregulation of type IIA SPLA2 transcript after TNF-a
stimulation and a nearly two fold increase after addition of phenylephrine to the culture
medium of neonatal rat cardiomyocytes (Figure 7).
Discussion
«V
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In this study we describe the cloning of the cDNA sequence of a type IIA SPLA2
present in rat cardiomyocytes and in the cardiac-derived fibroblast-like cell line CFLC-
122. It appears to be a low-molecular mass enzyme, the presence of which has been
previously described in rat spleen, platelets, and liver (Ishizaki er a/., 1989, Komada er
a/., 1989,VanSchaickera/., 1993).
""' At the DNA level
f*^  to rt>
the differences with the spleen
and platelet sequences are
minimal and have no
consequences for the amino
acid composition. The
differences with the cDNA
sequence of type ILA SPLA2
isolated from liver were more
pronounced and resulted in the
substitution of one amino acid
residue. The question could
be raised whether the
275 bp differences between the
previously reported rat type
IIA SPLA2S and the one we
cloned from rat heart represent
cloning/sequencing artefacts,
strain differences, or are the
result of differential splicing of
one or more related genes.
Firstly, it should be noted that
100-
Figure 6
Determination of cellular distribution by RT-PCR
amplification. The presence of type IIA SPLA2 in different
cardiac cell types was assessed by means of PCR with
primers PLA-F1 and PLA-R1 on reverse transcribed RNA
from adult myocytes, cardiac-derived endothelial cell line
RHEC-50 and RHEC-116, and the cardiac-derived
fibroblast-like cell line CFLC-122. As positive controls RT-
PCR amplifications were performed on RT-RNA from
ileum and total heart. A PCR reaction without template was
also included (control). Lane M, molecular weight standard
(100 bp ladder, Gibco BRL.)
the sequence of a part of the
cDNA that shows
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differences with the platelet and spleen type ILA SPLA2, has been obtained in three
independent ways, i.e., after sequencing (i) the 273 bp product of the PCR reaction on
reverse-transcribed myocyte RNA, (ii) the fragment picked up from the rat heart
cDNA library, and (iii) the product obtained after performing the 5 RACE-PCR.
Therefore, the occurrence of cloning or sequencing artefacts of the cardiac PLA2
cDNA can be ruled out. Hence, it can concluded that the basepair differences are
genuine.
With respect to strain differences, it is noteworthy that in various inbred mouse
strains a naturally occurring thymidine insertion within the coding region of the mouse
type HA SPLA2 gene has been observed (Kennedy e/ a/., 1995, MacPhee e/ a/., 1995).
In addition, the amino acid sequence deduced from platelet type IIA PLA2 cDNA
(Komada e/ a/., 1989) was found to be different from the previously determined amino
acid sequence of the purified platelet enzyme as published by the same research group
(Hayakawa e/ a/. 1988). In this case, the discrepancy between the two sequences was
also explained on the basis of strain differences. Accordingly, it could be taken into
consideration that the few basepair differences between the sequence cloned from the
heart in the present study, on the one hand, and the sequences cloned from spleen and
platelets, on the other, are due to the use of different rat strains. Indeed, the rat heart
type IIA SPLA2 cDNA of the present study was cloned from a heart cDNA library of
Wistar-Kyoto rats, while the platelet type ILA SPLA2 cDNA was cloned from a
megakaryocyte cDNA library of Sprague-Dawley rats (Komada ef a/., 1989).
The gene encoding rat type ILA SPLA2 has been cloned (Komada er a/., 1990)
and Southern blot analysis of genomic DNA revealed that only one single copy exists,
which would imply that type ILA SPLA2 cDNA s cloned from various cell types or
tissues should be identical or derived by differential splicing. However, Chen and
coworkers recently published cDNA sequences of two new, low molecular mass
PLA2S, one cloned from a rat genomic library and relatively abundantly present within
the heart and to a lesser extent within the lung (Chen e/ a/., 1994a), and the other
cloned from a rat brain library, the mRNA of which was detected in rat testis only
(Chen ef a/., 1994b). These sequences exhibit a limited homology to the type ILA
enzymes mentioned in the present study and was therefore designated type V SPLA2.
For instance, the cDNA of rat heart type ILA SPLA2 shows a homology of 64.5% and
43.8% at the DNA and protein level, respectively, with the sequence found by Chen
and coworkers (1994a) in the heart. For the testis enzyme these values are even lower
(59.7% and 29.5%, respectively). In addition, when screening a rat megakaryocyte
cDNA library for the cDNA of platelet type ILA SPLA2, Komada and coworkers
(1989) found two highly homologous sequences that differed at various positions,
which was taken as an indication for the presence of two or more type ILA isoforms.
The latter findings point to the existence of several isoforms of type II PLA2S in
mammalians. Accordingly, based on the available data no conclusive answer can be
given as to whether the observed minimal differences in the type ILA SPLA2 cloned
from various rat tissues/cells are due to strain differences and/or to the existence of
splice variants.
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Via Northern blotting analysis we examined the tissue distribution of the type IIA
SPLA2, yielding high levels of mRNA in the ileum, and lower levels in spleen, heart,
and soleus muscle, while no signal could be detected in EDL muscle, liver, lung, brain,
stomach, and kidney. More interestingly, the mRNA of type IIA SPLA2 was present in
isolated cardiomyocytes and cardiac-derived fibroblast-like cells, but not in the
immortalized cardiac-derived endothelial cell lines RHEC-116 and RHEC-50 as
assessed by Northern blotting and RT-PCR, which points to the absence of a type IIA
SPLA2 in the endothelial compartment of the heart. However, to definitively establish
whether type IIA SPLA2 is not expressed in endothelial cells under /« v/vo conditions,
/« SJTU hybridization experiments on myocardial tissue are required.
The low intensity of the hybridization signal in total heart and in the different
cardiac cell types suggests that the type HA SPLA2 is present at relatively low
abundance. This notion is supported by the finding that only one positive clone was
picked up after screening more than a million plaques of the commercial rat heart
cDNA library.
The presence of an eukaryotic secretory signal peptide at the N-terminal end of
the type ILA SPLA2 raises the question as to whether this enzyme will be secreted by
cardiac myocytes. Information about the localization of the other members of the type
IIA SPLA2 does not give a conclusive answer. In platelets the type IIA SPLA2 is
localized in secretory granula and is secreted after certain stimuli, the spleen type was
found to be membrane-associated, whereas the liver form was purified from the
mitochondrial fraction (Aarsman ef a/., 1989). Some insights into the possible
localization of the type ILA SPLA2 in the cardiac myocyte is provided by an
immunohistochemical study of Kriegsmann and colleagues (1993). Using a
monoclonal antibody raised against bee venom type II PLA2 they observed cross-
immunoreactivity at the level of the sarcolemma of cultured neonatal rat cardiac
myocytes, which could indicate that the enzyme cloned in the present study is also
membrane-associated.
Myocardial ischemia and reperfusion are associated with disturbances in phospholipid
homeostasis. The net loss of membrane phospholipids and concomitant accumulation
of lysophospholipids and fatty acids are likely to compromise cellular integrity (Van
der Vusse e/ a/., 1992). Earlier findings support the notion that the degradation of
phospholipids is directly due to the activation of myocardial phospholipases A2,
although an impairment of resynthesis processes cannot be excluded (Chien e/ a/.,
1984, Van Bilsen e/ a/., 1989).
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Northern blot analysis of stimulated neonatal cardiomyocytes. / I , Northern blot analysis of
type IIA SPLA2 mRNA in neonatal cardiomyocytes cultured for 16 h in serum-free
designated (-), in the presence of TNF-a (final concentration 1 nM) designated (T), or
phenylephrine (final concentration 10 |iM) designated (P). The signals in the RNA samples
obtained with the "P-labeled probe for rat heart type IIA SPLA2 and the 18S probe are
designated. £ , Quantitative presentation of Northern blot data. The PLAi signal was
normalized to the 18S signal. The PLA2/I8S ratio in control cells was set at 1.0. The
Northern blot data of two independent cell cultures are shown. In the other experiment the
degree of induction was comparable (4.3- and 1.5-fold for TNF-a and phenylephrine,
respectively).
Several lines of evidence suggest that type IIA SPLA2 plays a crucial role in the
hydrolysis of myocardial phospholipids under these pathological conditions. Firstly,
the composition of the fatty acids accumulating in the isolated rat heart after a period
of ischemia and reperfusion argue in favor of the involvement of an aspecific PLA2,
rather than an arachidonoyl-specific PLA2 (Van Bilsen e/ a/., 1989). Secondly, it has
been known that reperfusion is associated with the influx of massive amounts of
calcium, so that the activation of calcium-dependent phospholipases has to be
anticipated. Finally, some immunological evidence exists for a role of type ILA SPLA2
in ischemia/reperfusion induced membrane phospholipid degradation. In a study by
Prasad and colleagues (1991) it was shown that pretreatment of isolated rat hearts with
antibodies raised against a snake venom type HA SPLA2 effectively inhibited the
degradation of phospholipids and the release of cytoplasmic proteins during the acute
reperfusion phase. Furthermore, antibodies against a type II SPLA2 were found to
decrease the rate of phospholipid hydrolysis in homogenates of rat hearts that had been
subjected to a period of hypoxia and reoxygenation (Kikuchi-Yanoshita e/ a/., 1993).
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All these observations point to a role of type IIA SPLA2 in phospholipid degradation
and subsequent membrane destabilization after a period of ischemia and reperfusion.
Besides its requirement for calcium, very little is known about the regulation of
type IIA SPLA2S. The presence of a putative IL-6 responsive element in the 5' flanking
region of the type ILA SPLA2 gene has been demonstrated (Crowl ef a/., 1991). Upon
stimulation with lipopolysaccharides or cytokines, such as IL-1, IL-6 or tumor necrosis
fector-a, a rapid increase in type ILA SPLA2 mRNA and enzyme activity has been
observed in rat vascular smooth muscle cells (Nakano ef a/., 1990), in hepatoma cells
(Crowl ef a/., 1991), and in renal mesangial cells (Pfeilschifter er a/., 1989). Northern
blot data presented in this paper suggest that also in rat cardiac myocytes cytokines
stimulate the transcription of the type ILA SPLA2 gene. In addition, the present findings
indicate that the transcription level of type ILA SPLA2 enzymes is upregulated in
response to the (Xi-adrenergic agonist phenylephrine, suggesting that type IIA SPLA2
present in rat cardiac myocytes may be involved in the signalling pathways leading to
cardiac hypertrophy. It should be noticed, however, that at the concentration used in
the present study (10 uM), phenylephrine may also exert some ß-adrenergic effects. In
this respect, it is worth mentioning that in neonatal rat cardiomyocytes ß-adrenergic
receptor stimulation was also coupled to a rise in phospholipase A2 activity (Wallukat
e/a/, 1991).
In summary, a cDNA encoding the type ILA SPLA2 present in cardiac tissue was
cloned, predicting an enzyme that, on the basis of the presence of an eukaryotic signal
peptide, theoretically could be secreted from myocytes. Analysis of its tissue
distribution shows it to be expressed at high levels in ileum, and at lower levels in
heart, spleen, and soleus muscle. Within the heart it is present in cardiomyocytes and
fibroblasts, but probably not in endothelial cells. Stimulation of cultured rat neonatal
myocytes with TNF-a and PE shows an increase in the cellular level of mRNA coding
for this type ILA SPLA2, suggesting its involvement in cellular signal transduction. The
demonstration of the presence of a type HA SPLA2 in cardiomyocytes and its cloning
allow a more detailed analysis of the biological role of PLA2S in the heart.
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Chapter 4
Immunological determination of
type IIA secretory phospholipase A2
Abstract
In the present study the cDNA coding for type IIA phospholipase A2
(type IIA SPLA2) cloned from rat myocardium was used to generate
and purify a recombinant 6xHis-tagged type IIA SPLA2 from £. Co//
via a single step chromatographical procedure. The yield of purified
recombinant type HA SPLA2 typically amounted to 1 mg/liter £.Co//.
Against this purified fraction a polyclonal antibody was raised in
rabbit. The ability of this antibody to detect type IIA SPLA2 in a
number of cell types and tissues, including rat and mouse myocardium,
via Western blotting procedures was compared with four other anti-
small molecular mass PLA2 antibodies. It was found that all five
antibodies tested were able to detect purified recombinant type IIA
SPLA2. In addition, the detection level of a monoclonal antibody raised
against type IIA SPLA2 present in rat liver was limited to a purified rat
platelet fraction which contains relatively high amounts of type IIA
SPLA2. Finally, a commercially available polyclonal antibody
originally raised against recombinant human type IIA SPLA2 present in
synovial fluid specifically detected the protein not only in human and
rat platelets, but also in rat ileum. None of the antibodies tested,
however, was able to detect type IIA SPLA2 in cardiac tissue via
Western blotting procedures. These results provide strong indication
that under physiological conditions type IIA SPLA2 protein levels in rat
and mouse myocardium are relatively low and, hence, can not be
detected by Western blotting using the techniques preesently available.
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Phospholipase A2 (PLA2) catalyzes the hydrolysis of phospholipids to generate fatty
acids and lysophospholipids. To date, three major types of mammalian PLA2S can
be distinguished: high molecular mass cytoplasmic PLA2 (type IV CPLA2), 40 kD
Ca^-independent plasmalogen specific PLA2 (type VI iPLA2), and the Ca^-
dependent low molecular mass (14 kD) PLA2 (Van Bilsen er a/., 1995, Tischfield er
a/., 1997, De Windt er a/., 1998). The mammalian 14-kD PLA2S are subdivided into
a type I or pancreatic PLA2, type ILA or secretory PLA2 and type V PLA2. Type IIA
secretory phospholipase A2 (type IIA SPLA2) is present at high concentrations in rat,
mouse and human intestine (Ishizaki er a/., 1989, Nevalainen er a/., 1995, De Windt
er a/., 1997) and in the secretory granula of platelets (Aarsman er a/., 1989), while
varying amounts have been detected in most other tissues, among which cardiac
tissue (Ishizaki er a/., 1989, De Windt er a/., 1997).
Type IIA SPLA2 has been considered to play a role in the physiological
deacylation-reacylation cycle of phospholipids (Van Bilsen er a/., 1995, De Windt
er a/., 1998) and in signal transduction pathways involving the liberation of
membrane phospholipid-derived arachidonic acid in a number of cell types (Van
Bilsen er a/., 1995). Furthermore, type IIA SPLA2 activity may play a crucial role in
the degradation of membrane phospholipids leading to cellular injury as observed
during ischemia/reperfusion in the small intestine (Otamiri er a/., 1987), the brain
Lauritzen er a/., 1994) and the heart (Van der Vusse er a/., 1989, Van Bilsen er a/.,
1995, De Windt er a/., 1998). To study the pathophysiological role of type IIA
SPLA2 in the heart during ischemia and reperfusion the development of Western
blotting analyses to quantitate type IIA SPLA2 protein levels will be instrumental.
Furthermore, the availability of specific anti-sPLA2 antibodies will also enable
future immunohistochemical localization studies at the light or electron
microscopical level to determine the (sub)cellular localization of SPLA2 in the heart
and potential changes thereafter during ischemia and reperfusion.
A first attempt was made to detect cardiac type IIA SPLA2 in
immunoblotting analyses by using a previously described monoclonal anti-rat liver
type IIA SPLA2 antibody (De Jong er a/., 1987, Van Schaick er a/., 1993,
Kriegsmann er a/., 1993). This particular antibody, however, only detected type IIA
SPLA2 in rat platelets among the various tissues tested. Therefore we decided to
raise antibodies against type ILA SPLA2 ourselves, making use recombinant rat heart
type IIA SPLA2 and a bacterial expression system.
In the present study a recombinant rat heart type IIA SPLA2 was produced
and purified from £. Co// to near homogeneity via a single step Chromatographie
purification procedure. A polyclonal antibody was raised against the recombinant
rat heart type IIA SPLA2 in the rabbit. The presence of rat heart type IIA SPLA2 in
rat and mouse heart homogenates and various rat and mouse tissues was
investigated by immunoblotting using the polyclonal anti-rat heart type IIA SPLA2
antibody. The applicability of this antibody to detect type IIA PLA2 in Western
blotting experiments was compared to that of a number of monoclonal and
polyclonal anti-14 kD type II PLA2 antibodies recently developed by other research
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groups (Van Schaick ef a/., 1993, Kriegsmann e/ a/., 1993, Murakami e/ a/., 1998)
or commercially available.
Materials and Methods
Bovine serum albumin (BSA) was purchased from Boehringer Mannheim
(Germany). Tween-20, glycine, imidazole and glycerol were purchased from Merck
(Darmstadt, Germany). Urea and guanidine hydrochloride were purchased from
Sigma (St. Louis, MO, USA) and ICN Biochemicals (Cleveland, OH, USA),
respectively. Ni-NTA Agarose and Polyacrylamide were obtained from Qiagen
(Leusden, The Netherlands) and Bio-Rad Laboratories (Hercules, CA, USA),
respectively. Goat-anti-rabbit IgG/HRP complex (GARPO) and rabbit-anti-
mouse/HRP complex (RAMPO) were both purchased from Dako A/S (Glostrup,
Denmark). Monoclonal antibody against rat liver SPLA2 was a kind gift of Dr. Van
den Bosch. Monoclonal antibody against bee venom PLA2 was a kind gift of Dr.
Kriegsmann. Rabbit polyclonal antibody against rat platelet SPLA2 was a kind gift
of Dr. Murakami. Afa/a Afa/a venom PLA2 and porcine pancreatic PLA2 were
obtained from Sigma and Boehringer Mannheim, respectively. All other chemicals
used were of analytical grade and purchased from Merck.
For the generation and purification of the recombinant rat heart type IIA SPLA2 an
N-terminal 6xHis extension was applied, which allows rapid purification of target
proteins from £. Co// using a metal-chelating resin (TAe ö/v4ex/>res.s/om".s/, Qiagen,
Leusden, The Netherlands, Bush ef a/., 1991, Hofmann e/ a/., 1991). To produce N-
terminal 6xHis-tagged rat heart type IIA SPLA2 in £. Co//, a vector containing the
recently cloned full length rat heart type IIA SPLA2 cDNA (PCRII-PLA2) was
digested with Bel I to release a 479 bp fragment containing the complete rat heart
type IIA SPLA2 coding region except for the first 10 N-terminal amino acids (De
Windt e/ a/., 1997). The Bel I fragment was ligated into BamH I linearized pQE9,
pQElO and pQEll vectors, which were subsequently designated pQE9-PLA2,
PQEIO-PLA2 and pQEl I-PLA2, respectively. These vectors allow generation of N-
terminal 6xHis-tagged recombinant heterologous proteins in £. Co// (Figure 1).
Candidate clones were subjected to restriction analysis and sequenced using the T7
sequence kit (Pharmacia, Uppsala, Sweden). As expected, only PQEH-PLA2
contained the type IIA SPLA2 coding region in the correct reading frame (Figure 1).
To achieve high levels and tight regulation of protein expression, pQEl I-PLA2 was
transformed to the K12 derived £. Co// strain M15[pREP4] (Qiagen).
rom £. Co//
LB-broth (1 liter) containing 100 mg/ml ampicillin and 25 mg/ml kanamycin was
inoculated with £. Co//Ml5[pREP4](pQEl I-PLA2) and grown at 37 ...C under
vigorous shaking until a OD600 of 0.7 was reached. To induce recombinant 6xHis-
tag type IIA SPLA2 production in £. Co//, IPTG was added to the culture at a final
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concentration of 2 mM and the culture was continued to grow overnight. The next
day cells were harvested by centrifugation at 5,000 g for 10 min at 4 ...C. All
subsequent handlings were performed at room temperature, unless indicated
otherwise. The pellet was resuspended in 6 M guanidine hydrochloride, 0.1 M
NaH2PC>4, 0.01 M Tris (pH 8.0) in one tenth of the original culture volume and cells
were lysed by gentle vortexing and subsequent mixing for 30 min. After
centrifugation at 5,000 g for 10 min, 2 ml of Ni-NTA resin was added to the
supernatant and mixed gently for 30 min. To pellet the resin, the suspension was
centrifuged at 1,500 g for 5 min. The recombinant protein was allowed to renaturate
while immobilized to the Ni-NTA resin by repeated resuspension and recollection
of the resin by centrifugation in 500 mM NaCl, 20 % glycerol, 0.1 mM NaH2PÜ4,
0.01 mM Tris-HCl, pH 8.0, containing consecutively 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0,
1.0, 0.5, and 0.25 M Urea.'* The complete renaturation procedure lasted
approximately 2 h. After renaturation the proteins were eluted from the Ni-NTA
resin by addition of 2 column volumes of 0.25 M Urea, 500 mM NaCl, 0.1 mM
NaH2PO4, 0.01 mM Tris-HCl and 250 mM imidazole (pH 8.0). The eluted proteins
were extensively dialysed against PBS for 8 h at 4 ...C, aliquoted, and stored at —70
...C until further use. Typically, this procedure yielded 1 mg 6His-tag type IIA
SPLA2 per liter of £. Co// Ml5[pREP4](pQEl I-PLA2) culture.
Polyclonal antibodies were raised against purified recombinant soluble 6xHis-tag
rat heart type IIA SPLA2 in a Flemish giant rabbit by subcutaneous immunization
with 250 |ig purified recombinant 6xHis-tag type IIA SPLA2 in PBS dissolved in
Specol (Leenarts e/ a/., 1995; Specol:PBS 1:1 v/v). The injection fluid (2 ml) was
divided equally over a number of injection sites along the backside of the rabbit.
After four and five weeks the rabbit was boosted by intracuteneous injection of 250
|Xg 6xHis-tag type IIA SPLA2 in Specol (1:1 v/v). Six weeks after the first
immunization, the rabbit was boosted intravenously with 250 (i.g 6xHis-tag type IIA
SPLA2 in Specol and bleeded two days after the final boosting. Collected blood
(approximately 100 ml) was allowed to cloth on ice, centrifuged at 1,500 g for 10
min and the serum was stored at —70 ...C until further use. Before the first
immunization (0-serum) and two days after each boost, 2 ml of blood was collected
in glass tubes and allowed to cloth on ice. After centrifugation at 1,500 g for 10
min, the resulting serum was stored at —70 ...C until further use. The whole
porcedure was approved by the Institutional Animal Care and Use Committee of the
Maastricht University.
The titer of the antisera was assessed as described previously (Vork er a/.,
1991). Briefly, serial dilutions of the antisera collected (0-serum, 4-, 5-week
boosting, and final antisera) were added to a microtiterplate, previously coated with
10 ng of purified recombinant 6xHis-tag type IIA SPLA2. Detection was performed
by incubation of GARPO diluted 1:2,500 in phoshate buffered saline containing
0.34 mM NaCL, 0.1 % BSA and 0.05 % Tween-20, pH 7.4 (PBT) and visualized
using the TMP Enzymatic Kit (Roche Diagnostic Systems Inc., Somerville, NJ,
USA) according to the supplier s instructions. The titer of the antisera was defined
as the antiserum dilution at which the measured extinction amounted to 50 % of the
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maximal extinction and amounted to 0, 300, 800 and 1500 for the 0-serum, 4-, and
5-week boosting and final antiserum, respectively. > -
Tissues were homogenized in SET buffer (mM sucrose, 10 mM Tris-HCL, 2 mM
EDTA, 1 mM PMSF, pH 7.4; 1:10 v/v) on ice using a Ultra-Turrax T25 (IKA
Labortechnik, Staufen, Germany). Thereafter the homogenate was briefly sonicated
(Soniprep 150, Beun-De Ronde, Abcoude, The Netherlands). Platelets were isolated
from heparinized murine, rat and human blood by a one step centrifugation
procedure at 160 g for 15 min and brief sonification on ice. Liver and heart
subcellular fractions were obtained as described previously (Aarsman e/ a/., 1989).
Briefly, subsequent centrifugation steps of liver and heart homogenates at 600 g for
10 min, 3,600 g for 10 min, 10,000 g for 10 min, 26,500 g for 20 min and 104,000 g
for 60 min, resulted in fractions relatively enriched with nuclei and cell debris,
heavy, intermediate, and light mitochondria, a microsomal fraction and a cytosolic
fraction, respectively. Protein concentration of the homogenates was determined
using the Micro BCA Protein Assay (Pierce, Rockford, IL, USA) following the
manufacturer s instructions. Prior to sodium dodecyl sulfate - polyacrylamide
gelelectrophoresis (SDS PAGE) an identical volume of sample buffer (125 mM
Tris-HCl, 10 % glycerol, 10 % SDS, 5 % ß-mercaptoethanol, pH 6.8) was added to
the samples and the electrophoresis samples were heated to 100 ...C for 5 min. For
non-reducing SDS PAGE ß-mercaptoethanol was omitted from the sample buffer.
bestem
Proteins were separated by electrophoresis in 12 or 15 % polyacrylamide gels in the
presence of 0.1 % SDS. The separated proteins were either stained with Coomassie
Brilliant Blue, or were electrophoretically transferred to nitrocellulose membrane
(Protan, Schleicher & Schuell, Dassel, Germany). For Western blot analyses, non-
specific protein binding on the nitrocellulose filter was blocked by incubation with
phosphate-buffered saline (PBS; 10 mM phosphate, 154 mM NaCl, pH 7.4)
containing 1 % BSA, either for 2 h at room temperature or overnight at 4 jC under
continuous gentle shaking. First and secondary antibody incubation were performed
in PBT at room temperature under gentle shaking for 2 and 1 hrs, respectively. First
and secondary antibody preparations and their dilutions used in Western blotting
analyses are presented in Table I. After antibody incubations the filter was washed
four times with PBT under gentle shaking, treated with ECL Western blotting
detection system (Amersham, Buckinghamshire, UK) according to the
manufacturer s instructions and exposed to hyperfilm (Amersham).
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Figure 1
Overview of cloning strategy resulting in the construction of the bacterial expression vector
pQEl I-PLA2, which allows production of 6xHis-tagged SPLA2. In the upper panel the outline of
the PCRII-PLA2 plasmid is designated, containing the full length cDNA of rat heart SPLA2.
Digestion of pCRII-PLA2 with Bel I released a 479 bp fragment containing the major part of the
coding region and 80 bp of the 3 -untranslated region of rat heart SPLA2. Ligation of the latter
fragment into the BamH I site of the multiple cloning site of the pQEll vector resulted in the
production of a N-terminal 6xHis-tagged rat heart sPLAa in £.Co/;.
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Table I .
Overview of the antisera used in the present study.
Rat liver mitochondrial type HA SPLA2
6 x His-tag rat heart type ILA SPLA2
Bee venom type II sPLAj
Rat platelet type IIA SPLA2
Recombinant human type IIA SPLA2
RGD 6 x His-tag
Rabbit IgG
Mouse IgG
Monoclonal, IgG
Polyclonal
Monoclonal, IgG
Monoclonal, IgG
Polyclonal, IgG
Monoclonal, IgG
Gaot polyclonal, IgG
Rabit polyclonal, IgG
Di/urion
1:5,000
1:100
1:20
1:3,000
1:1,000
1:1,000
1:2,500
1:2,500
12
•
IS
16
17
• *
* « •
• • • *
*, Antibody raised against recombinant 6xHis-tag type IIA SPLA2 as described in the present study;
•*, recognizes N-terminal 6xHis-tag protein epitope with amino acid sequence R-G-H-H-H-H-H-H
(purchased from Qiagen, Westburg, Leusden, The Netherlands); ***, recognizes rabbit IgG and is
complexed with horseradish peroxidase (HRP; Dako A/S, Glostrup, Denmark);
mouse IgG and is complexed with HRP (Dako A/S, Denmark).
recognizes
Results
To detect the presence of type IIA SPLA2 protein in (subcellular) rat heart
(fractions), a monoclonal anti-rat liver type IIA SPLA2 antibody was first tested on
subcellular fractions of liver homogenates, relatively enriched with cell nuclei,
heavy, intermediate, and light mitochondria, microsomes and cytosol via
immunoblotting procedures. In contrast to earlier studies (De Jong e/ a/., 1987,
Aarsman e/ a/., 1989, Van Schaick e/ a/., 1993) using the identical antibody and
technical procedures, no signals were obtained in the various liver subcellular
fractions (lanes 1-6, Figure 2), despite several technical modifications, nor in a
number of subcellular heart and myocyte fractions (lanes 8-12, Figure 2),. However,
in all Western blot analyses a strong signal of the expected size (14 kDa) was
obtained in rat platelet fraction with the anti-rat liver type IIA SPLA2 antibody.
Platelets were included in the experiments since type IIA SPLA2 is relatively
abundantly present in these cells (lane 7, Figure 2).
SO
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Rat liver fractions
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Figure 2
Result of a typical immunoblotting experiment using a monoclonal anti-rat liver type IIA
SPLA2 antibody on a number of rat liver subcellular fractions (left panel) and rat heart
subcellular fractions (right panel). 1-6: rat liver fractions with 1, nuclei; 2, heavy mitochondria;
3, intermediate mitochondria; 4, light mitochondria; 5, microsomal fraction; 6, cytosolic
fraction. 8-12: rat heart subcellular fractions with 8, nuclei; 9, heavy mitochondria; 10,
intermediate mitochondria; 111, light mitochondria; 12, microsomal fraction; 13, cytosolic
fraction. Lanes 7 and 14 were included as a positive controls ( rat platelets). Black arrow
indicates expected size of type IIA SPLA2.
artö?/?wrz/?ca/7o« o/öx/Zw-tagged sPL^
To raise antibodies that detect rat heart type IIA SPLA2 immunoblots, recombinant
6xHis-tagged type IIA SPLA2 was produced as described in the Materials and
Methods section. After overnight IPTG induction of £. Co// M15[PREP4](pQEll-
PLA2) at 37 °C and purification using a Ni-NTA resin, a relatively pure protein
fraction was obtained consisting of a prominent 17-18 kDa band as determined by
Coomassie Brilliant Blue staining (solid arrow; Figure 3). In addition, two other
protein bands of lower intensity were co-purified in a highly reproducible manner: a
diffuse product smaller than the prominent 17-18 kDa band and one sharp band
which migrated as a 29 kDa band on SDS-PAGE (open arrows; Figure 3). The
slightly slower mobility of the intact 6xHis-tagged type IIA SPLA2 in SDS-PAGE
experiments compared to native type IIA SPLA2 (~ 14 kDa) might be due to the
presence of the 6 N-terminal histidine residues in addition to the 21 amino acids N-
terminal signal peptide of type IIA SPLA2, which is normally cleaved from the
mature protein.
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To confirm the specific
purification of a 6xHis-tagged
recombinant protein, non-
induced and IPTG-induced
£. Co// M15[PREP4](pQEll-
PLA2) and the chromato-
graphically purified products
were run on a 15 % SDS-PAGE
gel and subjected to
immunoblotting using a
monoclonal anti-His epitope
antibody. To control the
purification method and
specificity of the Ni-NTA resin,
£. Co// M15[PREP4](pQE16)
(provided by the manufacturer)
was IPTG-induced to produce a
25 kDa recombinant 6xHis-
tagged murine dihydrofolate
reductase (DHFR) and purified
using similar procedures as
described for the purification of
6xHis-tagged rat heart type IIA
sPLAj.
No signals were
obtained in the non-IPTG
induced £. Co// M15 [PREP4]
(PQEH-PLA2), while in protein
isolated from IPTG-induced
£. Co// two strong signals were
obtained, which electrophoresed
at similar heights as the Ni-NTA
agarose purified 17-18 kDa and
5-10 kDa proteins fractions.
In both IPTG induced £. Co// M15[PREP4](pQE16) crude lysates and the
purified fraction, 6xHis-tagged murine DHFR was specifically recognized by the
monoclonal anti-6xHis epitope antibody (data not shown). These results indicate the
production and specific purification of a candidate recombinant 6xHis-tagged type
IIA SPLA2 protein which migrates in SDS-PAGE electrophoresis as a 17-18 kDa
protein. The detection of the smaller protein fraction of 5-10 kDa with this antibody
points towards the co-purification of degradation products of 6xHis-tagged type IIA
SPLA2.
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Figure 3
Coomassie Brilliant Blue staining of total protein
in a 15 % SDS-PAGE gel. First lane, molecular
weight marker (MW); second lane, Ni-NTA
purified protein fraction of IPTG-induced £.Co//'
M15[PREP4](pQEll-PLA2> as described in the
Materials and Methods section.
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Figure 4
Coomassie Brilliant Blue total protein staining (left panel) and immunoblotting (right panel) of Ni-NTA purified 6xHis-tagged type IIA
SPLA2, pancreatic PLA2 and A/ia/a Maya venom PLA2 electrophoresed under reducing and non-reducing conditions. Solid arrow denotes the
recombinant 6xHis-tagged type IIA SPLA2 product of about 17-18 kD. For immunoblotting the rabbit polyclonal anti-6xHis-tagged type HA
SPLA2 antibody fraction was used.
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Figure 5
Result of a representative Western blot containing a number of rat and mouse tissues using the
polyclonal anti-recombinant rat heart type IIA sPLAj antibody. The molecular weights of the
molecular marker are indicated (MW). Naja Naja venom type PLA2 was included as a positive
control. Open arrow denotes product of expected size.
After using this purified fraction to raise antibodies in the rabbit, the cross-reactivity
of the polyclonal anti-6xHis tagged type IIA SPLA2 antibody was tested on purified
recombinant 6xHis tagged type IIA SPLA2, pancreatic PLA2 (type IA PLA2) and
Mo/a Afa/a venom PLA2 (type IB PLA2) in immunoblotting experiments. Figure 4
demonstrates differences in electrophoretic mobility of the three small molecular
mass PLA2S, prepared under reducing and non-reducing conditions, as demonstrated
after staining the gel with Coomassie Brilliant Blue (left panel; Figure 4).
Immunoblotting of an identical gel resulted in very strong signals in the
recombinant type HA SPLA2 lane, a weak signal in the lane with pancreatic PLA2
and a strong signal for jVa/'a Afa/a venom PLA2, following treatment of the protein
samples under reducing conditions (right panel; Figure 4). In contrast,
electrophoresis of the same preparations in the absence of reducing agents resulted
only in a strong signal for recombinant type IIA SPLA2 and no detectable signals for
pancreatic and Afa/'a Afa/a PLA2 (right Panel; Figure 4). The latter result indicates
that the polyclonal anti-6xHis-tagged type IIA SPLA2 antibody strongly reacts with
the purified 6xHis-tagged proteins under reducing as well as under non-reducing
conditions. In addition, the polyclonal anti-6xHis-tagged type IIA SPLA2 antibody
reacted to a lesser extent with reduced and non-reduced type IA and IB PLA2S as
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compared to the 6xHis-tagged type IIA SPLA2. A 29 kD product purified from
IPTG-induced £. Co// M15[PREP4](pQEl I-PLA2) gave rise to an additional and
reproducible strong signal in immunoblotting experiments, while the purified
degradation products of 5-10 kD only gave a weak and diffuse signal in the
immunoblot using the polyclonal anti-6xHis tagged type IIA SPLA2 antibody.
Figure 5 demonstrates the result of an immunoblot to detect the presence of
type IIA SPLA2 in a number of tissue homogenates using the polyclonal anti-6xHis
tagged type IIA SPLA2 antibody. As expected, the polyclonal anti-6xHis tagged
type IIA SPLA2 antibody readily detected 1 ug of Afa/a Atya PLA2 (indicated by an
open arrow; Figure 5). In contrast, despite many technical modifications and
antibody dilutions tested no signals of the expected mass of 14 kD could be
obtained in cell types and tissues which contain relatively high amounts of type IIA
SPLA2 such as rat platelets or rat ileum (Figure 5) or human platelets (data not
shown). As could be expected from the latter result, no signals of were ever
obtained in either rat or mouse heart homogenates (Figure 5).
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Figure 6
Representative Western blot obtained with monoclonal anti-bee venom type PLA2 containing a rat
ileum, rat platelets and rat heart homogenates. The molecular weights of the molecular marker are
indicated (MW). Recombinant 6xHis-tagged SPLA2 was included as a positive control. Solid arrow
denotes specific detection of a product of expected size in the 6xHis-tagged SPLA2 fraction.
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Figure 7
Immunoblots of Ni-NTA purified 6xHis-tagged SPLA2, pancreatic PLA2 and A^ aya A q^/a venom
PLA2 electrophoresed under reducing conditions. For immunoblotting both the rabbit
polyclonal anti-human synovial fluid SPLA2 antibody (left panel) and rabbit polyclonal anti-
6xHis-tagged SPLA2 antibody (right panel) were used. Solid arrow denotes the specific
detection of recombinant 6xHis-tagged SPLA2.
\C>
Figure 8
Representative Western blot obtained with polyclonal anti-human SPLA2 antbody containing human
platelets, rat platelets , rat ileum, rat heart and mouse heart homogenates. The molecular weights of
the molecular marker are indicated (MW). Recombinant 6xHis-tagged SPLA2 was included as a
positive control. Solid arrow denotes expected size of SPLA2 in the various fractions.
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Due to the above negative results, we decided to test anti-14 kDa PLA2 antibodies
recently produced by other investigators to explore whether rat heart type IIA
SPLA2 is present in cardiac tissue, using Western blotting. A monoclonal anti-bee
venom 14 kDa PLA2 antibody (Figure 6) and a monoclonal anti-rat platelet type IIA
SPLA2 antibody (data not shown) were tested on purified 6xHis tagged type IIA
SPLA2, rat ileum, rat platelet and rat or mouse heart homogenates. Figure 6 depicts a
representative result obtained with monoclonal anti-bee venom PLA2 in an
immunoblot containing rat ileum, rat platelets, rat heart and 1 |ig recombinant type
IIA SPLA2. The monoclonal anti-bee venom PLA2 antibody readily detected 1 (ig of
6xHis tagged type IIA SPLA2 fraction included as a positive control (Figure 6). In
contrast, no signals could be obtained in any other cell type or tissue tested under
conditions recommended by the suppliers.
Finally, a commercially available polyclonal anti-human synovial fluid type
IIA SPLA2 antibody was tested for its specificity to discriminate between different
types of PLA2. Figure 7 depicts two immunoblots each containing 1 u.g of 6xHis
tagged type IIA SPLA2, pancreatic PLA2 and Afa/a Afa/a PLA2, respectively, similar
to the immunoblot as depicted in Figure 4. The polyclonal anti-human recombinant
type IIA SPLA2 antibody detected specifically the 6xHis tagged type IIA SPLA2
(left panel; Figure 7). As a reference, the result obtained with the polyclonal anti-
6xHis tagged type IIA SPLA2 antibody in a similar immunoblot is depicted in the
right panel of Figure 7.
The ability of the polyclonal anti-human synovial fluid type IIA SPLA2
antibody to detect type IIA SPLA2 in human platelets, rat platelets, rat ileum and rat
and mouse total heart homogenates was tested. A strong signal was obtained both in
the 6xHis tagged type IIA SPLA2 and human platelets fractions (lanes 1 and 2;
Figure 8). The cross reactivity of this particular antibody, originally raised against
human recombinant synovial type IIA SPLA2, was demonstrated by the fact that
signals of about 14 kD were obtained rat platelet and in rat ileum homogenates
(lanes 3 and 4; Figure 8). In heart homogenates, however, no signals were observed,
not even so after increasing the amounts of cardiac protein (200 |0.g protein/lane)
and/or by increasing the concentration of the antibody 10 fold to a 100 x dilution
(data not shown).
Discussion
Experimental data on the quantity and subcellular distribution of type HA SPLA2 in
cardiac tissue are scarce. In the present study a number of anti-14 kDa PLA2
antibodies were tested for their ability to detect type IIA phospholipase A2 (type IIA
SPLA2) via immunoblotting procedures. Therefore, the availability of a sensitive
and functional anti-type IIA SPLA2 antibody would be helpful in obtaining more
specific information regarding the presence and localization of type IIA SPLA2 in
the myocardium. Western blotting procedures would further provide a relatively
straight-forward procedure to quantitate relative differences in SPLA2 protein levels
in cardiac tissue of transgenic mice generated with a cardiac-specific
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overexpression of type IIA SPLA2 in order to provide more insight into the possible
participation /« v/vo of SPLA2 in membrane degradation during cardiac ischemia
and reperfusion.
In Table 2 the results obtained in Western blotting experiments with the
antibodies tested in the present study are summarized. It was found that, in contrast
to earlier studies'"'^, a monoclonal antibody raised against type ILA SPLA2 present
in rat liver mitochondria was not able to detect type IIA SPLA2 in liver and heart
total homogenates or subcellular fractions. This particular antibody was able to
detect type IIA SPLA2 in a purified rat platelets fraction, a cell type that was
included in the present study as a positive control since a number of studies indicate
that type IIA SPLA2 protein is abundantly present in this particular cell type
(Aarsman e/ a/., 1989, De Jong e/ a/., 1993, Van Schaick e/ a/., 1993, Murakami e/
a/., 1988; Table 2). However, neither in ileum, which also contains relatively high
amounts of type IIA SPLA2, nor in cardiac tissue a signal could be detected.
Because of these results it was decided to produce a recombinant type IIA
SPLA2 protein using a type IIA SPLA2 cDNA recently isolated from a rat heart
cDNA library (De Windt e/ a/., 1997). The cloning strategy applied to obtain
recombinant type IIA SPLA2 involved the bacterial expression of a N-terminal
öxHistidine tag, which allows rapid and relatively easy purification of
heterologously expressed proteins (Bush er a/., 1991, Hofmann e/ a/., 1991). Using
this strategy a 6xHis-tagged type IIA SPLA2 was produced and purified to near
homogeneity with a typical yield of 1 mg total protein/liter 2s.Co/i culture. Against
this fraction a polyclonal antibody was raised in the rabbit. The resulting antibody
easily detected purified 6xHis-tagged type IIA SPLA2 fraction and other purified
types of PLA2S, which confirms that the antibody raised against 6xHis-tagged type
IIA SPLA2 contained antigenicity against this enzyme, but does not discriminate
between the different (sub)types of small molecular weight PLAj enzymes.
Unfortunately, this antibody did not demonstrate cross-reactivity with type IIA
SPLA2 present in rat or human platelet fractions or rat ileum homogenates, nor in rat
or murine cardiac homogenates (Table 2).
Therefore, it was decided to test a number of other antibodies used in other
studies to detect type IIA SPLA2 protein, albeit in other cell types or tissues than the
myocardium (Kriegsmann e/ a/., 1993, Murakami e/ a/., 1988, Dorsam e/ a/., 1995).
Two monoclonal antibodies, one originally raised against 14 kDa bee venom type
PLA2 and one against rat platelet type IIA SPLA2, gave similar results in Western
blotting experiments. Both antibodies were able to detect 6xHis-tagged type IIA
SPLA2, probably since this fraction contained relatively high amounts of the protein,
but failed to detect type IIA SPLA2 in platelets and rat ileum, both known to contain
high amounts of type IIA SPLA2, nor in cardiac homogenate (Table 2). This result is
unexpected since the latter antibody was actually raised against rat type HA SPLA2
purified from rat platelets (Murakami e/ a/., 1988). Up till now no satisfying
explanation for the negative results obtained with latter antibody fractions can be
provided.
Finally, a polyclonal antibody originally raised against type IIA SPLA2 from
human synovial exudate was tested in immunoblotting experiments (Dorsam ef a/.,
1995). With this commercially available antibody type IIA SPLA2 was readily
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detected in the purified 6xHis-tagged protein fraction. Moreover, signals of about
14 kD were obtained in positive control preparations such as human and rat
platelets and rat ileum (Table 2). Unfortunately, no type IIA SPLA2 protein could be
detected in cardiac homogenates, indicating that the levels of SPLA2 protein in the
heart are below the detection levels of immunoblotting detection procedures. The
latter finding lends further support to previously obtained circumstantial evidence of
relative low abundance of type HA SPLA2 in myocardial cells (De Windt e/ a/.,
1997). This notion was based on the findings that only one positive type IIA SPLA2
cDNA clone was obtained after screening over one million plaques of a rat heart
library. Additionally, low intensity of type IIA SPLA2 hybridization signals were
found in total heart and in different cardiac cell types in Northern blotting
experiments (De Windt e/ a/., 1997). Moreover, results from other studies
(Vervoordeldonk e/ a/., 1996, Nakano e/ a/., 1990) repeatedly indicate barely
detectable type IIA SPLA2 protein levels in various cell types or tissues under
physiological circumstances via immunoblotting procedures, either with the
antibodies of the present study or with other anti-type IIA SPLA2 antibodies. Only
after stimulating cells with) cytokines like TNFa and/or IL-lß or with a number of
growth factors a clear upregulation of type IIA SPLA2 protein levels and detection
in Western blots is obtained (Vervoordeldonk e/ a/., 1996, Nakano <?/ a/., 1990).
These findings are in line with our own observations that type IIA SPLA2 mRNA
levels are over five fold upregulated in cultured neonatal rat cardiomyocytes after
stimulation with TNFa or IL-lß (De Windt er a/., 1997). The results in the present
study suggest that under physiological conditions cardiac type IIA SPLA2 is present
in amounts difficult to detect by means of Western blots. Future application of
improved techniques, such as the use of radio-isotope imaging as an alternative
detection procedure (Hunger era/., 1994), might increase the sensitivity of type IIA
sPLAi Western blotting to a level allowing the detection of type IIA SPLA2 protein
normal cardiac tissue.
In summary, a number of anti-PLA2 antibodies were tested for their ability
to detect type IIA SPLA2 in non-stimulated cardiac tissue. It was found that all
antibodies used in the present study were able to detect a purified, recombinantly
expressed 6xHis-tagged type IIA SPLA2 albeit with different sensitivity. Only a
monoclonal anti-rat liver type IIA SPLA2 antibody and a commercially available,
polyclonal anti-human synovial fluid type IIA SPLA2 antibody were able to detect
type IIA SPLA2 in rat platelets and/or rat ileum to some extent, both preparations
containing relatively high amounts of type IIA SPLA2. However, none of the
antibodies tested were able to detect type IIA SPLA2 in non-stimulated cardiac
homogenate, which indicates that relatively low amounts of type IIA SPLA2 are
present in cardiac tissue under physiological circumstances.
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Table II
Summery of results obtained in immunoblotting experiments with five seperate antibodies in
detecting SPLA2 in purified fractions and in a number of tissues and cell types.
Antigen 6xHis-tag Pancreatic
SPLA2 sPLA,
A/q/a A/q/a
venom
SPLA;
Rat/human Rat ileum Rat
platelets heart
Antibodies tested
Monoclonal anti-rat
liver SPLAT
Polyclonal anti-
6xHis-tag SPLA2
Monoclonal anti-rat
platelet SPLA2
Monoclonal anti-bee
venom sPLAi
Polyclonal anti-
human SPLA2
ND ND
ND
ND
ND
ND
ND, not determined; ++, strong specific signal obtained against antigen; +, specific signal
obtained against signal; +/- weak, but specific signal obtained against antigen; -, no signal
obtained against signal.
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Chapter 5
Functional and metabolic evaluation
of an improved isolated, left ventricular
ejecting murine heart model.
LJ De Windt, J Willems, RS Reneman, GJ Van der Vusse, T Arts, M Van
Bilsen. An improved isolated, left ventricular ejecting, murine heart model.
Functional and metabolic evaluation. £V./f7j)>.sio/(Pagers .4 rc///v,)
1999;437:182-190.
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Abstract
An improved isolated, left ventricular ejecting murine heart
model is described and evaluated. Special attention was paid to
the design and impedance characteristics of the artificial aortic
outflow tract and perfusate composition, which contained
glucose (10 mM + insulin), and pyruvate (1.5 mM) as substrates.
During antegrade perfusion (preload 10 mm Hg, afterload 50
mm Hg, 2.5 mM Ca^) proper design of the aortic outflow tract
provided baseline values for cardiac output (CO), left ventricular
developed pressure (LVDP) and the first maximal derivative of
left ventricular pressure (LV dP/dWx) of 11.1 - 1.7 ml.min"', 83
- 5 mm Hg and 6283 - 552 mm Hg.s"', respectively, resembling
findings in the intact mouse. During 100 min of normoxic
antegrade perfusion CO decreased by less than 10 %. Varying
pre and afterload resulted in typical Frank-Starling relationships
with maximal CO values of 18.6 - 1.8 ml.min*' at pre and
afterload pressure of 25 and 50 mm Hg, respectively. Left
ventricular function curves were constructed at free [Ca^*] of 1.5
and 2.5 mM in the perfusion medium. Significantly higher
values for CO, LVDP and LV dP/dt™* and LV dP/dt„,,„ were
obtained at 2.5 mM Ca~* at all loading conditions investigated.
Phosphocreatine and creatine levels remained stable throughout
the perfusion period. Despite a small but significant decline in
tissue ATP content, the sum of adenine nucleotides did not
change during the normoxic perfusion period. The tissue content
of glycogen showed a statistically significant increase.
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Introduction *•?;; ' r
Advances in molecular biology have made it possible to experimentally alter the
mammalian genome allowing the elucidation of the functional role of specific genes
in the whole animal. Transgenic or gene targeting techniques have contributed to
these advances. In this respect, the mouse is the animal model of choice, because of
the relative ease by which DNA can be stably introduced into the germline and the
availability of embryonic stem cell lines for gene-targeting. In cardiovascular
research an increasing number of genetically altered murine models are being
generated, which have proven to be of great importance for a better understanding
of the underlying mechanisms in complex cardiovascular disorders (Chien, 1996,
Franz era/., 1997).
Prerequisite for the evaluation of these cardiovascularly relevant altered
murine phenotypes are adequate techniques to measure cardiac function. Efforts
have been made to assess cardiac performance in the anesthetized open-chest mouse
(Barbee er a/., 1992, Milano er a/., 1994, Lembo er a/., 1996) and in the
anesthetized or conscious closed-chest mouse (Hartley er a/., 1995, Tanaka er a/.,
1996, Lorenz er a/., 1997). In studies on cardiac function and metabolism, however,
the use of isolated heart preparations is preferred, because hemodynamic
performance can be assessed in a standardized way, while possible interferences
such as changes in sympathetic drive, peripheral resistance, substrate supply and
circulating hormone levels are avoided. For this purpose, isolated retrogradely
perfused murine heart models have been developed independently by a number of
investigators (Ng er a/., 1991, Manier er a/., 1995, Plumier er a/., 1995, Radford er
a/., 1996, Yoshida er a/., 1996, Li er a/., 1997, Matheme er a/., 1997). Although
these so-called Langendorff heart preparations are of use for specific applications,
the antegradely perfused or left ventricular ejecting heart preparation is generally
preferred, because of its more physiological resemblance and because cardiac
performance can be analyzed more accurately. The development of such a model,
however, is not without problems. Hemodynamic function in terms of cardiac
output and contractility of the isolated ejecting mouse heart reported in previous
studies (Ng er a/., 1991, Bittner er a/., 1996, Gauthier er a/., 1998a and 1998b)
differs markedly from the performance reported in the intact mouse (Barbee er a/.,
1992, Milano er a/., 1994, Hartley er a/., 1995, Lembo er a/., 1996, Lorenz er a/.,
1997, Kassera/., 1998).
In the present study we developed an improved isolated, left ventricular
ejecting mouse heart model paying special attention to the impedance
characteristics of the aortic outflow tract, and to perfusate composition and
temperature. The stability of the murine heart in this model was investigated during
prolonged normoxic perfusion (up to 100 min), using cardiac output, left ventricular
developed pressure and the first maximal and minimal derivatives of left ventricular
pressure as variables. Metabolic consequences of prolonged normoxic perfusion in
this model were evaluated by measuring the tissue content of high energy
phosphates and glycogen. Left ventricular function curves were obtained by
stepwise variations of pre and afterload. The effect of perfusate calcium
concentration on hemodynamic performance was addressed by varying preload,
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using perfusion media containing either 1.5 or 2.5 mM nominally free Ca . - =
Materials and methods
All chemicals used for the Krebs-Henseleit solution were of the highest grade
available and purchased from Merck (Darmstadt, Germany) except for D(+)-
glucose and pyruvate (Sigma Chemical Co., St. Louis, MO, USA).
An assisted-mode perfusion
system was used, which
ensures proper coronary
perfusion by an automatic
switch from antegrade to
retrograde perfusion when the
heart is temporarily unable to
generate its coronary perfusion
in order to avoid unwanted
underperfusion of the heart
(Snoeckx *?/ a/., 1986, Van
Bilsen e/ a/., 1991). The
perfusion system was placed in
a temperature adjustable cage,
the temperature of which was
maintained at 38.5 jC. From a
water-jacketed reservoir
(38.5 jC) the perfusion fluid
was pumped at a rate of
0.5 l.min"' through a Millipore
filter (pore size 1.2 urn) into a
1.0 1 bottle to suppress pressure
pulsations generated by the
pump. The perfusion solution
passed through a film-
oxygenator and was returned to
the reservoir via an overflow
(Figure 1).
In this way the total
buffer solution was circulated,
filtered, oxygenated and
temperature controlled. The
perfusion solution was
periodically checked for pH,
pC>2 and pCC<2.
Oxygenator
Figure 1
Schematic representation of the perfusion system for left
ventricular ejecting mouse hearts, /frrowi indicate the
direction of the perfusate flow, Ä: variable resistance used
to adjust perfusion pressure (retrograde perfusion) or
afterload pressure (antegrade perfusion), S/ bubble trap in
aortic line, 5.» compliance chamber, ß j bubble trap in
venous return line, F/ IN inline flow probe, Fj 2N inline
flow probe, /4OP aortic pressure transducer, LKP left
ventricular pressure transducer.
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pH values ranged between 7.40 and 7.45, while pC>2 exceeded 650 mm Hg.
Aortic pressure was regulated by the air compression in the bottle and by a variable
hemodynamic resistance (R) placed between bubble trap Bi and the film-
oxygenator. An inline IN flow probe (Fi; Transonic System Inc., Ithaca, NY, USA)
was placed between bubble trap Bi and the compliance chamber (B2) to measure
retrograde and antegrade aortic flow. Left atrial filling pressure was determined by
the height of the overflow level in the film-oxygenator. Entry of air-bubbles, if any,
was prevented by a bubble trap (B3) in the left atrial filling line. An inline 2N flow
probe (F2; Transonic System Inc.) was placed before bubble trap B3 to measure
atrial filling flow (venous return). •*'*;
Design o///?e aorf/c ou(/2W /rac7
In the design of an artificial system for isolated ejecting hearts, the hemodynamic
characteristics of the aortic conduit are often neglected. This may result in a too
high aortic impedance, leading to an unphysiologically high pressure load to the left
ventricle, and subsequently to poor performance of the isolated heart (Van Bilsen er
a/., 1991). To avoid this situation, the aortic conduit was designed to match the
hemodynamic characteristics of an isolated murine heart. The most critical part of
the artificial aortic outflow tract is the short, rigid cannula between the heart and the
compliance chamber distal to the aortic cannula. The major determinants of the
pressure drop over the cannula are fluid mass acceleration (inertia term) and the loss
of kinetic energy in the distal jet stream (Bernouilli term) (Van Bilsen e/ a/., 1991).
The viscous losses in the Poisseuille term appear to be negligible. The pressure drop
in the cannula should be kept below 4 kPa (31 mm Hg). Setting the pressure loss
(Pbem) due to the Bernouilli term to this maximum leads to the following condition
for the internal diameter d of the cannula:
(1)
where k, = a constant, AOF = mean aortic flow and p fluid density. Substitution of
realistic values in equation (1), i.e., AOF = 0.25 ml.s' (Barbee <?/ a/., 1992), p =
1050 kg.m "^  and k| = 24, results in d > 0.79 mm. To make the design of the cannula
less critical, the internal cannula diameter should be chosen as large as possible. In
our set-up we were able to set the diameter at d = 0.92 mm.
An important second design criterium is to keep the fluid inertia term of the
pressure drop, Pj„ert, below about 2 kPa (15.5 mm Hg). This condition results in a
maximum value for the length of the cannula /:
Substituting for the diameter ^ = 0.92 mm, for the cardiac cycle duration tcyde = 150
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ms, for Pj„e„ = 2 kPa (15.5 mm Hg) and for k2 = 237, yields / < 4.1 mm. Based on
these estimations an aortic cannula was made with a length of 4.0 mm and inner
diameter of 0.92 mm. The outer diameter was 1.1 mm, which was just small enough
for attachment of the murine aortic stump to the cannula (Hartley e/ a/., 1995). A
schematic drawing of the cannula is presented in Figure 2.
. 9.0 mm
(5.9 mm
S.flmm
, 0 0.(54 mm
0.92 mm
N H
5.0 mm
Figure 2
Detailed schematic representation of the dimensions of the
outflow tract. y4 indicates the cannula to which the aorta of the
heart is attached. The inner diameter (0A) is 0.92 mm. The
position of the aortic pressure outlet (5) is shown with an inner
diameter (0B) of 0.64 mm.
am/surgery
Adult female and male Swiss mice (Iffa Credo, Lyon, France), average body
weights 33.7 - 3.1 g and 46.1 - 1.6 g, respectively, were kept under standard
housing conditions with an artificial 12 h light cycle. The animals had free access to
food (Diet SRM-A, Hope farms, Woerden, the Netherlands) and tap water.
Experiments were approved by the Institutional Animal Care and Use Committee of
the Maastricht University.
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Before surgery, the mice
underwent mild CO2
anesthesia followed by a
50 mg.kg*' sodium
pentobarbital injection i.p.
(Nembutal, Sanofi Sante
BV., Maassluis, the
Netherlands). After
thoracotomy the hearts
(average weight of 197 -
29 and 266 - 26 mg, and
heart weight/body weight
ratio of 5.9 - 0.9 and 5.8
- 0.5 mg.g"' for female
and male mice ,
respect ive ly) were
quickly excised and
placed in ice-chilled
perfusion buffer. After
removal of remnant lung
and fat tissue, the aorta
was connected to the
aortic cannula and
retrograde perfusion was
started immediately at a
perfusion pressure of 50
mm Hg, after which the
hearts started to beat
spontaneously. The left
atrium was cannulated
with an atrial 20-gauge
cannula
(inner diameter 0.64 mm, outer diameter 0.90 mm, length 10.6 mm) through one of
the lung veins.
Left ventricular pressure was measured with a PE-50 catheter, inserted into
the left ventricular cavity through the apex, connected to a Baxter Pressure
transducer (Baxter Healthcare Corp., Irvine, CA, USA). Aortic pressure was
measured through a side branch of the aortic cannula, located 3 mm above its
entrance (Figure 2).
The hearts were perfused with a modified Krebs-Henseleit solution,
consisting of (in mM): NaCl (118), KC1 (4.7), CaCb (3.0), MgSC>4 (1.2), KH2PO4
(1.2), NaHCOj (25), Na-EDTA (0.5), D(+)-glucose (10) and Na-pyruvate (1.5),
which was gassed with carbogen (95% O2, 5% CO2). Due to the presence of 0.5
mM EDTA, the nominally free calium concentration of this perfusion medium was
2.5 mM. Insulin (5 U/l) was added to the perfusate. Due to losses (sticking to the
glass wall of the perfusion system) the final insulin concentration in the circulating
69
Table I
Hemodynamic values measured in isolated, ejecting
Swiss mouse hearts after 20 min of perfusion to allow the
hearts to adapt to the working mode.
197 ±29
11.111.7
7.0 ±2.1
4.1 ± 1.3
29 ±5
88 ±5
5±3
6,283 + 552
-3,374 ± 293
Data are expressed as means ± SD (n=8). Hearts were
paced at 380 beats.min-1, pre- and afterload pressures
were 10 and 50 mm Hg, respectively. HW, heart weight;
CO, cardiac output; AOF, aortic flow; CF, coronary flow;
SV, stroke volume; LVSP, left ventricular systolic
pressure; LVEDP, left ventricular end-diastolic pressure;
LV dp/dt™*, first maximal derivative of left ventricular
pressure; LV dP/dtm,n. first minimal derivative of left
ventricular pressure.
C/rapter 5
perfusion medium amounted to 0.15 U/l as determined by an insulin
radioimmunoassay (Amersham, Buckinghamshire, UK).
During preliminary experiments the performance of the isolated perfused
murine heart was found to be highly sensitive to temperature fluctuations. Therefore
efforts were undertaken to avoid excessive cooling of the hearts due to, for instance,
evaporation of moisture from the epicardial surface. Moreover, the perfusate
entering the heart was consistently 38-39 jC, similar to core body temperatures in
the mouse (Conroy e/ a/., 1980, Miller e/ a/., 1994).
data
All hemodynamic variables were continuously recorded on a personal computer,
using specialized software (Hemodynamic Data Acquisition System, Technical
Department Maastricht University), allowing the on-line acquisition, calculation
and presentation of aortic flow (AOF), left ventricular systolic pressure (LVSP), left
ventricular end-diastolic pressure (LVEDP), diastolic aortic pressure (AOPD) and
the first maximal and minimal derivatives of left ventricular pressure (LV dP/dtmax
and LV dP/dtmm)- Left ventricular developed pressure (LVDP) was defined as the
difference between LVSP and LVEDP. Cardiac output (CO) was defined as the sum
of aortic flow (AOF) and coronary flow (CF). CF was determined from the
difference between aortic flow (AOF), as measured by flow probe Fi, and left atrial
filling flow, as measured by the inline flow probe F2 (Figure 1).
In a separate test, it was investigated whether LV dP/dtmax was limited by
the frequency response of the pressure transducer (Baxter). In a closed container a
pressure step was induced with a rise time of 2 ms as measured with a Millar
pressure transducer. The rise time of the pressure measuring system used in the
present study was 3 ms. The rise times of LVP as measured experimentally were
found to be about five times higher, i.e., 15-20 ms. Therefore, it can be concluded
that measured LV dP/dt,™« was not limited by the frequency response of the
pressure measurement system.
In the experiments to test the stability of the preparation, antegrade perfusion was
started by opening the left atrial conduit after an initial 10 min retrograde
stabilization period at 50 mm Hg. The hearts were perfused at a left atrial filling
pressure (preload) of 10 mm Hg, while diastolic aortic pressure (afterload) was kept
at 50 mm Hg. Five minutes after the onset of antegrade perfusion, the hearts were
paced via platina electrodes attached to the right atrium at a rate of 380 beats.min"'
until the end of the experiment, i.e., 100 min after the onset of antegrade perfusion.
After completion of the experiments the ventricles of the individual hearts were
separated from the atria and immediately frozen between aluminum clamps,
previously cooled in liquid nitrogen, and stored at -80jC for further analysis. In a
separate series of experiments, hearts were normoxically perfused for a 20 min
stabilization period, after which the ventricles of the individual hearts were
separated from the atria and immediately freeze clamped between aluminium
clamps, previously cooled in liquid nitrogen, and stored at -80 °C for further
biochemical analysis.
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In another series of . ; :• / ^ > . ^iqn»^ &ri)
experiments left ventricular • : • ; . ; - : , inifiiisdsui
function curves were
constructed by increasing
left atrial filling pressure
stepwise from 10 to 15, 15
to 20, and from 20 to 25 mm
Hg at diastolic afterload
pressures of 50, 75 and 100
mm Hg, respectively. At
each preload pressure the
paced hearts (380 beats,
min"') were allowed to
stabilize for 5 min during
which hemodynamic data
were recorded. After
completion of data
collection at the maximal
preload pressure, hearts
were allowed to recover in
the antegrade mode for 10
min at baseline loading
conditions (i.e., preload
pressure of 10 mm Hg,
afterload pressure of 50 mm
Hg), after which the next
function curve was
performed.
In a third series of
experiments the influence of
different free Ca* *
concentrations in the
perfusate (1.5 and 2.5 mM)
on left ventricular function
was investigated.
To this end male murine hearts were perfused in an antegrade manner with
Krebs-Henseleit perfusion medium containing 1.5 mM nominally free Ca^ (2.0
mM CaCh plus 0.5 mM Na-EDTA). Hearts were allowed to equilibrate for 20 min,
after which left ventricular function curves were constructed by increasing preload
pressure in a stepwise fashion from 10 to 15, 15 to 20, and 20 to 25 mm Hg at a
constant afterload pressure of 50 mm Hg. At each preload pressure the hearts were
allowed to stabilize for 5 min during which LVP, AOP, CO, AOF and CF were
recorded. After data collection at the maximal preload pressure, the hearts were
allowed to recover in the antegrade mode for 10 min at pre and afterload pressures
of 10 and 50 mm Hg, respectively. Hereafter CaCb was added to the perfusion
medium to a nominally free Ca^* concentration of 2.5 mM. Hearts were allowed to
equilibrate for 10 min, whereafter the same experimental protocol was followed.
200 300
Time (ms)
Figure 3
Typical recordings of left ventricular pressure curves of a
normoxically perfused, isolated ejecting mouse heart.
Depicted are left ventricular preessure tracings at a preload
pressure of 10 mm Hg and an afterload pressure of 50 mm
Hg.
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During the complete experiment hearts were paced at 400 beats.min"' due to the
slightly higher intrinsic heart rate of the murine hearts.
To assess the lactate content in the coronary effluent, samples of 1 ml were
immediately frozen in liquid nitrogen and stored at -80 jC for further analysis. To
stabilize lactate dehydrogenase (LDH) activity in coronary effluent samples, bovine
serum albumin was added to the samples (final concentration 3 %), after which they
were frozen in liquid nitrogen and stored at -80 jC. Lactate and LDH in the
coronary perfusate were assessed spectrophotometrically using a Cobas Bio
autoanalyzer according to the method of Bergmeyer and Bemt ((1974) and Apstein
e/ a/. (1970), respectively. Tissue contents of high energy phosphates [adenine
nucleotides, (phospho)creatine] and glycogen were determined as described
previously (Van Bilsen er a/., 1991, Van der Vusse ef a/., 1994).
The results are presented as mean values - standard deviations (SD). Differences
within and between groups were evaluated for statistical significance using
Student s t-test for paired and unpaired data, respectively. P values < 0.05 were
considered to be statistically significant.
Results
and .v
The baseline values of the various hemodynamic variables as measured 20 min after
the start of antegrade perfusion are presented in Table 1. Under the conditions
applied (10 mm Hg preload pressure; 50 mm Hg afterload pressure; pacing at 380
beats.min') AOF, CF and CO amounted to 7.0 - 2.1, 4.1 - 1.3 and 11.1 - 1.7
ml.min"', respectively. Values of 88 - 5, 5.0 - 3.2 and 8 3 - 5 mm Hg were found
for left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure
(LVEDP) and left ventricular developed pressure (LVDP), respectively. A
representative tracing of a left ventricular pressure curve measured under basal
conditions (pre and afterload pressures of 10 and 50 mm Hg, respectively) is shown
in Figure 3.
To test the stability of the preparation, hearts were antegradely perfused for
100 min. During this period CO decreased by about 10 % (Figure 4). No significant
changes were observed in LVEDP between the onset (6.0 - 3.2 mm Hg) and the
end of antegrade perfusion (6.4 - 4.1 mm Hg). LVSP, and consequently LVDP,
showed a decline of about 20 %. LV dP/dtn™ decreased by about 25 %, whereas LV
dP/dtm,n did not change significantly (Figure 4). The changes in hemodynamic
function were confined to the first 40 min of perfusion, whereafter cardiac function
did not show a statistically significant change.
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Figure 4
Cardiac output (CO) and coronary flow (CF; upper panel), left ventricular developed pressure
(LVDP; middle panel), and in the lower panel the first maximal and minimal derivative of left
ventricular pressure (LV P/dt^« upper trace and LV dP/dt^m lower trace, respectively) as a function
of time in the normoxically perfused, isolated working mouse heart under basal conditions (10 and 50
mm Hg pre- and afterload, respectively). Data are expressed as means ± SD (n = 8). * P < 0.05
vs value after 20 min of normoxic perfusion.
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Tissue content of phosphocreatine (PCr), creatine (Cr) and their sum [X (PCr + Cr)]
after 20 min normoxic perfusion amounted to 33.3 - 9.0, 36.6 - 6.4 and 69.9 - 12.0
|imol per g dry weight ventricular tissue, respectively, and did not change
significantly during the additional 80 min of normoxic perfusion (Table 2). After 20
min of perfusion the tissue content of adenine nucleotides, ATP, ADP and AMP,
amounted to 18.9 - 2.0, 4.3 - 0.5 and 0.6 - 0.1 umol.g"' dry weight ventricular
tissue, respectively. During the additional perfusion period of 80 min the tissue ATP
content decreased slightly (Table 2), while no significant reduction in the total
adenine nucleotide content [X (ATP + ADP + AMP)] was observed. The energy
charge of the isolated ejecting murine hearts did not change between 20 and 100
min of normoxic perfusion. In contrast, ventricular glycogen content of the isolated
ejecting murine hearts increased from 245 - 68 after 20 min to 409 - 100 |imol.g"'
dry weight after 100 min of normoxic antegrade perfusion.
Additional indication of the stability of the working heart preparation is
provided by the finding that LDH (45 - 22 and 22 - 20 mU.min"' .heart"', onset vs.
end; N.S.) and lactate (0.60 - 0.12 and 0.91 - 0.23 |imol.min"'.heart"', onset vs. end;
N.S.) release into the coronary effluent did not change between the onset (0-10 min)
and the end of antegrade perfusion (90-100 min).
curves
Left ventricular functions curves resembling Frank-Starling curves were constructed
by varying both pre and afterload. At an afterload pressure of 50 mm Hg a marked
rise in CO was observed in response to the stepwise elevation of preload pressure,
increasing from 12.0 - 0.6 to 18.6 - 1.2 ml.min"' at preload values of 10 and 25 mm
Hg, respectively (Figure 5, Panel A). As expected, the increases in CO were less
pronounced at afterload pressures of 75 mm Hg and 100 mm Hg (Figure 5, Panel
A). At all afterload pressures CF increased approximately 1.5 fold from the lowest
to the highest preload pressure level tested, reaching maximal values of 7.8 - 2.3
ml.min"' at an afterload pressure of 100 mm Hg (Figure 5, Panel A). LVEDP
substantially increased when preload pressure was enhanced (Figure 5, Panel B).
In general the left ventricular end-diastolic pressure (LVEDP) measured was lower
than the preload pressure applied by the height of the oxygenator overflow level.
Interestingly, at an afterload pressure of 50 mm Hg the preload dependent increase
in CO observed (Figure 5, Panel A) was not associated with significant rises in
LVSP and LV dP/dtmax (Figure 5, Panel B and C). In contrast, at afterload pressures
of 75 and 100 mm Hg, LVSP and LV dP/dUax displayed preload-dependent
elevations (Figure 5, Panel B and C). LV dP/dtmm did not show a preload dependent
change at any afterload tested, but showed a more negative value at 75 and 100 mm
Hg, indicating faster relaxation, than at 50 mm Hg.
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Table II
Tissue content of phosphocreatine (PCr), creatine (Cr), ATP, ADP, AMP, energy charge and
glycogen of isolated left ventricular ejecting mouse hearts after 20 and 100 min of
normoxic, antegrade perfusion.
Dura/ion o/per/us/on
f/x/wo/.g cfry weign/,) 20 . ' /00
• ' '- ' " 31.3 ±4.7
PCr . 36.6±5.9 ' J 4 „^ 34.2±6.2
Cr 69.9 ±10.9 -;>s 65.6 ±5.4
33.3 ±
.6 
+
18.9 ±
4.3
0.6
23.8
0.89
8.2
5.9
10.
1.8
±0.4
±
±
±
0.1
2.0
0.01
.Energy c«arge
G/ycogen fg/wcose
15.3 ±1.4*
4.6 ±1.0
0.7 ± 0.4
20.6 ±1.6
0.86 ± 0.04
245±68 43^,,4*
Values are presented as means ± SD (both groups n = 6). Energy charge is defined as
(ATP + 0.5 ADP)/(ATP + ADP + AMP) and is unitless.
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To test the effect of the perfusate calcium concentration on cardiac performance,
left ventricular function curves were constructed at 1.5 mM and 2.5 mM free
calcium. At both concentrations typical Frank-Starling curves were obtained by
increasing the preload pressure in a stepwise manner from 10 to 25 mm Hg with
intervals of 5 mm Hg at an afterload pressure of 50 mm Hg. In both the low and
normal calcium group a significant rise in CO was observed in response to the
stepwise elevation of preload pressure. In the low calcium group CO increased from
75
11.9 - 2.6 to 14.9 - 3.3 ml.min' (P < 0.05) when elevating preload pressure from
10 to 25 mm Hg (Figure 6). At the preload pressures tested CO values were
significantly higher in the 2.5 mM Ca^ * group, increasing from 14.5 - 2.0 ml.min'
to 21.8 - 2.6 ml.min"', when elevating preload pressure from 10 to 25 mm Hg
(Figure 6). Similarly, AOF values were about 45 % lower in the low extracellular
calcium group over the whole range of loading conditions tested (7.0 - 1.9 and 9.9
- 1.9 ml.min"' at preload pressure of 10 and 25 mm Hg, respectively) as compared
to those measured at a nominally free Ca^ concentration of 2.5 mM (9.9 - 1.4 and
14.2 - 2.2 ml.min' at preload pressure of 10 and 25 mm Hg, respectively). In
contrast, in both groups CF increased approximately 1.6 fold from the lowest to the
highest preload pressure tested and did not demonstrate a significant difference
between the two groups at corresponding loading conditions. LVEDP values
demonstrated preload dependent elevations, but did not show significant differences
between both groups at all corresponding preload pressures tested. In the low
calcium group LVSP, LV dP/dWx and LV dP/dUn amounted to 80 - 16 mm Hg,
5100 - 1617 mm Hg.s' and -2885 - 476 mm Hg.s', respectively, at baseline
loading conditions. Elevation of the Ca^-concentration in the perfusion medium to
2.5 mM resulted in significantly higher values for LVSP, LV dP/dt^ax and
LVdP/dt™„ (109 - 17 mm Hg, 7480 - 1632 mm Hg.s"' and -3537 - 705 mm Hg.s"',
respectively) at similar pre and afterload pressures.
Discussion
In the present study an improved isolated working mouse heart model is described.
In developing this model special attention was paid to the characteristics of the
aortic outflow tract and the composition and temperature of the perfusion medium.
The design of the aortic outflow tract is critical to avoid a too high aortic impedance
and, hence, a too high load to the ejecting left ventricle (Van Bilsen er a/., 1991). A
high impedance of the aortic outflow tract will lead to a high systolic left ventricular
pressure and enhanced oxygen demand of the isolated heart (Neely er a/., 1967,
Kobayashi e/a/., 1983). The aortic cannula of the present study was designed using
hemodynamic values as measured in the mouse /w v/vo (Barbee er a/., 1992, Hartley
er a/., 1995) and the dimensions of the mouse ascending aorta (Hartley er a/., 1995).
The proper design of the aortic outflow tract likely explains the physiological
hemodynamic values observed during ejection (see below).
Another factor influencing hemodynamic performance of isolated, perfused
mouse heart preparations is the substrate composition of the perfusion medium.
Pyruvate was included as co-substrate to the perfusate solution, as its beneficial
effects on hemodynamic and metabolic stability of isolated heart preparations have
been well documented (Van Bilsen er a/., 1989 and 1991, De Groot er a/., 1993). A
concentration of 1.5 mM pyruvate was chosen to substitute for all monocarboxylate
substrates present in the physiological situations. Increasing the final concentration
of pyruvate to 5 mM in the Krebs-Henseleit buffer, previously described for
isolated rat heart preparations (Snoeckx er a/., 1986, Van Bilsen er a/., 1989 and
1991), did not improve hemodynamic stability (data not shown). The presence of
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insulin in the perfiision medium and addition of pyruvate as co-substrate ensures
sufficient extractable substrates for the isolated heart, as demonstrated by the
accumulation of glycogen during prolonged normoxic perfusion.
The presence of insulin and pyruvate in the perfusion medium most likely
contributed to the relative stability of ventricular high energy phosphate content
during prolonged normoxic perfusion. The slight reduction of tissue ATP content is
consistent with findings in the normoxically perfused working rat heart preparation.
This imbalance between ATP degradation and formation in the isolated heart
preparation is still incompletely understood (Van Bilsen er a/., 1989). It should be
noted that the total adenine nucleotide content, the energy charge and the
phosphocreatine content remained constant during prolonged aerobic perfusion. -
By including 0.5 mM Na-EDTA in the Krebs-Henseleit solution, an
effective concentration of nominally free calcium of 2.5 mM was achieved. As
evidenced in the present study, Ca** concentrations lower than 2.5 mM, that are
frequently being applied in isolated mouse heart studies (Ng er a/., 1991, Grupp er
a/., 1993, Marber er a/., 1995, Yoshida er a/., 1996, Matherne er a/., 1997, Li er a/.,
1997), clearly resulted in a lower cardiac output and contractility of the isolated
ejecting mouse heart. The temperature of the perfusion medium and, hence, of the
isolated hearts was set at 38- 39 ...C because this temperature corresponds well with
the core body temperature of the intact laboratory mouse (Conroy er a/., 1980,
Miller e/a/., 1994).
It is shown that in the present experimental set-up, at loading conditions
comparable to those reported by the groups of Bittner er a/. (1996), Grupp er a/.
(1991 and 1993) and Gauthier er a/. (1998a and 1998b) the hemodynamic function
of the isolated working mouse heart is relatively stable for at least 100 min. Cardiac
output decreased by less than 10 % over this period. More importantly,
hemodynamic performance in terms of cardiac output and contractility compares
favorable to the ;'n v/vo situation in contrast to the other studies. In the present study
cardiac output increased from about 12 to 19 ml.min' when preload was increased
from 10 to 25 mm Hg at a fixed afterload pressure of 50 mm Hg. These cardiac
output values are close to those (16 ml.min') found in mice /« v/vo (Barbee er a/.,
1992, Hartley er a/., 1995) and significantly higher than the cardiac output values of
1 - 4 ml.min' reported by Bittner er a/ (Bitnner er a/., 1996) at comparable loading
conditions as in the present study.
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Figure 5
Left ventricular function curves of normoxically perfused, isolated working mouse hearts. Shown are
the effects of varying preload and afterload pressures on A cardiac output (CO; closed squares) and
coronary flow (CF; open squares); B left ventricular systolic pressure (closed circles) and left
ventricular end-diastolic pressure (open squares); and C the first maximal derivative of left ventricular
pressure (closed diamonds) and the first minimal derivative of left ventricular pressure (open diamonds)
in isolated antegradely perfused, murine hearts. • indicates P < 0.05 vs lowest preload pressure (10 mm
Hg) at comparable afterload pressure, # indicates P < 0.05 vs corresponding preload pressure.
A comparison with the functional characteristics reported by the group of
Grupp (Ng e/ a/., 1991, Grupp e/ a/., 1993) is more difficult as these investigators
standardly used a fixed left atrial inflow instead of a fixed filling pressure.
Nevertheless, it is of interest to note that in their model at an afterload of 50 mm Hg
approximately 90 % of cardiac output (4.6 of 5.1 ml.min') is used for coronary
flow (Grupp e/ a/., 1993). The model described in the present study compares
favorably in this respect as less than 40 % of cardiac output is used to supply the
coronary vasculature. Most likely, these differences in performance are attributable
to differences in the impedance of the aortic outflow tract, since in other studies
longer and narrower cannulas were used, illustrating the importance of proper
design of this part of the perfusion system. The stroke volumes values of 29 - 5 |0.1
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resemble those reported for the i« v/vo situation by Barbee and colleagues (26 (il)
and Hartley and colleagues (33 n.1) (Barbee e/ a/., 1992, Hartley e/ a/., 1995).
The coronary flow rates
found in the present study
under baseline loading
conditions are comparable to #
those described previously (Ng ^5
e/ a/., 1991, Grupp e/ a/., 1993,
Bittner er a/., 1996, Gauthier ef
a/., 1998a and 1998b). The
observation that coronary flow
rates could increase by an
additional 50 % during the
construction of left ventricular
function curves, demonstrates
that in the present model the
murine coronary vascular bed is
not fully dilated under basal
conditions (10 and 50 mm Hg
pre and afterload pressure,
respectively). Additionally, the
absence of and increase in LDH
and lactate release during
prolonged perfusion indicates
that the mouse hearts are not
compromised with regard to
oxygen supply.
The finding that the
effective preload pressure
(LVEDP) was lower than the
applied left atrial filling
pressure is consistent with
findings in other isolated
working mouse heart models
(Ng er a/., 1991, Grupp er a/.,
1993, Gauthier er a/., 1998a
and 1998b). It is of interest to
note that this phenomenon was
obse rved under all
experimental conditions
(varying pre and afterload). At
present no explanation is at
hand for this phenomenon.
Only a few reports give insight into the /« v/vo contractile state of the
mouse heart. Lembo e/ a/. (1996) and Milano er a/. (1994) reported values for LV
in open-chest mice of 4000-4500 mm Hg.s"', while Lorenz e/ a/. (1997)
0
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Figure 6: Left ventricular function curves of isolated
working mouse hearts perfused with 1.5 mM calcium
(open circles) and 2.5 mM calcium (closed circles).
The curves were constructed by measuring cardiac
output at varying preloads with the afterload kept
constant at 50 mm Hg. Data are expressed as means
± SD (both groups n = 5). * indicates P < 0.05 vs
lowest preload (10 mm Hg) at comparable Ca**
concentration, # indicates P < 0.05 vs corresponding
preload pressure.
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found LV dP/dtmax values of 7830 - 670 mm Hg.s"' in anesthetized closed-chest
mice. Again, the LV dP/dtmax values of 6000-7500 mm Hg.s' found in the present
study are comparable to the zw v/vo situation and considerable higher than those
reported in other isolated ejecting mouse heart studies (Ng e/ a/., 1991, Grupp e/ a/.,
1993, Bittner e/ a/., 1996, Gauthier e/ a/., 1998a and 1998b). It should be noted,
however, that in the conscious mouse (heart rates typically higher than 550
beats.min"') LV dP/dtmax values of more than 14,000 mm Hg.s ' should be
anticipated (Kass er a/., 1998). The observation that LV dP/dt™, does not change
when increasing preload at an afterload of 50 mm Hg may be explained by the fact
that the aortic valve opens before the physiological maximal value of the first
derivative of left ventricular pressure has been reached, as earlier discussed by
Reneman and Pollack (1971). This notion is supported by the finding that at higher
afterloads LV dP/dtmax increases with enhanced preload pressure. Therefore, the use
of this parameter of contractile performance has to be interpreted in the light of the
actual pre and afterload pressures applied.
In conclusion, the model described in the present study allows detailed
evaluation of the performance of isolated, antegradely perfused mouse hearts.
Because the functional characteristics of the isolated heart model in general
corresponds well with wi v/vo findings, the present model will be asset in the
interpretation of the function of specific gene products investigated in transgenic
and gene-targeting mouse models for heart diseases.
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Chapter 6
Functional recovery, energy metabolism
and lipid homeostasis in the
ischemic-reperfused mouse heart. *•-
•SKfc/w/'Weo' or^u// pape
U De Windt, J Willems, GJ Van der Vusse, RS Reneman, M Van Bilsen.
Assesment of ischemia tolerance of the isolated left ventricular ejecting mouse
heart: Functional and biochemical correlates,
LJ De Windt, J Willems, GJ Van der Vusse, RS Reneman, M Van Bilsen.
Ischemia-reperfusion induced damage in isolated left ventricular ejecting
mouse heart. FoseftJ 1998;12:A75 (Abstract).
Abstract
In the murine heart the effects of ischemia and reperfusion on cardiac
high energy metabolism and lipid metabolism were investigated and
related to functional recovery and the degree of irreversible cell
damage. To this end, isolated ejecting murine hearts were subjected to
10, 15 and 20 min of normothermic, no-flow ischemia, whether or not
followed by 60 min of reperfusion. During ischemia cardiac ATP
levels gradually declined, which was associated with a transient rise in
ADP and a sharp increase in AMP content (from a pre-ischemic value
of 0.6 ± 0.1 (imol.g"' dry weight to 6.3 ± 2.0 nmol.g"' dry weight after
20 min of ischemia). During reperfusion hemodynamic function almost
completely recovered following 10 min of ischemia (83 ± 14 %
recovery of cardiac output [CO]), but was severely depressed
following 15 and 20 min of ischemia (40 ± 24 and 31 ± 24 % recovery
of CO, respectively). Reperfusion following 20 min of ischemia was
accompanied by disturbed reflow as evidenced by delayed wash-out of
lactate dehydrogenase (LDH) and post-ischemic accumulation of small
molecular weight degradation products such as lactate and
(oxy)purines. The percentage necrotic cells as assessed by cumulative
release of LDH during reperfusion was calculated to be 4.8, 8.4 and
10.0 % of total cardiac muscle cells following 10, 15 and 20 min of
ischemia, respectively. Reperfusion per se was associated with an
enhanced degradation of phospholipids as indicated by the
accumulation of fatty acids (FA) in reperfused hearts (0.9 ± 0 . 1
(imol.g"' and 3.6 ± 1.3 jxmol.g"' dry weight in pre-ischemic and
reperfused hearts following 20 min of ischemia, respectively). In the
reperfused heart a positive correlation was found between levels of FA
(r = 0.70) and arachidonic acid (r = 0.65) on the one hand and
cumulative release of LDH during reperfusion on the other. The latter
observation strongly suggests that membrane phospholipid degradation
and loss of cellular viability are closely related phenomena.
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Introduction
Murine models are increasingly used to study the molecular mechanisms of cardiac
dysfunction following ischemia and reperfusion due to the widespread availability
of transgenic and gene-targeted models. The isolated heart preparation is
particularly suitable to assess ischemia/reperfusion-induced functional and
biochemical alterations independent of potentially compensatory extra-cardiac
factors. So far, functional and structural alterations in the mouse heart following
global ischemia and reperfusion have almost exclusively been investigated by
means of retrogradely perfused heart preparations (Hampton e/ a/., 1998, Eberli e/
a/., 1998). In addition, Langendorff perfused hearts from transgenic mice have been
used to document the protective effects of heat shock protein 72 (Marber e/ a/.,
1995; Plumier e/ a/., 1995; Radford <?/ a/., 1996; Trost er a/., 1998), catalase (Li <?/
a/., 1997), A| adenosine receptor (Matherne ef a/., 1997) and Cu-Zn Superoxide
dismutase (Wang ef a/., 1997) on postischemic functional recovery. Furthermore,
changes in high energy phosphate metabolism were subject of study in a number of
genetically altered murine hearts (Headrick e/ a/., 1998; Spindler e/ a/., 1998; Saupe
e? a/., 1998), either or not in conjunction with ischemia/reperfusion.
An important limitation of the isolated Langendorff perfused heart model is
that it does not perform external work. As a consequence, this empty-beating
heart model has limited physiological resemblance and the biological significance
of the functional parameters obtained is uncertain. These disadvantages can largely
be overcome by using a left ventricular ejecting (working) heart preparation
allowing, in addition to pump performance, the accurate assessment of left
ventricular diastolic and systolic function. Using isolated rat hearts it has been
shown that with the use of these parameters left ventricular dysfunction following
an ischemic insult can be adequately described (Van Bilsen ef a/., 1989a and 1989b,
De Groot <?/ a/., 1993a and 1993b, Comelussen e/ a/., 1997).
In a previous study we developed and characterized a normoxically
perfused isolated working murine heart model in terms of functional stability and its
reponse to changes in workload (De Windt ef a/., 1999). Up to now detailed
information of the murine heart regarding the functional recovery and its relation to
post-ischemic energy status and lipid metabolism are lacking. The first main
objective of the present study was to delineate the vulnerability of the isolated
murine heart towards normothermic ischemia followed by reperfusion. Therefore,
we determined the degree of hemodynamic recovery and alterations in cardiac high
energy phosphate levels and related compounds after ischemia, varying in duration
from 10 to 20 min followed by reperfusion. Moreover, post-ischemic release of
LDH was monitored to estimate the degree of irreversibly damaged cardiac cells.
The second main objective was to assess whether and to which extent ischemia
and/or reperfusion-induced damage of the murine heart is associated with
disturbances in membrane phospholipid homeostasis reflected by accumulation of
tissue fatty acids, including arachidonic acid.
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Materials and methods
All chemicals used for the Krebs-Henseleit solution were of the highest grade
available and purchased from Merck (Darmstadt, Germany), except for D(+)-
glucose and pyruvate (Sigma Chemical Co., St. Louis, MO, USA). Insulin was
purchased from Novo Nordisk A/S (Bagsvaerd, Denmark).
a«*/surgery
For this study 3-4 month old female Swiss mice (Iffa Credo, Lyon, France) with an
average body weight of 32.7 ± 2.4 g were used. The mice were kept under standard
housing conditions with an artificial 12 h light cycle with free access to standard
rodent food (Diet SRM-A, Hope farms, Woerden, the Netherlands) and tap water.
All experimental protocols were approved by the Institutional Animal Care and Use
Committee of the Maastricht University.
/so/atea" wor/t/Mg mouse /?ear/prepara//of?
The isolated ejecting mouse heart preparation used in the present study has been
described in detail before (De Windt e/ a/., 1999). Briefly, animals were
anesthetized by 50 mg.kg"' sodium pentobarbital, i.p. (Nembutal, Sanofi Sante BV.,
Maassluis, the Netherlands). After thoracotomy the hearts were quickly excised and
transferred to ice-chilled perfusion buffer (for composition see below). Remnant
thymic and fatty tissue was carefully removed and the ascending aorta was
cannulated with a recently described aortic cannula that was designed to match the
hemodynamic aortic impedance characteristics of the isolated murine heart (De
Windt e/ a/., 1999). Retrograde perfusion was started immediately at a perfusion
pressure of 50 mm Hg, after which the hearts started to beat spontaneously. The left
atrium was cannulated with an atrial cannula through one of the lung veins. The
recirculating modified Krebs-Henseleit perfusion buffer was prefiltered by a
microfilter (0.45 |im diameter; Millipore Corp.) and consisted of the following
composition: 118 mM NaCl, 4.7 mM KC1, 3.0 mM CaCb, 1.2 raM MgSC>4, 1.2 mM
KH2PO4, 25 mM NaHCCh, 0.5 mM Na-EDTA, 10 mM D(+)-glucose, 1.5 mM Na-
pyruvate and 5 U/l insulin. The buffer was continously gassed with 95 % O2 - 5 %
CO2. Care was taken to maintain the temperature of the perfusate, and thus the
heart, at 38.5 jC. Left ventricular pressure was measured with a PE-50 catheter,
inserted into the left ventricular cavity through the apex (De Windt e/ a/., 1999) and
connected to a Baxter pressure transducer (Baxter Healthcare Corp., Irvine, CA,
USA). Aortic pressure was measured through a side branch located 3 mm above the
entrance of the aortic cannula using a pressure transducer (Baxter Healthcare
Corp.).
All hemodynamic variables were continuously recorded on a personal computer,
using specialized software (Hemodynamic Data Acquisition System, Technical
Department Maastricht University), allowing the on-line acquisition, presentation
and calculation of left atrial filling flow, aortic flow (AOF), left ventricular systolic
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pressure (LVSP), left ventricular end-diastolic pressure (LVED), diastolic aortic
pressure (AODP) and the first maximal and minimal derivatives of left ventricular
pressure (LV dP/dt„,ax and LV dP/dtm,n). Left ventricular developed pressure
(LVDP) was defined as the difference between LVSP and LVEDP. Cardiac output
(CO) was defined as the sum of AOF and coronary flow (CF). CF was determined
from the difference between AOF, as measured by a IN inline aortic flow probe and
left atrial filling flow as measured by a 2N inline flow probe placed in the left atrial
inflow tract (De Windt er a/., 1999). Calculated CF data were periodically checked
by timed collection of the coronary perfusate. CF data were used to calculate
coronary resistance (CR), which was defined as AODP divided by CF normalized
for individual heart weights. < r
During all experiments,
antegrade perfusion was
started by opening the left
atrial conduit after an
initial 10 min retrograde
stabilization period at 50
mm Hg. Left atrial filling
pressure was set at 10 mm
Hg, while diastolic aortic
pressure was kept at 50
mm Hg. Except for the
ischemic period and
during the first 5 min of
reperfusion, the hearts
were paced artificially
throughout the whole
experiment at a frequency
of 380 beats.min', which
is slightly higher than the
intrinsic rate of an
isolated, perfused murine
heart of this strain.
For ischemia/reperfusion
experiments, the hearts
were normoxica l ly
perfused for 20 min as
described above (pre-
ischemic period).
Tablel • ' • • • • • • ' ' • • ^ • ^ - -*••••• " • •. • • • • : , >
Pre-ischemic hemodynamic values measured in isolated, left
ventricular ejecting murine hearts.
10.8 ±
3.8 ±1
6.8 ± 1
27 ±6
77 ±9
86 ±9
1±3
7 ± 4
1.8
.8
.8
5,652 ±831
-3,054 ±415
Data are expressed as means ± SD (n =13). Isolated hearts were
perfused at a pre and afterlaod of 10 mm Hg, respectively.
Hearts were paced at 380 beats.min'. CO, cardiac output; CF,
coronary flow; AOF, aortic flow; SV, stroke volume; LVDP,
left ventricular developed pressure; LVSP, left ventricular
systolic pressure; LVPDia, left ventricular diastolic pressure;
LVEDP, left ventricular end-diastolic pressure; LV dP/dt™,,
first maximal derivative of left ventricular pressure; LV
first minimal derivative of left ventricular pressure.
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Just prior to the ischemic period the water-jacketed chamber was filled with warm
(38.5 °C) perfusate solution until the heart was completely submersed, pacing was
stopped, and the aortic and atrial lines were clamped for 10, 15 or 20 min to create
normothermic, global ischemia. After the ischemic period, the water-jacketed
chamber was emptied and hearts were reperfused retrogradely at a perfusion
pressure of 50 mm Hg for 10 min. Subsequently, the left atrial conduit was re-
opened and the hearts were allowed to work in the antegrade mode at a preload
pressure of 10 mm Hg and a diastolic aortic pressure of 50 mm Hg for an additional
50 min.
Hearts were freeze-clamped either after the 20 min stabilization period (pre-
ischemia), after 10, 15 or 20 min of no-flow normothermic ischemia (end-
ischemia), or following ischemia and 60 min of reperfusion (ischemia/reperfusion).
To assess the lactate content in the coronary effluent samples of 1 ml were
immediately frozen in liquid nitrogen and stored at -80 jC for further analysis. For
the determination of lactate dehydrogenase (LDH) activity in coronary effluent
samples, bovine serum albumin was added to the samples (final concentration 3 %),
after which they were frozen in liquid nitrogen and also stored at -80 jC.
LDH and lactate content in the coronary perfusate were assessed
spectrophotometrically using a Cobas Bio autoanalyzer as described earlier
(Bergmeyer and Bemt e/ a/., 1974, Apstein e/ a/., 1970).
Tissue contents of adenine and guanine nucleotides, IMP, and (oxy)purines
was determined by high-performance liquid chromatography (Varian Vista 5500
HPLC) according to a variation of the procedures of Wynants and Van Belle (1985)
and as described previously in detail (Van Bilsen er a/., 1989a). Briefly, aliquots of
deeply frozen tissue were extracted with perchloric acid and samples of the
neutralized extract were applied to a precolumn (LiChroCART 4-4, Merck,
Germany) and a reversed phase LiChrosorb RP-18 column (stainless steel, narrow
bore, 250 x 4 mm ID, Merck). Stepwise gradient elution (flow speed 0.8 ml.min"'),
using two solvents, was applied to separate the compounds of interest. Solvent A
[aqueous buffer of NH4(H2PO,») 150 mM, pH = 6.0] was prepared by mixing H3PO4
and NH4OH. Solvent B consisted of a 1:1 (vol/vol) mixture of acetonitrile and
methanol. Each run started with a 6 min elution period of 100 % solvent A. From 6
to 11 min solvent A was reduced to 95 % and solvent B increased to 5 %. From 11
to 27 min solvent A was further decreased to 85 %, after which solvent A was
increased to 100 % within 2 min. Peaks were detected at 254 nm using an
ultraviolet detector (Varian UV-200, flow cell 4.5 ml, path length 4 mm, spectral
band width 5 nm). The sensitivity was set at 0.005 AUFS at a time constant of 0.5 s.
Peaks were identified by comparing retention times with known standards.
The determination of cardiac fatty acids, phospholipids and triacylglycerols
was performed as recently described in detail (Van der Vusse and Roemen, 1995).
All fatty acyl values were expressed as moles per gram dry weight. Dry weight was
determined in a subset of hearts by freeze drying overnight and amounted to 14.6 %
of wet weight, which corresponds to a conversion factor of 6.85 for wet weight to
dry weight murine ventricular tissue.
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Table II
Total tissue content of individual purines and their sum in pre-ischemic, ischemic and
ischemic-reperfused mouse hearts.
70 77
/Ve-7 70 mm 7 70/mw7/R 75/win 7 75/mn7/K 20m/n7 20min//R
0.07 ±0.02 0.82 ± 0.35* 0.20 ± 0.20* 1.07 ±0.57* 0.09 ±0.07* 1.8710.45* 0.41 ±0.20**
ND 0.71 ±0.26 0.03 ±0.02* 1.27±0.65 0.3210.45* 1.8510.38 1.2011.31
HX 0.0410.02 0.21+0.04*0.2810.31 0.3410.08* ND 0.48 ±0.14* 0.32 ±0.08
X ND ND 0.81 ±0.53 0.08 ±0.07* 0.93 ±0.72 0.21 ±0.12 1.00 ±0.70*
7bto/ 0.0810.03 1.6010.60*0.7410.73* 6.75 1 1.65* 0.88 1 1.21** 4.13 10.72* 2.28 1 2.08*
Data are expressed as means - SD. Presented are individual purines in umol.g'' dry weight ventricular
tissue, n indicates number of hearts analyzed. Pre-I, Pre-ischemia; I, ischemia; R, reperfusion. Total
refers to the sum of adenosine (A), inosine (I), hypoxanthine (HX) and xanthine (X) and is expressed as
umol.g"' dry weight. * indicates P < 0.05 vs pre-ischemic value, # indicates P < 0.05 vs corresponding
end-ischemic value. ND, not detectable.
The results are presented as mean values - standard deviations (SD). All statistical
analyses were performed using InStat 3.0 software (GraphPad Software Inc., San
Diego, CA). Changes in functional variables in time were statistically analyzed by
repeated measures ANOVA with Tukey s HSD post-hoc correction test for multiple
comparisons. Differences between values of functional variables and biochemical
parameters between experimental groups were analyzed using one-way ANOVA
followed by the Tukey s test. Linear regression was performed with the least
squares method and the Pearson rank correlation coefficient (r) was used to estimate
the strength of the relation between two variables. In all tests significance was
accepted at P values < 0.05.
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Table III
Total tissue content of GTP, GDP, IMP, NADP and NAD in pre-ischemic, ischemic and ischemic-
reperfused mouse hearts.
/>re-/ 70 mm/ 70m/>i7/R 75 mm 7 75 m 7/7? 20 min 7 20 mm 7/7?
srP
GDP
GAiP
JMP
AMAP
AMD
1.3 ±0.1
0.2 ±0.1
ND
0.2 ±0.1
0.1 ±0.0
3.4 ±0.3
0.9 ± 0.2
0.3 ± 0.0
ND
0.2 ±0.1
0.1 ± 0.0
3.2 ±0.7
0.9 ±0.3
0.2 ±0.1
ND
0.1 ±0.1
0.1 ±0.1
3.2 ±0.7
0.7 ±0.2*
0.3 ±0.1
0.1 ±0.1
0.2 ±0.1
0.1 ±0.0
3.4 ± 0.2
0.8 ±0.2
0.2 ±0.1
ND
0.2 ± 0.2
0.1 ±0.0
2.7 ±0.5
0.5 ±0.1*
0.2 ± 0.0
0.1 ±0.1
0.4 ± 0.2
0.1 ±0.0
3.0 ±0.5
0.7 ± 0.2*
0.2 ±0.1
0.1 ±0.1
0.4 ± 0.2
0.1 ±0.1
2.6 ±0.7
Data are expressed as means - SD in |imol.g' dry weight ventricular tissue, n indicates number of
hearts analyzed. Pre-I, Pre-ischemia; 1, ischemia; R, reperfusion; ND, not detectable. * indicates
P < 0.05 vs nre-ischemic value.
Results
Fi//jc//ona/ recovery
Pre-ischemic values of the hemodynamic variables tested were not significantly
different between the experimental groups and, hence, pooled data are presented in
Table I. Following 10 min of global ischemia and 60 min of reperfusion functional
recovery was almost complete. CO recovered to 83 ± 14 % of its pre-ischemic value
(P < 0.05 vs pre-ischemia), while no significant difference was observed between
pre-ischemic and post-ischemic CF (Figure 1A). Similarly, post-ischemic LVDP,
LV dP/dtmax and LV dP/dt^,, all recovered to near pre-ischemic values (Figure 1C).
Extending the ischemic duration to 15 min resulted in a depression of the
recovery of CO and AOF (Figure 1A). Post-ischemic LVDP amounted to 62 ± 18 %
of its pre-ischemic value (P < 0.05 vs pre-ischemia). Recovery of LV dP/dtma, and
LV dP/dtmm was also more severely depressed after 15 min of ischemia (Figure 1C).
Hemodynamic recovery was severely impaired following 20 min of
ischemia. CO recovered to only 31 ± 24 % of its pre-ischemic value (P < 0.01 vs
pre-ischemia; Figure 1A), while in the majority of hearts virtually no recovery of
AOF was observed. Additionally, CF was severely compromised and amounted to
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2.6 ± 1.9 ml.min'', corresponding to a doubling of calculated coronary resistance
(CR) from a pre-ischemic value of 15.8 ± 7.6 mm Hg.min.ml' to 30.0 ± 21.8 mm
Hg.min.ml"' (P < 0.05). Due to a marked rise in LVEDP and a reduction in systolic
function LVDP recovered to only 28 ± 21 % of its pre-ischemic value (P < 0.01 vs.
pre-ischemia; Figure IB).
e :._i.-» •.-..,»
Enzyme a«*/ /ac/ate re/ease
Pre-ischemic LDH release was low in all groups and amounted on the average to 37
± 22 mU.min"'. Following 10 min of global ischemia a small additional release of
LDH was observed during the initial 20 min of the reperfusion phase. During 60
min of reperfusion, the cumulative release of LDH into the coronary effluent
amounted to 2.9 - 0.8 U in this group. The cumulative release of LDH increased as
a function of the duration of the preceding ischemic period and amounted to 5.1 -
1.7 U and 6.1 - 2.7 U following 15 and 20 min of ischemia, respectively. To
estimate the percentage of irreversibly damaged cells, the cumulative release of
LDH was normalized to the total LDH content of the murine heart (60.5 U/heart).
Accordingly, the percentage of necrotic cardiac myocytes was calculated to be 4.8,
8.4 and 10.0 % following 10, 15 and 20 min of ischemia, respectively.
Prior to the onset of ischemia cardiac lactate release into the coronary
effluent amounted to 0.8 - 0.2 |imol.min'\ Following 10 and 15 min of ischemia a
significantly higher lactate release rate was observed during the first 5 min of
reperfusion (1.6 - 0.1 and 1.6 - 0.6 umol. min"', respectively; P < 0.05 vs pre-
ischemia), reflecting the wash-out of lactate accumulated during the preceding
ischemic period. Thereafter, lactate release returned to pre-ischemic values. In
contrast, following 20 min of ischemia no significant washout of lactate was
observed in the initial reperfusion phase. Lactate release amounted to 0.9 - 0.3
umol. min"' and remained constant during the remainder of the reperfusion phase.
The pre-ischemic tissue content of ATP, ADP and AMP amounted to 18.9 - 2.0,
4.3 - 0.5 and 0.6 - 0.1 uinol.g"' dry weight, respectively, corresponding to an
adenylate energy charge (EC) of 0.89 ± 0.01 (Figure 2). The sum of adenine
nucleotide degradation products, i.e., adenosine, inosine, hypoxanthine and
xanthine, was very low in normoxically perfused pre-ischemic ventricular tissue
(Table II).
During 10 and 15 min of ischemia tissue ATP content progressively
decreased, while ADP and AMP levels increased (Figure 2). Extension of the
ischemic duration to 20 min was associated with marked reductions in both ATP
and ADP content. In contrast, tissue AMP levels increased dramatically. As a result,
the tissue adenylate EC fell to 0.42 ±0.16 following 20 min of ischemia (Figure 2).
Adenine nucleotide degradation products substantially increased (Table II).
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Figure 1
Post-ischemic recovery of cardiac output and coronary flow (CO and CF; Figure 1A), left
ventricular systolic pressure and left ventricular end-diastolic pressure (LVSP and LVEDP;
Figure IB) and first maximal and minimal derivative of left ventricular pressure (LV
dP/dt„„ and LV dP/dt„,„,; Figure 1C) following 10 (closed rectangles), 15 (closed triangles)
and 20 min (open rectangles) of normothermic no-flow ischemia. Indicated on the x-axis is
the 20 min pre-ischemic perfusion time in min, the global ischemic period and 60 min of
reperfusion. Data are expressed as means - SD (n = 10, following 10 and 15 min of
ischemia; n = 11, following 20 min of ischemia), indicates P < 0.05 vs postischemic
recovery following 10 min of ischemia.
Restoration of flow for 60 min resulted in an almost complete recovery of
tissue ATP levels following 10 min of ischemia. In contrast, following an ischemic
insult of 15 or 20 min only partial restoration of tissue ATP content was observed
(Figure 2). Tissue ADP and AMP levels returned to pre-ischemic values regardless
of the duration of the preceding ischemic episode (Figure 2). EC recovered to pre-
ischemic values following 10 and 15 min of ischemia, but only to 0.79 ± 0.09
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following 20 min of ischemia and reperfusion (P < 0.05 vs pre-ischemia).
Restoration of flow resulted in decreased tissue content of adenine degradation
products relative to ischemic hearts regardless of the ischemic duration. At the end
of reperfusion, however, hearts subjected to 10 or 15 min of ischemia demonstrated
a significantly lower tissue (oxy)purine content than hearts subjected to 20 min of
ischemia and 60 min of reperfusion (Table II). The tissue content of lactate in
reperfused hearts was found to be 15.4 ± 11.3, 21.0 + 9.6 and 41.1 ± 24.8 umol.g'
dry weight following 10, 15 and 20 min of ischemia, respectively. The finding of
markedly enhanced tissue levels of lactate and adenine degradation products in
hearts subjected to 20 min of ischemia plus reperfusion, in combination with a
substantially elevated postischemic coronary resistance, is indicative of impaired
recovery of coronary flow in this group.
G7P, GDP,
Similar to ATP, guanine triphosphate (GTP) was gradually degraded in ischemic
tissue following 20 min of ischemia (P < 0.05 vs pre-ischemia; Table III). This
reduction, however, was not associated with significant changes in GDP and GMP
levels. Restoration of flow during 60 min was not sufficient to restore tissue GTP
content back to pre-ischemic values, regardless of the preceding ischemic duration.
Tissue NAD and NADP contents remained unaffected during ischemia, or ischemia
followed by 60 min of reperfusion (Table III).
The total pre-ischemic tissue content of fatty acids (FA), phospholipids (PL) and
triacylglycerols (TG) in the murine hearts and their relative fatty acid composition
is shown in Table IV. The fatty acyl composition of the PL and FA pool
demonstrated high resemblances with a relative abundance of palmitic (16:0),
stearic (18:0), linoleic (18:1) and docosahexaenoic acid (22:6), with each species
accounting for 10-20 % of total fatty acids present (Table IV). The poly-unsaturated
FA arachidonic acid (20:4) accounted for 6.7 ± 0.7 and 4.0 ± 0.4 % of total fatty
acids in the PL and FA pool, respectively (Table IV). Cardiac TG s mainly
comprised of 16:0, 18:1 and 18:2 moieties, each representing about 30 % of all TG
fatty acyl moieties. In contrast to the FA and PL pool, 18:0, 20:4 and 22:6
accounted for only a small percentage of fatty acids esterified in the TG pool (Table
IV).
Oxygen deprivation for 10, 15 or 20 min did not affect the tissue PL and TG
content (Tables VI and VII). Total cardiac FA content declined significantly in
hearts subjected to 10 or 15 min of ischemia (P < 0.05 vs pre-ischemia). Increasing
the ischemic duration with an additional 5 min resulted in an elevation of cardiac
FA content relative to the end-ischemic value at 15 min of ischemia (Figure 3 and
Table V). The reduction in total FA content was associated with marked changes in
the mol % of individual FA species (Table V). In general, the mol % of saturated
FA species increased, whereas the mol % of poly-unsaturated FA s declined. In this
respect the shift in the mol % of 16:0 and 22:6 were most outspoken. A small but
significant increase of 22:6 in the PL pool and a decrease in the amount of 16:0 and
a small increase in the amount of 18:2 esterified in the TG pool were observed.
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Reperfusion itself resulted in a marked increase in tissue FA content
following 10 and 15 min of ischemia, respectively (P < 0.05 vs pre-ischemia; Figure
3). The increase in tissue FA was found to be most pronounced in hearts previously
deprived of oxygen for 20 min (P < 0.01 vs pre-ischemia). Irrespective of the
duration of the preceding ischemic episode, reperfusion was accompanied by a
substantial rise in the tissue content of 18:2, 20:4 and 22:6, in both absolute
amounts (not shown) and in the percentage contribution to the total FA pool (Table
V). Following reperfusion the amounts of the polyunsaturated fatty acyl species
20:4 and 22:6 in the PL pool tended to decrease compared to end-ischemic values,
the decrease reaching statistical significance only for 22:6 following 10 min of
ischemia and 60 min of reperfusion (Table VI). The relative fatty acyl composition
of the cardiac TG pool showed a significant change only in the 18:2 content, which
decreased during reperfusion following 20 min of ischemia (Table VII).
Discussion
//i r/ie /sc/jem/c-reper/wsed mowse
In the present study it is demonstrated that murine hearts tolerated 10 min of
ischemia well, as evidenced by a near complete recovery of hemodynamic function
and adenylate energy charge and the limited LDH release upon reperfusion.
Nonetheless, reperfusion was associated with a marked rise in the tissue FA content,
reflecting release of FA from endogenous lipid pools. Extending the ischemic
duration to 15 or 20 min resulted in a diminished recovery of cardiac function, more
pronounced decreases in the adenylate energy charge, enhanced tissue FA
accumulation and release of cytosolic proteins.
The nearly complete recovery of hemodynamic function after 10 min of
global ischemia is at variance with earlier observations of Bittner and colleagues,
who reported that 6 min of global ischemia using their working mouse heart
preparation was already sufficient to induce substantial impairment of postischemic
cardiac output (Bittner er a/., 1996, Chen er a/., 1997). The apparent discrepancy
between these studies and the present one are not clear. However, the pre-ischemic
hemodynamic values of the quoted studies deviate to such an extent from the //i v/vo
murine cardiac function and the present study, probably as a result of a higher aortic
impedance and differences in perfusate composition, that comparisons are hard to
make. This issue has been discussed earlier in more detail (De Windt er a/., 1999).
In all other studies to date the so-called isolated Langendorff perfused heart
model was typically used to study ischemia and reperfusion-induced cardiac
dysfunction of isolated hearts, either or not derived from trangenic animals (Eberli
er a/., 1998, Li er a/., 1997, Marber er a/., 1995, Headrick er a/., 1998, Matheme er
a/., 1997, Plumier er a/., 1995, Radford er a/., 1996, Sumeray er a/., 1998, Trost er
a/., 1998, Wang er a/., 1998, Yoshida er a/., 1996, Xi er a/., 1998). The minimal
duration of flow-deprivation required to induce marked functional impairment on
Langendorff perfused isolated mouse hearts in these studies ranges from 30 min
(Yoshida er a/., 1996) to as long as 50 min (Li er a/., 1997). A number of factors
may account for the large variation in ischemia tolerance of the murine hearts as
reported by the various research groups.
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Figure 2
Myocardial content of ATP, ADP, AMP
and their sum ( I ATP + ADP + AMP)
and adenylate energy charge (EC) in pre-
ischemic hearts (P), hearts subjected to 10
min (10-I), 15 min (15-I) or 20 min (20-I)
of global normothermic ischemia, either
or not followed by reperfiision for 60 min
(R). EC refers to energy charge and is
defined as (ATP + 0.5 ADP)/(ATP + ADP
+ AMP) and is unitless. * indicates
P < 0.05 vs pre-ischemia, # refers to
P < 0.05 vs ischemic hearts.
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Table IV
Total amount and relative fatty acid composition of tissue phospholipid
(PL), triacylglycerol (TG) and (unesterified) fatty acid (FA) pool in pre-
ischemic mouse hearts.
/I
7bta/
76.0
76:/
/«:0
/«:/
7«.2
20.0
20:4
22:4
22:6
6
P I
198.4 ±10.3
19.0 ±0.5
0.5 ±0.1
18.6 ±0.8
11.4 ±0.6
15.9 ±0.5
0.2 ±0.1
6.7 ±0.7
0.2 ± 0.0
22.7 ±1.4
7t?
40.8 ± 5.3
30.9 ±6.2
4.5 ±1.2
5.4 ±1.1
29.2 ±4.0
27.3 ± 5.9
0.2 ±0.1
0.9 ±0.1
0.3 ±0.1
4.3 ±1.0
/ *
0.9 ±0.1
18.0± 1.6
0.7 ±0.1
17.0 ±2.5
13.2 ±0.6
12.5 ±0.8
0.4 ±0.1
4.0 ± 0.4
0.7 ±0.1
28.7 ±3.5
Data are expressed as means ± SD. Total refers to total (unesterified) fatty
acid and is expressed as mmol.g"' dry weight. Individual fatty acids are
presented as percentages of total tissue fatty acid.
Factors likely to play a role are variations in nominally free Ca^*
concentrations in the perfusate, choice of substrates, temperature of the isolated
hearts during global ischemia and differences in workload (perfusion pressure,
retrograde versus antegrade perfusion).
The findings in the present study are in line with the earlier expressed
notion of a higher susceptibility of the mouse heart to ischemia and reperfusion-
induced damage as compared to other species (Headrick e/ a/., 1998). Using also an
assisted mode perfusion setup and comparable experimental conditions as in the
present study, De Groot and colleagues found substantial cardiac dysfunction as
measured by recovery of cardiac output, coronary resistance, post-ischemic LDH
release and ventricular accumulation of arachidonic acid in isolated working rat
hearts only following ischemic periods of 30 min or longer (De Groot e/ a/., 1993a).
Reperfusion of mouse hearts following 20 min of ischemia was associated with a
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significant increase in coronary resistance and, hence, a substantial decline in
coronary flow. Although it cannot be excluded that this increase in coronary
resistance results from a reduced oxygen demand of the left ventricle due to
decreased work performance during reperfusion, it is more likely that the increase
in coronary resistance is caused by ischemia-induced hypercontracture of
cardiomyocytes and/or substantial damage to the coronary vasculature. Latter
notion is stressed by the observation that the increase in coronary resistance during
reperfusion and reduced myocardial perfusion is accompanied by impaired wash-
out of small molecular mass degradation compounds such as lactate and adenine
nucleotide degradation products. Indeed, a relatively strong correlation was found
between coronary resistance following 60 min of reperfusion, on the one hand, and
post-ischemic ventricular accumulation of lactate, on the other (r = 0.87; Figure 4).
Although not the subject of the present study, it may be anticipated that in mouse
hearts subjected to 20 min of global ischemia especially the inner layers of the left
ventricle will be affected by flow impairment (De Groot e/ a/., 1993b).
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Figure 3.
Tissue content of (unesterified) fatty acids in the pre-ischemic myocardium
and in mouse hearts subjected to 10, 15 and 20 min of ischemia, either or not
followed by reperfusion. Data are expressed as means ± SD (n = 4 for pre-
ischemic hearts, n = 5 for 10 min I/R. 20 min 1 and 20 min I/R, and n = 6 for
the remaining groups). I, ischemia; R, reperfusion. * indicates P < 0.05 vs
pre-ischemia, # indicates P < 0.05 vs corresponding end-ischemic period.
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Prolonged ischemic duration resulted in a substantial reduction of ATP (to less of
25 % of pre-ischemia) and tissue accumulation of AMP and (oxy)purines, mainly
adenosine and inosine. The accumulation of AMP suggests a limited activity of
endo-5 -nucleotidase during ischemia or a confinement of AMP to a compartment
distinct from the localization of this enzyme (Van Bilsen e/ a/., 1989a). Similarly,
the accumulation of adenosine and inosine, combined with relatively low tissue
levels of hypoxanthine and xanthine strongly suggests a constraint at the level of
nucleoside phosphorylase in the ischemic murine heart. This might be caused by
inhibition of the enzyme under ischemic conditions or a difference in localization of
inosine production and nucleoside phosphorylase in the mouse heart. Similar
findings were obtained in the isolated working rat heart subjected to varying periods
of ischemia and reperfusion (Van Bilsen er a/., 1989a, De Groot er a/., 1993b)
The recovery of ATP and adenylate energy charge during reperfusion
indicates that mitochondrial ATP production is not seriously hampered by the
preceding ischemic insult or hampered by accumulating fatty acids. The data
suggest that the reduced total adenine nucleotide pool (sum of ATP, ADP and
AMP) at the end of reperfusion is mainly due to wash-out of its degradation
products, which prevents resynthesis of the parent adenine nucleotides. Although
post-ischemic hemodynamic function of the murine heart is severely impaired
following 20 min of ischemia, the recovery of tissue ATP content and the adenylate
energy charge still amounted to about 60 and 80 % of pre-ischemic levels,
respectively, demonstrating a dissociation between hemodynamic recovery and
post-ischemic energy metabolism.
lomeavtauv zn /Ae isc/je/wzc-repe//«.^*/ mouse /»ear/
The small but significant transient decrease in tissue fatty acid levels during initial
ischemia is in accordance with previous findings in the ischemic rat heart, in which
also a biphasic pattern in tissue fatty acid content was observed (Van Bilsen et al.,
1989b). In these studies it was also found that substantial amounts of glycerol
accumulated during early ischemia, which indicates increased triacylglycerol-fatty
acid cycling (Van Bilsen et al., 1989b, De Groot et al., 1993a). The observation that
the arachidonoyl content of the tissue (unesterified) fatty acid pool increased during
prolonged ischemia is in favor of a switch from increased triacylglycerol cycling to
enhanced deacylation and/or decreased reacylation of the phospholipid pool during
more prolonged ischemia (Van der Vusse et al., 1992). Restoration of flow resulted
in a substantial elevation of fatty acids, the level being dependent on the length of
the preceding ischemic episode. The high contribution of poly-unsaturated fatty
acids such as arachidonic acid and docosahexaenoic acid relative to saturated fatty
acids is in agreement with an accelerated net degradation of the cardiac
phospholipid pool during the reperfusion phase (Van der Vusse et al., 1992, Van der
Vusse et al., 1998).
It is of interest to note that in the mouse hearts under investigation the phospholipid-
plasmalogen content is substantially lower than earlier reported values in the rat
heart (Van Bilsen et al., 1989), guinea pig heart (Arthur et al., 1985) and bovine
heart (Shaikh et al., 1981). Ischemia and reperfusion did not affect the absolute
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Table V
Relative fatty acid composition of the ventricular (unesterified) fatty acid content in pre-ischemic, ischemic and ischemic-reperfused mouse hearts.
/0 min / /0 in in / •
(SO min Ä
/5 /5 min / +
60 rain Ä
20 min / 20 min / +
(SO min Ä
7b/n/ 0.9 ±0.1 0.5 ± 0.2 2.2 ± 1.3 0.4 ± 0.2 2.5 ±0.3 1.0 ±0.7 3.6± 1.3
/<5.0
/«. /
/S.0
/«: /
/«:.'
.?0.-O
2O.<
22.<
22.0
18.0 ± 1.6
0.7 ±0.1
17.0 ±2.5
13.2 ±0.6
12.5 ±0.8
0.4 ±0.1
4.0 ±0.4
0.7 ± 0.1
28.7 ±3.5
32.7 ±5.7
4 . 1 ± I . I *
22.3 ± 5.0
14.0 ± 1.9
11.2 ±2.1
1.8 t 2.7
1.8 ± 1.7
N.D.
7.2 ± 2 . 7
21.8 ± 1.6
0.4 ± 0.2 '
27.1 ± 3 . 9 "
15.9 ± 1.4
15.9 ± 1.4"*
0.5 ± 0.2
2.9±0 2*
0.4 1 0.1 '"
15.8 ± 2 . 2 " '
31.9 ±3.5
4.0 ± 1.9"
27.0 ± 5 . 4 "
12.5 ± 2 . 7
9.8 ± 3.2
0.4 ±0.2
0.8 ± 0.9
N.D.
8.0 ±3 .2"
22.1 ±2.7
0.5 ± 0.3 '
27.7 ±3.5**
16.3 ± 2 . 3 "
12.1 ±3.1
0.2 ± 0.1
3.0 ± 0.8 *
0.5 ±0.1 '
15.0 ±3.8°*
31.3±6.l
2.4 ± 1.4"
21.6 ±3.4
13.5 ±2.0
14.1 ±2.3
0.5 ± 0.4
2.2 ± 1.4
0.8 ±0.2
9.3 ±5 .o"
22.2 ± 1.9
l.4± 1.8
21.5 ± 2 . 3 *
15.8± 1.5*
14.9 ±2.5
0.1 ±0.1
4.4 ± 1.0*
0.5 ±0.1
14.7 ± 1.5**
Data are expressed as means ± SD. Presented are percentages of total tissue (uneslerified) fatty acids, n indicates number of hearts analyzed.
/: ischemia. Ä: reperfusion. Toto/ refers to total ventricular (unesterified) fatty acid content and is expressed as nmol.g ' dry weight. Values less than 0.1 %
are indicated with N.D. (not detectable) * indicates P < 0.05 vs corresponding end-ischemic value, indicates P < 0.05 vs pre-ischemic value.
Table VI
Total amount of ventricular phospholipids and relative fatty acyl composition in pre-ischemic. ischemic and ischemic-reperrused murine hearts.
To/«/
/ « 0
/<S0,,
/ 6 7
/«0„.
« 7
/«/,,.
_'0.<<
Pr<?-/
198.4 ± 10.3
19.0 ±0.5
0 2 ± 0 0
0.5 ± O.I
18.6 ± 0 8
0.5 ± 0.0
11.4 ±0.6
1.1 ±0.3
15.9 ±0.5
0.2 ± 0.1
6.7 ± 0 . 7
0.2 * 0.0
22.7 ± 1.4
/0 mm /
213 0 ±9.5
19.4 ±0.3
0.4 ± 0.1
0.4 ±0.1
176 ± 0 4
0.2 ± 0.0
11.0 ±0.6
0.1 ± 0.0
17.0 ±0.8
0.2 ±0.1
7.2 ± 0.5
0.2 ±0.1
25 6 ± 1.0 '
;o • ; • / *
60 min Ä
194.0 ±45.6
18.8 ±0.4
2.0 ± 1.2*"
0.4 ± 0.1
18.0 ±0.7
0.8 ± 0.4
11.2 ±0.8
0.4 ± 0.1 ' *
16.5 ±0.5
0.3 ± 0.2
6.9 ± 0.3
0.2 ± 0.0
22.3 ± 0.4 *
/J mi/i /
210.7 ± 20.0
19 4 ±0.7
I I ± I.I
0.4 ± 0.0
17.7 ±0.5
0.4 ± 0.3
II 0 t 06
0.2* 0.1
16.3 ±0.7
0.3 ±0.1
7.2 ± 0.6
0.3 ±0.1
24.8 ±2 .7 *
/5 MM / ••
60 mm Ä
202.7 ± 20.8
19.4 ± 0.6
2.3 ± 0.3 '
05±0 .1
18.3 ±0.7
0.9 ± 0.2
111 ±0.7
0.4 l 0.0* "
16.2 ± 0.9
0.2 ±0.1
6.6±0 5
0.2 ± 0.0
22.1 ± 0 . 7
JO mm /
244.7 ±21.9
19.4 ± 1.0
1.3 ± I.I
0.4 ± 0.1
17.7 ±0.5
0.4 ± 0.3
10.9 ± 0.6
0.2 ± 0 2
17.3 ± 1.0
0.3 ± 0.1
7.2 ± 0.6
0.3 ± 0.1
23.5 ± 2.6
JO nil / +
60 • « Ä
200.0 ± 11.2
19.3 ±0.1
2.5 ± 0.3 '
0.5 ±0.1
18.2 ±0.5
0.9 ± 0.1
11.2 ±0.4
0.5 ± 0 . 1 * "
16.4 ± 0.9
0.3 ± 0.0
7.0 ±0.3
0.3 ± 0.0
21.6 ±0.5
Data are expressed as means ± SD. Presented are percentages of total tissue fatty acyl composition, « indicates number of hearts analyzed. I: ischemia, R: reperfusion,
Tor»/ refers to total ventricular phospholipid content and is expressed as nmol.g ' dry weight. PL refers to the dimethylacetal form of the corresponding fatty aldehyde.
• indicates P < 0.05 vs pre-ischemic value. » indicates P < 0.05 vs corresponding end-ischemic value.
Table V/I
Total amount and relative fatty acyl composition of ventricular triacylglycerol in pre-ischemic, ischemic and ischemic-reperfused murine hearts.
n
7b(a/
/4.0
/(SO
/6.7
/«.0
/«: /
/S:2
20.0
20.4
22:4
22.«
/>«-/
40.8 ±5.3
2.0 ± 0.2
30.9 ± 6.2
4.5 ± 1.2
5.4± 1.1
29.2 ± 4.0
27.3 ± 5 9
0.1 ±0.1
0.2 ±0.1
0.9 ±0.1
0.3 ±0.1
4.3 ± 1.0
6
/0/m/i/
41.9 ±8.9
1.9 ±0.4
25.2 ±3.8
3.4 ± 1.5
4.5 ±0.2
29.2 ± 1.7
28.8 ± 2.4
0.1 ±0.0
0.3 ±0.1
1.1 ±0.4
0.4 ± 0.2
4.9 ± 2.5
5
/Omin/ +
(50 n i l fi
31.1 ±7.4
2.2 ± 0.2
25.0 ±0.7
2.8 ±0.3
4.8 ± 0.3
28.1 ±0.8
28.2 t 1.9
0.1 ±0.1
0.2 ± 0.0
1.3 ±0.2
0.4 ±0.1
5.7 ± 1.2
(>
/5 mm /
38.5 ±7.4
1.9 ±0.6
22.7 ± 2 . 9 '
2.7 ±0.3
4.6 ±0.3
29.2 ± 1.1
31.3 1 2 .8 '
0.1 ±0.0
0.2 ±0.1
1.3 ±0.5
0.4 ± 0.2
5.4 ±2.0
6
/.5 mm / +
60 min Ä
27.8 ± 13.4
2.2 ±0.6
24.5 ± 2.3
3.4 ± 1.7
4.6 ± 0.6
27.5 ± 1.8
28.0 i 3.3
0.1 ±0.1
0.2 ±0.1
1.5 ±0.4
0.4 ±0.1
6.3 ± I.I
6
20 min /
49.8 ± 18.5
1.9 ±0.4
23.7 ±2 .8"
3.1 ±1.0
4.8 ± 0.6
27.5 ± 1.9
31.2 ±2.8*
0.1 ±0.0
0.2 ±0.1 r~
1.3 ±0.2 "'
0.4 ±0.1
5.4 ±2.1
5
20 mm / +
60 mm Ä
34.0 ± 9.6
2.1 ±0.4
24.0 ± 1.8
3.4 ± 1.2
4.6 ± 0.4
27.2 ± 1.8
27.2 ± 1.8«
0.1 ±0.0
0.2 ±0.1
1.5 ±0.4 '
0.4 ±0.1
7.2 ±2.1
Data are expressed as means ± SD. Presented are percentages of total fatty acyl composition, n indicates number of hearts analyzed. I: ischemia, R: reperfusion
7bNi/ refers to total ventricular triacylglycerol content and is expressed as nmol.g' dry weight. • indicates P < 0.05 vs pre-ischcmia, # indicates P < 0.05 vs
corresponding end-ischemic value.
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amount of plasmalogen, but caused a change in the nature of the aliphatic chain
connected via an ether-bond to the glycerol backbone. The cause and significance
of this alteration remains to be elucidated, especially in view of the potential
importance of type VI plasmalogen-specific phospholipases A2 in phospholipid
hydrolysis in the ischemic myocardium (Hazen et al., 1991,).
The positive correlation between the amount of LDH released during reperfusion,
reflecting irreversible cardiac muscle cell injury, on the one hand, and ventricular
total fatty acid or arachidonic acid accumulation during reperfusion, on the other
(Figure 5), which can also be observed in the rat heart (Van Bilsen et al., 1989b),
supports the notion of a causative relation between accelerated phospholipid
degradation during ischemia and/or reperfusion, on the one hand, and irreversible
cell damage, on the other (Van der Vusse et al., 1992, Van der Vusse et al., 1998).
The data in the present study suggest that the basic mechanisms leading to
disturbances in the lipid homeostasis during ischemia and reperfusion as
documented and studied in ischemic-reperfused hearts derived from other species
are also applicable to the murine heart. A distinct advantage of the availability of an
isolated working mouse heart model is the current technological facilities to alter
the expression level of one of the putative contributing factors, such as cardiac
phospholipases A2, to more definitively establish their roles in the sequela of events
leading to ischemia and reperfusion-induced cardiac dysfunction.
In conclusion, the model described in the present study allows detailed
evaluation of the performance of isolated, antegradely perfused mouse hearts during
transient ischemia. The results of the present study are indicative of a high
susceptibility of the mouse heart to ischemia and reperfusion-induced damage. This
model will be asset in the interpretation of the function of specific genes
investigated in transgenic and gene-targeted mouse models for heart diseases.
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Appendix
I/I
Routinely the ventricular phosphocreatine (PCr) and creatine (Cr) in pre-ischemic,
ischemic and ischemic-reperfused murine ventricles were determined using the
HPLC techniques. PCr and creatine (Cr) content in pre-ischemic hearts amounted to
33.3 ± 8.2 and 36.6 ± 5.4 |J.mol.g~' dry weight, respectively, as determined by
HPLC. Following 10 min of ischemia the tissue PCr content tended to decrease to
the expense of Cr, but this decrease did not reach the level of significance (Table
VIII). However, extending the ischemic duration to 15 or 20 min of ischemia
resulted in a substantial decrease of PCr content to 19.2 ± 1.6 and 18.7 ± 4.6
|imol.g"' dry weight, respectively, and significant increases in tissue Cr content, as
determined by HPLC (Table VIII). Large fluctuations were observed in the sum of
PCr and Cr following the different experimental procedures, reaching statistical
significantly lower end-ischemic values compared to post-ischemic values. The PCr
values in ischemic hearts were considered to be less reliable as close inspection of
the chromatogram revealed additional peaks with almost identical RF values as the
original PCr peak.
To explore this issue in more detail, a subset of hearts were subjected to 100
min of normoxic perfusion and PCr content was determined by both HPLC as well
as fiuorometrically. PCr content amounted to 22.0 ± 7.8 and 23.3 ± 3.8 (imol.g ' dry
weight as determined by HPLC and fluorometry (n = 4), respectively. Subjecting
the hearts to 20 min of ischemia resulted in a tissue PCr content of 26.7 ± 2.3 and
14.8 ± 2.0 fimol.g'' dry weight as determined by HPLC and fluorometry (n = 3),
respectively. Finally, following 20 min of ischemia and 60 min of reperfusion, PCr
content amounted to 11.4 ± 7.0 and 11.3 ± 6.8 u.mol.g' dry weight as determined by
HPLC and fluorometry, respectively (Table VIII). The above findings indicate
consistingly lower readings of tissue PCr content as determined by HPLC as
compared to fluorometry, and, hence, PCr values obtained with HPLC techniques in
ischemic hearts should be considered with caution.
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Table V I I I
Total tissue content phosphocreatine (PCr) and creatine (Cr) and their sum in pre-ischemic. ischemic and ischemic-reperfused mouse hearts
/>!•<;-/ /Omiii/ /Omii/t 7 j • • / /5 min / • _'0min/ JO mi»/*
äO min A 60 min A 60 min A
« > 3 . 1 . W « : 23 I ± 7 7 2 9 ! ± 7 6 1 9 2 * 1 6 * 27 6 t 6 I " 187 ± 4 6 * 25 6 ± 8 I
Cr 3 6 6 * 5 4 56 2 ± 10 2 " 34 7 ± 7 1 " 55 6 ± 5 0 ' 28 5 ± 7 2 " 6 0 0 * 1 1 6 ' 31 3 * 7 2 "
/>Cr • Cr 6 9 9 ± 1 0 9 79 3 * 15 5 6 4 5 * 9 5 74 9 ± 4 3 56 I ± 6 2 * 7 8 7 * 1 5 5 5 6 8 * 9 4 *
Data arc expressed as means ± SD Data arc presented in timol g ' dry weight ventricular tissue it indicates number of hearts analyzed Prc-/. pre-ischemia.
/. ischemia. Ä. repcrfusion • indicates P < 0 05 vs pre-ischemic value, ff indicates P < 0 05 vs corresponding end-ischemic value
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Chapter 7
Reduced ischemia tolerance
of hearts from mice with targeted deletion
of the insulin-like growth factor-1 gene.
Oiqp/er 7
, t
Abstract .xtf'JÖt n > - .
In the present study the ischemia tolerance of hearts derived from
heterozygous, insulin-like growth factor-1 (IGF-1) knockout mice
(IGF-1 +/-) was assessed in an isolated left ventricular ejecting mouse
heart preparation. Pre-ischemic coronary flow (CF) was significantly
lower and left ventricular end-diastolic pressure (LVEDP) was
significantly higher in IGF-1 +/- hearts. During reperfusion following
15 min of ischemia functional recovery was more compromised in
IGF-1 +/- hearts as compared to hearts from wildtype littermates, as
evidenced by a reduced recovery of cardiac output (11 ± 5 vs 31 ± 15
% recovery; P < 0.05) and left ventricular developed pressure (26 ± 11
vs 57 ± 11 % recovery; P < 0.05). The percentage irreversibly damaged
cardiac cells following 15 min of ischemia was higher in IGF-1 +/-
than wildtype hearts, as indicated by the greater release of LDH into
the coronary effluent during reperfusion (11.6 ± 4.1 and 5.1 ± 2.6 U.g"'
heart weight per 60 min, respectively). In contrast, following 20 min of
ischemia and 60 min of reperfusion hemodynamic recovery and the
amount of LDH released from the heart was similar in IGF-1 +/- and
wildtype hearts. Cardiac high-energy phosphate content was not
significantly different in reperfused hearts from IGF +/- and wildtype
mice following 15 as well as 20 min of ischemia. In contrast, tissue
fatty acid levels were higher in the reperfused IGF-1 +/- heart
following 15 min of ischemia due to substantial elevation of all major
fatty acid species, including arachidonic acid (115 ± 32 and 41 ± 10
nmol. g"' dry weight in IGF-1 +/- and wildtype hearts, respectively;
P < 0.05), suggesting increased net phospholipid degradation in
IGF +/- hearts. Collectively, these data indicate increased ischemic
vulnerability of the IGF-1 +/- heart, suggesting that IGF-1 affords
cardiac protection towards ischemia/reperfusion if the ischemic insult
does not exceed 15 minutes.
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Introduction
Insulin-like growth factor-1 (IGF-1) is part of the insulin family of peptides and acts
as a pleiotropic growth factor in many tissues and cell types (for a review see
Delafontaine, 1996). Recent studies indicate that IGF-1 may have beneficial effects
in myocardial infarction and in the hypertrophied and failing heart (Reiss er a/.,
1994, Jin er a/., 1995, Duerr er a/., 1996, Tanaka er a/., 1998). In transgenic mice
with cardiac-specific overexpression of IGF-1 necrotic and apoptotic cell death
following coronary artery Hgation was found to be reduced and cardiac function
was found to be better as compared to wildtype littermates (Li er a/., 1997, 1999).
In an earlier study, however, no differences in hemodynamic performance
following myocardial infarction were found between heterozygous IGF-1 deficient
mice and their wildtype littermates (Palmen er a/., 1999). Therefore, in the present
study, it was tested whether partial deficiency of this growth factor would reduce
the vulnerability of the heart towards global ischemia followed by reperfusion. To
this end, hearts from heterozygous IGF-1 deficient mice, originally described by
Powell-Braxton and colleagues (Powell-Braxton er a/., 1993), and their wildtype
littermates were perfused ex v/vo in the working ejecting mode and subjected to
either 15 or 20 min of global ischemia followed by reperfusion for 60 min. The
experiments were performed on isolated hearts to avoid differences in loading
conditions and neurohumoral status which have been shown to be present in //» v/vo
studies (Lembo er a/., 1996). The extent of tissue damage was assessed by
measuring recovery of hemodynamic function and the release of lactate
dehydrogenase (LDH) into the coronary effluent, a marker of irreversible cell
damage, during reperfusion. In addition, tissue levels of high energy phosphates
were monitored. Accumulation of fatty acids, if any, was used as a marker of
disturbances in membrane phospholipid homeostasis in the ischemic/reperfused
heart (Van der Vusse er a/., 1992).
Materials and Methods
CVze/mca/s
All chemicals used for the Krebs-Henseleit solution were of the highest grade
available and purchased from Merck (Darmstadt, Germany) except for D(+)-
glucose and pyruvate (Sigma Chemical Co., St. Louis, MO, USA). Insulin was
purchased from Novo Nordisk A/S (Bagsvaerd, Denmark).
The IGF-1 deficient mice used in this study were originally generated by Powell-
Braxton and colleagues (Powell-Braxton er a/., 1993) by disruption of the coding
sequence in exon 3 of the murine ig/"-/ locus in AB.l embryonic stem cells, upon
which recombinant clones were injected into C57BL/6J blastocysts. Resulting
heterozygous (+/-) and homozygous (-/-) IGF-1 deficient mice were well
characterized (Powell-Braxton era/., 1993). More than 95 % of the homozygous
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IGF-1 knockout mice die at birth and have < 60 % of the body weight of wildtype
littermates. In contrast, heterozygous IGF-1 deficient mice are healthy and fertile in
spite of a 30-40 % reduction of circulating IGF-1 levels. Heterozygous IGF-1
deficient mice are 10-20 % smaller than their wildtype littermates and no obvious
abnormalities or differences can be detected upon histological examination (Powell-
Braxton e/ a/., 1993). In the present study only male IGF-1 +/- mice (n = 10) and
their wildtype littermates (n = 10) were included. The mice were kept under
standard housing conditions with an artificial 12 h light cycle and had free access to
standard rodent food (Diet SRM-A, Hope farms, Woerden, the Netherlands) and tap
water. All experimental protocols were approved by the Institutional Animal Care
and Use Committee of the Maastricht University.
Genotyping of the two mouse strains was performed by genomic PCR analysis to
detect the presence of the targeted vector in the murine jg/^ 7 locus. Briefly, genomic
DNA was isolated from tails using a Qiamp genomic DNA prep kit (Qiagen,
Leusden, The Netherlands). PCR analysis was performed using primers directed
against the neomycin cassette of the original targeting vector, which were
designated L62 (5 -primer) [5 -TGCTCTGATGCCGC-CGTGTTCCGC-3 ] and
L72 (3 -primer) [5 GGTCCGCCACACCCAGCCGGCCAC-3 ]. PCR reactions
were cycled 40 times at 94 °C for 1 min, at 55 °C for 1 min and at 72°C for 2 min,
with an additional amplification cycle of 10 min at 72°C using 1 ug of genomic
DNA as template and 50 pmol of each primer. Detection of a specific product of
about 600 bp was anticipated in the presence of the gene targeting vector and,
hence, the targeted genomic /g/-/ allele in IGF-1 +/- mice.
/.yo/ated HwVt/rtg wow^e Aearf/vepara//o«
The isolated ejecting mouse heart preparation used in the present study was
previously described in detail (De Windt e/ a/., 1999). Briefly, hearts of
anesthetized mice were mounted on the perfusion system and retrograde perfusion
was started immediately at a perfusion pressure of 50 mm Hg. Subsequently, the
left atrium was cannulated with an atrial cannula through one of the lung veins. The
oxygenated (95 % Ov 5 % CO2) Krebs-Henseleit perfusion buffer consisted of: 118
mM NaCl, 4.7 mM KC1, 3.0 mM CaClj, 1.2 mM MgSC>4, 1.2 mM KH2PO4, 25 mM
NaHCOi, 0.5 mM Na-EDTA, 10 mM D(+)-glucose, 1.5 mM Na-pyruvate and 100
mU/1 insulin. Left ventricular pressure was measured with a PE-50 catheter,
inserted into the left ventricular cavity through the apex, connected to a Baxter
pressure transducer (Baxter Healthcare Corp., Irvine, CA, USA). Aortic pressure
was measured through a side branch located 3 mm above the entrance of the aortic
cannula by means of a pressure transducer (Baxter Healthcare Corp.).
All hemodynamic variables were continuously recorded on a personal computer,
using specialized software (Hemodynamic Data Acquisition System, Technical
Department, Maastricht University), allowing the on-line acquisition, presentation
and calculation of left atrial filling flow, aortic flow (AOF), left ventricular systolic
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pressure (LVSP), left ventricular end-diastolic pressure (LVED), diastolic aortic
pressure (AODP) and the first maximal and minimal derivatives of left ventricular
pressure (LV dP/dtmax and LV dP/dtm,n). Left ventricular developed pressure
(LVDP) was defined as the difference between LVSP and LVEDP. Cardiac output
(CO) was defined as the sum of AOF and coronary flow (CF). CF was determined
from the difference between AOF, as measured by an IN inline aortic flow probe,
and left atrial filling flow, as measured by a 2N inline flow probe placed in the left
atrial inflow tract. Calculated CF data were periodically checked by timed
collection of the coronary perfusate.
Hearts were normoxically perfused in the antegrade mode for 20 min (pre-ischemic
period), whereupon the hearts were subjected to normothermic (38.5 ...C) no-flow
global ischemia for either 15 or 20 min (see Chapter 6 for details). Following this
ischemic period the hearts were reperfused retrogradely (perfusion pressure 50 mm
Hg). After 10 min the left atrial conduit was re-opened and the hearts were perfused
in the antegrade mode (preload 10 mm Hg, afterload 50 mm Hg) for an additional
50 min. Except for the ischemic period and during the first 5 min of reperfusion, the
hearts were paced throughout the experimental protocol at 450 beats.min"', a
frequency slightly higher than the intrinsic denervated heart rate of this mouse
strain. Coronary effluent was collected and samples were immediately frozen in
liquid nitrogen and stored at -80 °C for further biochemical analysis. To stabilize
lactate dehydrogenase (LDH) activity in coronary effluent samples, bovine serum
albumin was included (final concentration 3%). After completion of the
experimental protocol the ventricles of the individual hearts were separated from
the atria and immediately frozen between aluminum clamps, previously cooled in
liquid nitrogen, and stored at -80jC for further analysis.
LDH content in the coronary perfusate was assessed spectrophotometrically using a
Cobas Bio autoanalyzer as described earlier (Bergmeyer and Bernt e/ a/., 1974).
Tissue content of adenine nucleotides, IMP, nucleosides and (oxy)purines was
determined by high-performance liquid chromatography (Varian Vista 5500 HPLC)
as described in detail earlier (Chapter 6 and Van Bilsen e/ a/., 1989). The
determination of cardiac fatty acids, phospholipids and triacylglycerols was
performed as described in detail before (Chapter 6 and Van der Vusse and Roemen,
1995). All values were expressed as moles per gram dry weight of ventricular
tissue.
The results are presented as mean values - standard deviations (M + SD). All
statistical analyses were performed using InStat 3.0 software (GraphPad Software
Inc., San Diego, Ca). Differences between values of functional variables and
biochemical parameters were statistically analyzed using one-way ANOVA
followed by the Tukey s test. Linear regression was performed with the least
squares method and the Pearson rank correlation coefficient (r) was used to estimate
115
C/tcipter 7 _ _
the strength of the relation between two variables. In all tests significance was
accepted at P values < 0.05. ...... .
Results
Heterozygous mice with the targeting vector, disrupting the /g/^/ gene, integrated
into the genome, demonstrated a prominent PCR product of about 600 bp, whereas
this product was absent in wildtype littermates (Figure 1). The IGF-1 +/- hearts used
in the present study tended to be slightly smaller than wildtype hearts (215 ± 31 and
225 ± 30 mg wet weight, respectively; n = 10 for both groups), but the difference
did not reach the level of significance. Similarly, heart weight-to-body weight ratios
did not differ significantly between wildtype and IGF-1 +/- mice (6.3 ± 0.7 and 6.4
± 0.4 mg/g, respectively).
M W 1 2 3 4 5 6 7 8 9 1 0 1 1
V
700 —
600
500
400 —
Figure 1. Example of IGF-1 PCR genotyping. Heterozygous IGF-1 deficient animals
were identified by the presence of a prominent PCR product of about 600 bp following
PCR on their genomic DNA as template, resulting from amplification of the integrated
neomycine gene as part of the targeting vector (lanes 2, 3, 5 and 8; IGF-1 +/-), while in
wildtype littermates this product was absent (lanes 1, 4, 6, 7; wt).
recovery
Baseline hemodynamic performance, as measured during the pre-ischemic phase, of
wildtype and IGF-1 +/- hearts is depicted in Table I. No significant differences in
CO and AOF were observed between both groups. Coronary flow rate, however,
was approximately 25 % lower (P < 0.05) in IGF-1 +/- hearts than in wildtype
hearts. In addition, LVEDP was substantially higher in IGF-1 +/- hearts than in
wildtype hearts. Baseline contractility as measured by LV dP/dt™* and LV dP/dt,™
was similar in wildtype and IGF-1 +/- hearts (Table I).
Following 15 min of global ischemia and 60 min of reperfusion CO
recovered to 31 ± 15 % and 11 ± 5 % of the corresponding pre-ischemic values in
wildtype and IGF-1 +/- hearts, respectively (P < 0.05; Table II, Figure 2). LVDP
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recovered to 57 + 11% and 26 ± 11 % of their corresponding pre-ischemic values in
wildtype and IGF-1 +/- hearts, respectively (P < 0.05; Table II and Figure 2). In
both groups the decrease in post-ischemic LVDP could be attributed to both a rise
in LVEDP and a decrease in LVSP, Post-ischemic LV dP/dWx and LV dP/dUn
tended to be lower for IGF-1 +/- hearts, but the difference did not reach the level of
significance (Table II and Figure 2).
When the ischemic period was extended to 20 min in IGF +/- hearts
functional recovery during reperfusion was as poor as in the 15 min ischemia group
(Table II). In contrast, in wildtype hearts further deterioration of cardiac function
was observed (Table II). As a result, following 20 min of ischemia hemodynamic
recovery was severely depressed in all hearts and comparable between the two
groups. For instance, CO recovered to only 17 ± 20 % and 9 + 11 % of their
corresponding pre-ischemic value in wildtype and IGF-1 +/- hearts, respectively
(N.S.; Figure 2). . .
Table I
Pre-ischemic values of functional parameters of isolated, left ventricular ejecting hearts
from wildtype (wt) and heterozygous IGF-1 deficient mice [IGF-1(+/-)].
wf /GF-/ f+/-J
55.3 ±
13.5 ±
42.2 ±
8 ± 3
87 ±8
5.7
3.6
7.1
77 ±10
6,393:
-3,802
t 818
±865
48.2
10.2
37.2
13±
85 ±
72 ±
±
±
±
2
11.4
2.7*
10.6
**
10
7
6,808 ±1,102
-3,685 ±514
Data are expressed as means ± SD (both groups n = 10). Isolated hearts were perfused in the
antegrade mode for 20 min at a pre and afterload of 10 and 50 mm Hg, respectively, and paced at
450 beats.min'. CO, cardiac output; CF, coronary flow; AOF, aortic flow; LVDP, left ventricular
developed pressure; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic
pressure; LV dP/dt™*, first maximal derivative of left ventricular pressure; LV dP/dt^,,,, first
minimal derivative of left ventricular pressure. * indicates P < 0.05, ** indicates P < 0.01 between
wildtype and IGF-1 (+/-) mice.
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Pre-ischemic LDH release was comparable in wildtype and IGF-1 +/- hearts and
amounted to 0.2 ± 0.1 and 0.3 ± 0.1 U.min'.g"', respectively (N.S.; n=10 for both
groups). In contrast, the post-ischemic cumulative LDH release was significantly
higher in IGF-1 +/- hearts than in wildtype hearts following the shortest ischemic
period tested and amounted to 11.6 ± 4.1 and 5.1 ± 2.6 U.g'' per 60 min,
respectively (P < 0.05; n = 5 in both groups). Following 20 min of ischemia the
cumulative release of LDH release amounted to 19.4 ± 5.7 and 14.7 ± 4.1 U.g"' for
wildtype and IGF-1 +/- hearts, respectively, (N.S.; n = 5 in both groups).
recovery
In reperfused hearts previously subjected to 15 min of ischemia the tissue levels of
phosphocreatine (PCr) and creatine (Cr) were not significantly different between
both groups (Table III). Also, tissue ATP, ADP and AMP levels and adenylate
energy charge (EC) were similar between wildtype and IGF-1 +/- hearts (Table III).
The tissue content of adenine nucleotide degradation products (i.e., sum of
adenosine, inosine, hypoxanthine en xanthine), glycogen and lactate did not differ
between both groups either (Table III).
Following 20 min of ischemia and 60 min of reperfusion no significant
differences were observed in tissue PCr, ATP, ADP, AMP and EC between
wildtype and IGF-1 +/- hearts (Table III). The same holds for the tissue content of
(oxy)purines, glycogen and lactate (Table III). In reperfused hearts previously
subjected to 20 min of ischemia in both groups the tissue content of (oxy)purines
and lactate tended to be higher than after 15 min of ischemia. The tissue lactate
content was significantly higher in IGF +/- than in wildtype hearts.
No significant differences in either the cardiac phospholipid (PL) and
triacylglycerol (TG) content (Figure 3) or the fatty acid composition of these lipid
pools (data not shown) were observed between wildtype and IGF +/- hearts
following either 15 or 20 min of ischemia and reperfusion. However, following 15
min of ischemia and reperfusion the tissue content of total (unesterified) fatty acids
(FA) was significantly higher in IGF-1 +/- than in wildtype hearts (Figure 3). As
demonstrated in Figure 4, tissue levels of all individual fatty acid species were 2 to
2.5-fold higher in reperfused IGF-1 +/- than in wildtype hearts. In contrast, in
reperfused IGF +/- and wildtype hearts previously subjected to 20 min of ischemia
total tissue FA levels (Figure 3) and the levels of individual FA species, including
arachidonic acid (data not shown), showed no significant differences.
Discussion
The findings in the present study indicate that IGF-1 may have a protective effect in
myocardial ischemia of short duration, bacause the myocardium of heterozygous
IGF-1 deficient mice was more sensitive to ischemia/reperfusion than that of the
wildtype littermates following 15 min of ischemia. After 20 min of ischemia,
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however, the differences between the strains had disappeared. These results support
the notion that the trophic effects of IGF-1 delay cardiac ischemia/reperfusion-
induced dysfunction (Ross e/ a/., 1996). The findings are also in line with
observations of protective effects on hemodynamic function of IGF-1 following
myocardial infarction in transgenic mice overexpressing IGF-1 specifically in the
mouse heart (Li e/ o/., 1997).
Table II
Hemodynamic function of reperfused wildtype (wt) and IGF-1 (+/-) hearts following 15 and
20 min of global ischemia and 60 min of reperfusion.
CO (m/.m/w" V ;
^OF(m/.m/«'.gO
CFrm7.m/«'.g';
/ ^ D P ^
75 mm
vW
31.0 ±15.1
11.3 ± 17.1
19.7 ±9.7
10 ± 3
68 ±6
57+11
/scAem/a
/GF-7 r+/-;
11.3 ±4.9 *
0.2 ± 8.0
12.9 ±3.7
18 ±4 *
43 ±28
26 + 11 *
20 mm
w,
4.7 ±5.9^
-5.1 ±0.8
9.8 ±6.5
16±5*
26 ±25 *
17+13
/GF-7 (+/-;
9.1 ± 11.1
-1.0±8.7
10.1 ±9.0
18 ± 3
46 ±13
22+16
(mm//g.s'j 4,133 ±669 3,005 ± 2,235 1,138 ±77 * 2,067 ± 1,949
(mm //g.5"0 -2,676 ±450 -1,672 ± 1,062 -992 ±641 * -1,300 ± 867
Data are expressed as means ± SD (n = 5 for wt and IGF-1 (+/-) following each ischemic
period). Isolated hearts were perfused in the antegrade mode at a pre and afterload of 10 and
50 mm Hg, respectively, and paced at 450 beats.min"'. CO, cardiac output; CF, coronary
flow; AOF, aortic flow; LVDP, left ventricular developed pressure; LVSP, left ventricular
systolic pressure; LVEDP, left ventricular end-diastolic pressure; LV dP/dt„,ax, first maximal
derivative of left ventricular pressure; LV dP/dtn,,„, first minimal derivative of left ventricular
pressure. * indicates P < 0.05 between wt and IGF-1 (+/-) following identical ischemic
period, # indicates P < 0.05 vs group with identical genotype subjected to 15 min of
119
15 min I/R
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CF LVDP dP/dW dP/dtn
20 min I/R
LVDP dP/dtn dP/dtn
Figure 2. Post-ischemic percentage recovery of hemodynamic variables in isolated wildtype hearts
(wt; open bars) and IGF-1 deficient (IGF-1 +/-; closed bars) following 15 (upper panel) or 20 min
of global ischemia (lower panel). Data are presented as means ± SD. CO, cardiac output; CF,
coronary flow; LVDP, left ventricular developed pressure; LVSP, left ventricular systolic pressure;
LV dP/dtmax, first maximal derivative of left ventricular pressure; LV dP/dtn,,,,, first minimal
derivative of left ventricular pressure. * indicates P < 0.05 between wildtype and IGF +/-.
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15 min I/R 20 min I/R
Figure 3
Post-ischemie ventricular content
of the total (unesterified) fatty
acid, phosphol ipid and
triacylglycerol content in 1GF-1
deficient (IGF-1 +/-; closed bars)
and wildtype hearts (wt; open
bars) following 15 and 20 min of
ischemia. Data are presented as
means ± SD. * indicates
P < 0.05 between IGF-1 +/- and
wt.
15minI/R 20 min I/R
15minI/R 20 min l/R
Following 15 min of global ischemia a significantly greater extent of irreversibly
damaged cardiac muscle cells were found in the IGF-1 +/- mouse heart. The present
findings corroborate with observed protective effects of IGF-1 towards necrotic and
apoptotic cell death following myocardial infarction in transgenic mice with
cardiac-specific overexpression of IGF-1 (Li e/ a/., 1997) and following non-
occlusive coronary artery constriction in the mouse (Li er a/., 1999). Similar
beneficial effects of IGF-1 on cardiac performance of regional infarction have been
documented in experimental rat heart models where IGF-1 was administered
exogenously (Reiss «>/ a/., 1994, Jin e/ a/., 1995, Duerr e/ a/., 1996). The exact
mechanism through which IGF-1 exerts its protective effect is incompletely
understood. Previous studies provide indications that IGF-1 has potent anti-
apoptotic effects on the cardiomyocyte both /« v/vo and /AJ v/7ro (Reiss ef a/., 1994,
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Li ef a/., 1997, Parrizas <?f a/., 1997, Wang e/ a/., 1998a, Wang e/ a/., 1998b, Leri e/
a/., 1999, Palmen e/ a/., 1999). Although accelerated cardiac cell death in the
absence of IGF-1 may provide an attractive explanation for the observed
phenomena, other possible explanations should not be dismissed.
14-0 16-0 18-0 18-1 18-2 20-4 22-6
Post-ischemic ventricular content of the major individual fatty acid species
in wildtype hearts (wt; open bars) and IGF-1 deficient (IGF-1 +/-; closed
bars) folowing 15 min of ischemia. Individual fatty acid species are
indicated by their chemical notation. Data are presented as means ± SD.
* indicates P < 0.05 between IGF-1 +/- and wt.
In this respect the observed differences in baseline normoxic hemodynamic
performance between IGF-1 deficient and wildtype hearts deserve attention. Of note
are the observed differences in end-diastolic left ventricular pressure and coronary
flow. The significantly higher left ventricular end-diastolic pressure indicates
diastolic dysfunction and filling abnormalities in the heterozygous IGF-1 deficient
(IGF-1 +/-) heart under normoxic conditions. Another IGF-1 targeted mouse
model, the so-called IGF-1 midi mouse in which plasma IGF-1 levels are
approximately 30-40 % of normal, also display alterations in cardiac performance in
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terms of fluid ejection and left ventricular pressure development as measured /«
v/'vo (Lembo e/ a/., 1996). The significantly lower baseline coronary flow rate in
IGF-1 +/- hearts than in wildtype hearts is in line with a recent observation of
reduced capillary density in the hearts of the same IGF-1 +/- mice (Palmen ef a/.,
1999) and the reported requirement of IGF-1 for the proper development of the
microvasculature in other tissues (Sonntag e/ a/., 1997, Tonshoff e/ a/., 1998).
Reduced capillary density and, hence, diminished tissue perfusion may contribute to
the reduced ischemia tolerance under conditions of chronic IGF-1 shortage.
The present data demonstrate enhanced accumulation of (unesterified) fatty
acids, including arachidonic acid, indicative of increased net phospholipid
degradation, in IGF +/- reperfused hearts subjected to 15 min of ischemia. The
present findings, however, do not allow to conclude that the increased net
phospholipid degradation is directly related to enhanced phospholipase activity in
the hearts of IGF +/- mice. Nonetheless, relatively strong correlations were
observed between the extent of arachidonic acid accumulation in reperfused hearts,
on the one hand, and the cumulative release of LDH or recovery of cardiac output
during the reperfusion phase, on the other (Figure 5).
A number of studies have provided evidence for an inhibitory effect of
IGF-1 on phospholipase activity via trancriptional as well as post-transcriptional
mechanisms in various cell systems (Berenbaum ef a/., 1994, Jacques e/ a/.,
1997;Pruzanski e/ a/., 1998). It is tempting to speculate that mufa/« mu/an&
reduced IGF-1 levels are associated with a stimulatory effect on cardiac
phospholipase activity. Collectively, these observations suggest that phospholipase
A2-mediated net degradation of membrane phospholipids might play a role in the
events associated with the increased ischemia vulnerability of the IGF-1 deficient
heart.
In conclusion, using an isolated working murine heart model, it was found
that hearts from mice with chronically reduced IGF-1 levels are more susceptible to
cardiac dysfunction following no-flow ischemia of short duration, as demonstrated
by reduced recovery of cardiac output, increased irreversible cell damage, and
higher tissue fatty acid levels following 15 min of ischemia and reperfusion. These
findings lend additional support to the notion that IGF-1 exerts salutatory effects on
the ischemic/reperfused myocardium. The present findings also support the notion
that the e* v/vo ejecting mouse heart model as characterized in CAa/?/er 5 and
C/jop/er 6 allows the detection of both subtle differences in hemodynamic function
under baseline conditions and small differences in susceptibility towards global
ischemia and reperfusion between hearts derived from gene-targeted or transgenic
mouse models and their wildtype littermates.
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Chapter 8
Type IIA secretory phospholipase A2-
deficiency fails to attenuate decline in
mechanical function, cellular viability and
accumulation of fatty acids in the ischemic-
reperfused mouse heart. ,
LJ De Windt, J Willems, TM Roemen, WA Coumans, RS Reneman, GJ Van
der Vusse, M Van Bilsen. Type IIA secretory phopholipase A2-deficiency
fails to attenuate cardiomyocyte damage in the ischemic-reperfused mouse
heart.
A b s t r a c t '•'* ^ « - > ^ — , • • • ^ ••--•
In the present study the role of type IIA secretory phospholipase A2
(type IIA SPLA2) in cardiac ischemia/reperfusion-induced fatty acid
accumulation, cellular damage and loss of function was investigated by
subjecting isolated ejecting hearts derived from wildtype (C57BL/Ks)
and type IIA sPLA2-deficient mice (C57BL/6) to 17.5 min of global
ischemia followed by 60 min of reperfusion. Pre-ischemic cardiac
output (CO), aortic flow (AOF) and coronary flow (CF) normalized for
heart weight was comparable between the two groups. Post-ischemic
functional and metabolic recovery between type IIA SPLA2 wildtype
and type IIA SPLA2 deficient hearts did not demonstrate significant
differences (37 ± 23 and 39 ± 25 % recovery of CO, respectively;
recovery of energy charge to 0.79 ± 0.04 and 0.83 ± 0.05,
respectively). The post-ischemic tissue content of total unesterified
fatty acids (FA) and arachidonic acid amounted to 2671 ±1151 and 70
± 32 nmol.g' dry weight for wildtype and 2683 ± 911 and 107 ± 87
nmol.g' dry weight for type IIA sPLA^-deficient hearts, respectively.
Cumulative lactate dehydrogenase release into the coronary effluent
during reperfusion, reflecting irreversible cell damage, amounted to
10526 ± 3610 and 11306 ± 3545 mU.g"' wet weight for C57BL/Ks and
C57BL/6 hearts, respectively. In addition, no differences were
observed in either total phospholipid and triacylglycerol content or
their respective fatty acyl composition between the two strains. Based
on these results it is doubtful whether cardiac type IIA SPLA2 plays a
substantial role, if any, in acute ischemia/reperfusion-induced injury of
cardiac structures.
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Type IIA secretory phospholipase A2 (type IIA SPLA2) catalyzes the hydrolysis of
sn-2 fatty acyl ester bonds of phospholipids, yielding lysophospolipids and
unesterified fatty acids (FA), including arachidonic acid (AA). Type IIA SPLA2 has
been detected in a wide variety of cell types where it plays a role in AA-dependent
cell signaling, in the physiological turnover of membrane phospholipids and in
inflammatory processes such as rheumatoid arthritis and septic shock (Vadas er a/.,
1993, Lin er a/., 1996, Murakami er a/., 1995). Likewise, type IIA SPLA2 transgenic
mice display more severe inflammatory responses to proinflammatory stimuli
(Grass er a/., 1996, Nevelainen er a/., 1997, Fox er a/., 1996). Additionally, its
activity has been associated with intestinal tumorigenesis (Cornier er a/., 1997), and
brain and intestinal ischemia-reperfusion injury (Otamiri er a/., 1987, Lauritzen er
a/., 1994).
In contrast to other tissues (Balsinde er a/., 1996, Reddy er a/., 1997,
Murakami er a/., 1998), the physiological role of phospholipase A2 (PLA2) and its
potential involvement in ischemia and reperfusion-induced cellular damage has not
been well defined in cardiac tissue. Cardiac PLA2S have been implicated in the
deacylation cycle of the physiological membrane phospholipid turnover (Van der
Vusse er a/., 1992), in mediating the rate-limiting step in the AA cascade (Van
Bilsen er a/., 1995), and in playing a role in myocardial ischemia and reperfusion-
induced phospholipid degradation (Van der Vusse er a/., 1982, Chien er a/., 1984,
Otani er a/., 1989, Van Bilsen er a/., 1989b). Accelerated hydrolysis of cardiac
membrane phospholipids during ischemia and reperfusion is thought to contribute
to membrane destabilization and concomitant generation of biologically active lipid
second messengers, which ultimately precipitate to electrophysiological dysfunction
and cellular injury (Gross er a/., 1992, Corr er a/., 1995, Van der Vusse er a/.,
1992). The assessment whether PLA2 activity indeed is crucial in the transition from
reversible to irreversible myocardial ischemia and reperfusion-induced injury and
identification of the dominant cardiac PLA2(s) responsible in this process could
therefore be of therapeutic importance.
It should, however, be noted that until now at least four different types of
PLA2 enzymes have been detected in myocardial tissue; the high molecular mass
(85-100 kDa) arachidonoyl-specific type IV cytosolic PLA2 (Sharp er a/., 1993), the
calcium-independent, plasmalogen-specific type VI PLA2 (Hazen er a/., 1993), and
the functionally closely related type IIA and type V secretory PLA2S (Chen er a/.,
1994, De Windt er a/., 1997). Which type of PLA2 likely plays a dominant role in
mediating cardiac I/R-induced membrane phospholipid-degradation remains a
matter of continuing speculation (Gross era/., 1992, Van Bilsen er a/., 1995, Van
der Vusse er a/., 1997, De Windt er a/., 1998). In this light, the recent finding of a
number of inbred mouse strains which display a frameshift mutation in the /?/a2ga
gene, resulting in the absence of a functional type IIA SPLA2 enzyme, is of interest
(Kennedy er a/., 1995, MacPhee e/ a/., 1995).
In an attempt to establish the role of type IIA SPLA2 in mediating cardiac
ischemia and reperfusion-induced membrane phospholipid degradation, isolated
ejecting hearts from the wildtype C57BL/K.S and the type IIA sPLA2-deficient
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C57BL/6 strain were subjected to 17.5 min of global, normothermic ischemia
followed by 60 min of reperfusion. Loss of function was monitored by
hemodynamic variables as cardiac output (CO), left ventricular developed pressure
(LVDP) and the first maximal and minimal derivative of left ventricular pressure
(LV dP/dtmax and LV dP/dtm,n)- The percentage irreversibly damaged
cardiomyocytes was determined by the cumulative LDH release into the coronary
effluent during the reperfusion phase. Post-ischemic high energy phosphate and
glycogen content was determined to compare the metabolic state of the hearts. Post-
ischemic cardiac AA content was assessed to specifically monitor potential
differences in PLA2 activity.
Materials and Methods
All chemicals used for the Krebs-Henseleit solution were of the highest grade
available and purchased from Merck (Darmstadt, Germany) except for D(+)-
glucose and pyruvate (Sigma Chemical Co., St. Louis, MO, USA). Insulin was
purchased from Novo Nordisk A/S (Bagsvaerd, Denmark).
M 1 2 3 4 5 6
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Figure 1. Genomic PCR analysis of />/a2ga gene. Analysis by PCR amplification of
exon 3 of thep/a2ga gene of genomic DNA isolated from C57BL/K.S (lanes 2, 4, 6) and
C57BL/6 mice (lanes 1, 3, 5). After amplification as described under Materials and
Methods PCR product were digested by BamHI. As demonstrated, p/a2ga exon 3
derived from C57BL/K.S mice was readily digested by BamHI resulting in two fragments
of about 200 and 300 bp (lane 2, 4, 6). In contrast, T insertional mutation disrupted the
p/a2ga exon 3 BamHI site in C57BL/6 mice (lane 1, 3, 7).
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Adult male inbred ' '
C57BL/Ks Table I
f wildtvoe p/a2j?a Characteristics of the C57BL/Ks mice [sPLAj (+/+)] and
) d i br d C57BL/6 mice [SPLA2 (-/-)] used in the present study.
C57BL/6 mice
(mutated p / a 2 g a
g e n e ) w e r e
purchased from M /4ge fweefo,) 15 ±2 18 ±2
& B, Ry, Denmark ^ ^ 237±22 302±16*
and B & K, Hull, tf»-^ — • - '
rlspetivdy^The ^ / ^ ^ ^
animals wereani als ere
allowed to adjust to °** "* expressed as means ± SD (n = 11 and 10 for
the new housine *"-*> ^ *"<* ^ ^ ^ > ' ^spectively). BW, body
, nuiiMiig weight; HW, heart weight. • indicates P < 0.05 between
conditions for two ^ ^ (+,+) and sPLA; (-/-).
weeks before
admiss ion to
experimental use.
The mice were kept under standard housing conditions with an artificial 12 h light
cycle. Standard rodent food (Diet SRM-A, Hope farms, Woerden, the Netherlands)
and tap water were freely accessible. All experimental protocols were approved by
the Institutional Animal Care and Use Committee of the Maastricht University.
PC/? ge/
Genotyping of the two mouse strains to detect functional type IIA SPLA2 deficiency
was performed as described previously (Kennedy ef a/., 1995). Briefly, genomic
DNA was isolated from tails using a Qiamp genomic DNA prep kit (Qiagen,
Leusden, The Netherlands). PCR analysis of type IIA SPLA2 exon 3 was performed
using the following primers: 5 -primer (5 -CTGGCTTTCCTTCCTGTCAGCCTGG
CC-3 ); 3 -primer (5 -GGAAACCACTGGGACACTGAGGTAGTG-3 ). PCR
reactions were cycled 35 times at 94 °C for 30 s, 60 °C for 30 s and 72°C for 30 s,
with an additional amplification cycle of 10 min at 72°C using 100 ng of genomic
DNA as template and 50 pmol of each primer. Since in type IIA sPLA2-deficient
mouse strains a thymidine insertion disrupts a BamHI site in exon 3 of the P/a2ga
gene, PCR products were digested with BamHI prior to subjection to gel
electrophoresis to confirm disruption of the BamHI restriction site and, hence,
occurrence of the mutation.
/so/ateo" worAr/flg wiowse Aearf preparafto«
The isolated ejecting mouse heart preparation used in the present study was
previously described in detail (De Windt e/ a/., 1999). Briefly, animals were
anesthetized by a 50 mg.kg' sodium pentobarbital injection i.p. (Nembutal, Sanofi
Sante BV., Maassluis, the Netherlands). After thoracotomy the hearts were quickly
excised and transferred to ice-chilled perfusion modified Krebs-Henseleit buffer
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(for composition see below). Remnant thymic and adipose tissue was carefully
removed and the ascending aorta was cannulated with a recently described aortic
cannula designed to match the hemodynamic aortic impedance characteristics of the
isolated murine heart (De Windt e/ a/., 1999). Retrograde perfusion was started
immediately at a perfusion pressure of 50 mm Hg, after which the hearts started to
beat spontaneously. The left atrium was cannulated with an atrial cannula through
one of the lung veins. The recirculating modified Krebs-Henseleit perfusion buffer
was prefiltered by a microfilter (0.45 u.m diameter; Millipore Corp.) and consisted
of the following composition: 118 mM NaCl, 4.7 mM KC1, 3.0 mM CaCU, 1.2 mM
MgSO„, 1.2 mM KH2PO4, 25 mM NaHCOj, 0.5 mM Na-EDTA, 10 mM D(+)-
glucose, 1.5 mM Na-pyruvate and 100 mU/1 insulin. The buffer was continously
gassed with 95 % O2- 5 % CO2. Cardiac output (CO) was defined as the sum of
aortic flow (AOF) and coronary flow (CF). CF was determined from the difference
between aortic flow (AOF), as measured by an IN inline flow probe (Transonic
System Inc., Ithaca, NY, USA) and left atrial filling flow as measured by an 2N
inline flow probe (Transonic System Inc.) placed in the left atrial filling line. Aortic
pressure was measured through a side branch located 3 mm above the entrance of
the aortic cannula using a pressure transducer (Baxter Healthcare Corp.). Left
ventricular pressure was measured with a PE-50 catheter, inserted into the left
ventricular cavity through the apex (De Windt e/ a/., 1999), connected to a Baxter
pressure transducer (Baxter Healthcare Corp., Irvine, CA). Left ventricular
developed pressure (LVDP) was defined as the difference between left ventricular
systolic (LVSP) and end-diastolic pressure (LVEDP).
Hearts were perfused under normoxic conditions for 20 min in the antegrade mode
following an initial 10 min retrograde perfusion period to adjust to the perfusion
apparatus (pre-ischemic period). Just prior to the ischemic period the water-jacketed
chamber was filled with perfusate solution until the heart was completely
submersed, pacing was stopped, and the aortic and atrial lines were clamped to
create a normothermic (38.5 °C) global ischemia. During prelimenary experiments a
limited number of wildtype C57BL/K.S hearts were subjected to either 15, 17.5 or
20 min of ischemia and their post-ischemic functional recovery and LDH release
was monitored. It was found that 15 min of ischemia resulted in a near complete
post-ischemic functional recovery and minimal LDH release. In contrast, 20 min of
ischemia resulted in a substantial loss of function (less than 10 % recovery of CO)
and loss of about 10 % of total cardiac LDH content. To this end, it was decided to
subject all hearts in the present study to 17.5 min of ischemia to obtain a loss of
function and LDH release in C57BL/K.S hearts which still allows measurable
potential improvement or deterioration of these parameters in the absence of type
IIA SPLA2. After the ischemic period, the water-jacketed chamber was emptied and
hearts were reperfused in a retrograde manner at
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Table II
Pre-ischemic hemodynamic values measured in isolated, left ventricular ejecting murine
hearts from the C57BL/K.S [sPLA2(+/+)l and C57BL/6 fsPLA2 (-/-)1 strain.
CO fa/-»"«" V ; 49.0 + 8.9 .. • , 52.3 ± 11.0
' • • • • • • • ' • • ' 4 4 . 3 ± 7 . 8
8.0 ±1.6
86± 14 *
97 ±15 *
5 ± 3
^ (mm //g. / ' j 6,461 ± 1,398 8,578 ± 1,734 *
„•„ from //g.s '; -3,435 ± 434 -4,102 ± 545 *
.  
37.9 ±
7.4 ± 1
68 ± 9
85 ±9
7±4
:
-3,435
.
7.1
.3
t 
434
Data are expressed as means ± SD (n =9 and 8 for SPLA2 (+/+) and SPLA2 (-/-),
respectively). Isolated hearts were perfused in the antegrade mode at a pre and after load
of 10 mm Hg, respectively, and paced at 380 beats.min"'. CO, cardiac output; CF,
coronary flow; AOF, aortic flow; LVDP, left ventricular developed pressure; LVSP, left
ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; LV
dP/dtmax) first maximal derivative of left ventricular pressure; LV dP/dtm,n, first minimal
derivative of left ventricular pressure. * indicates P < 0.05 between SPLA2 (+/+) and
SPLA2 (-/-).
a perfusion pressure of 50 mm Hg for 10 min. The left atrial conduit was re-opened
and the hearts were allowed to work in the antegrade mode at a preload pressure of
10 mm Hg and a diastolic aortic pressure of 50 mm Hg for an additional 50 min.
Except for the ischemic period and during the first 5 min of retrograde perfusion in
the reperfusion phase, the hearts were paced throughout the whole experiment at a
frequency of 380 beats.min"' that was slightly higher than their intrinsic denervated
heart rate. Coronary perfusate was collected and samples were immediately frozen
in liquid nitrogen and stored at -80 °C for further biochemical analysis. To stabilize
lactate dehydrogenase (LDH) activity in coronary effluent samples, bovine serum
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albumin was included (final concentration 3%). After completion of the
experimental protocol the ventricles of the individual hearts were separated from
the atria and immediately frozen between aluminum clamps, previously cooled in
liquid nitrogen, and stored at -80 jC for further analysis.
LDH content in the coronary perfusate were assessed spectrophotometrically using
a Cobas Bio autoanalyzer as described earlier (Bergmeyer and Bernt e/ a/., 1974).
Tissue content of adenine and guanine nucleotides, IMP, nucleosides,
(oxy)purines and (phospho)creatine was determined by high-performance liquid
chromatography (Varian Vista 5500 HPLC) as described previously in detail
(Chapter 6 and Van Bilsen <?/ a/., 1989a).
The determination of cardiac fatty acids, phospholipids and triacylglycerols
was performed by thin-layer chromatography followed by gas chromatography as
recently described in detail (Van der Vusse and Roemen, 1995).
All values were expressed as moles per gram dry weight tissue. Dry weight
was determined in a subset of hearts by freeze drying overnight and amounted to
14.6 % of wet weight, which corresponds to a conversion factor of 6.85 for wet
weight to dry weight murine ventricular tissue.
The results are presented as mean values - standard deviations (SD). All statistical
analyses were performed using InStat 3.0 software (GraphPad Software Inc., San
Diego, Ca). Changes in functional variables were statistically analyzed by repeated
measures ANOVA with Tukey s HSD post-hoc correction test for multiple
comparisons. Differences between values of functional variables between
experimental groups were analyzed using one-way ANOVA followed by the
Tukey s test. Differences between values of biochemical parameters were tested
using Student s t-test. In all tests significance was accepted at P values < 0.05.
Results
To confirm thymidine insertional mutation in exon 3 of the p/a2ga gene in the
inbred C57BL/6 strain and its absence in the inbred C57BL/K.S strain, exon 3 was
amplified from a number of individual mice from both strains and digested with
BamHI. Full length genomic PCR products from both strains were of the expected
length of 500 bp. The C57BL/6 exon 3 PCR fragments could not be digested by
BamHI, indicating disruption of the wildtype BamHI site, while digestion of the
C57BL/K.S PCR products resulted in two cleavage signals of 300 and 200 bp,
respectively (Figure 1). In the remainder of this chapter C57BL/Ks and C57BL/6
mice are referred to as SPLA2 (+/+) and SPLA2 (-/-) mice, respectively. Table I
presents some morphometric characteristics (age, body weight, heart weight) of the
mice used in the present study. It should be noted that the SPLA2 (+/+) mice used in
the present study had substantially lower heart and body weights as the SPLA2 (-/-)
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mice, which partially may be related to small differences in age and/or vendors of
the inbred mice (Table I). •. .--.-•
Fu/icf/orta/ recovery -' :
Pre-ischemic values of the hemodynamic variables tested of both experimental
groups are presented in Table II. No significant differences were found in absolute
pre-ischemic CF and LVEDP values between the two groups tested. Absolute
values for CO, AOF, LVSP, LV dP/dt,™* and LV dP/dt,™ were significantly lower
for hearts from SPLA2 (+/+) than for SPLA2 (-/-) hearts. When corrected for heart
weight, however, CO and AOF were comparable between both strains and
amounted to 49.0 ± 8.9 and 37.9 ± 7.1 ml.min'.g"' for SPLA2 (+/+) hearts and 52.3
±11.0 and 44.3 ± 7.8 ml.min'.g"' for SPLA2 (-/-) hearts, respectively (N.S.). Pre-
ischemic CF normalized to heart weight amounted to 7.4 ± 1.3 and 8.0 ± 1.6
ml.min"'.g"' for SPLA2 (+/+) and SPLA2 (-/-) hearts, respectively (P < 0.05; Table
II)).
Table HI
Percentage recovery of hemodynamic parameters of SPLA2 (+/+) and SPLA2 (-/-) hearts
following 17.5 min of ischemia and 60 min of reperfusion.
CO 37 ±23 39 ± 25
4OF 15 ±19 21 ±34
CF 127 ±46 104 ±58
Z.KD/> 69 ±21 57 ±27
LKSP 76 ±15 68 ±25
253 ±15 231 ± 105
65 ±18 70 ±32
67 ±24 55 ±29
Data are expressed as means ± SD (n =9 and 8 for SPLA2 (+/+) and SPLA2 (-/-),
respectively). Isolated hearts were perfused in the antegrade mode at a pre and afterlaod of
10 mm Hg, respectively, and paced at 380 beats.min'. CO, cardiac output; CF, coronary
flow; AOF, aortic flow; LVDP, left ventricular developed pressure; LVSP, left ventricular
systolic pressure; LVEDP, left ventricular end-diastolic pressure; LV dP/dt™*, first maximal
derivative of left ventricular pressure; LV dP/dt^,,, first minimal derivative of left
ventricular pressure. * indicates P < 0.05 between SPLA2 (+/+) and SPLA2 (-/-).
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Following 17.5 min of global, normothermic ischemia and 60 min of reperfusion
CO recovered to 19.6 ± 16.8 and 20.4 ± 13.9 ml.min'.g', representing 37 ± 23 and
39 ± 25 % of the corresponding pre-ischemic values in SPLA2 (+/+) and SPLA2 (-/-)
hearts, respectively (N.S.). LVDP values recovered to 46 ± 13 and 47 ± 19 mm Hg
at the end of the reperfusion period in wildtype and type IIA SPLA2 deficient hearts,
respectively (N.S.). The decrease in postischemic LVDP was caused by both a rise
in LVEDP and a reduction of LVSP, which decreased to 64 ± 14 and 64 ± 25 mm
Hg in SPLA2 (+/+) and SPLA2 (-/-) hearts following 60 min of reperfusion (P <
0.05 vs pre-ischemia; Table III). In both groups, post-ischemic LV dP/dtmax and LV
dP/dtmin were substantially reduced in the acute reperfusion phase as compared to
their pre-ischemic values and amounted to 4240 ± 1507 and —2306 d841 mm Hg.s'
for SPLA2 (+/+) and 4527 ± 2085 and —2748 ±1058 mm Hg.s"' for sPLAj (-/-)
hearts, respectively (Table III).
To measure the extent of irreversibly damaged cardiac muscle cells following
ischemia and reperfusion, the release of LDH into the coronary effluent was
continuously monitored throughout the experimental protocol. Pre-ischemic LDH
release was low in both the wildtype and type IIA sPLA2-deficient hearts and
amounted to 162 ±113 and 148 ± 51 mU.min'.g"', respectively (N.S.). Cumulative
LDH release collected during 60 min of reperfusion was not significantly different
between the two strains (10526 ±3610 and 11306 ± 3545 mU.g"' wet heart weight
for SPLA2 (+/+) and SPLA2 (-/-) hearts, respectively (N.S.).
recovery
Post-ischemic values of ventricular ATP content in SPLA2 (+/+) and SPLA2 (-/-)
amounted to 8.2 ± 2.3 and 10.3 ± 3.5 jimol.g"' dry weight tissue, respectively. ADP
and AMP values were low and comparable in both strains (Table IV). The adenylate
energy charge (EC) amounted to 0.79 ± 0.04 and 0.83 ± 0.05 for SPLA2 (+/+) and
SPLA2 (-/-) hearts, respectively (N.S.). No significant differences were observed
either between the two groups for total tissue glycogen content at the end of
reperfusion. Tissue content of small molecular weight degradation products such as
(oxy)purines and lactate were low and comparable in both groups (Table IV).
Fatfy acüft, /?Aavp/?o//p/*ft, /r/acy/g/ycero/.v
Pre-ischemic total fatty acid (FA) levels were low and comparable in pre-ischemic
SPLA2 (+/+) and SPLA2 (-/-) hearts (198 ± 80 and 334 ± 127 nmol.g"' dry weight,
respectively; N.S.). Similarly, no significant differences were either found in pre-
ischemic arachidonic acid levels in the pre-ischemic myocardium of both strains
(Table V). Total fatty acid levels significantly increased following ischemia and
reperfusion in both groups and amounted to 2671 ±1151 and 2683 ± 911 nmol.g"'
dry weight for sPLA^ (+/+) and sPLAi (-/-) hearts, respectively (Table V). Among
the most abundant saturated FA species to accumulate were palmitic (C16:0) and
stearic acid (C18:0), each representing about 20 % of total accumulated FA (Table
V). Of the individual poly-unsaturated FA species accumulating in the post-
ischemic heart the majority was comprised of linoleic acid (C18:2) and
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docosahexaenoic acid (C22:6); about 20 and 13 %, respectively in both groups
(Table IV). No significant differences with respect to the arachidonic acid (AA;
C20:4) levels, a sensitive marker reflecting membrane phospholipid degradadion,
was found between the two mouse strains. The tissue content of AA at the end of
the reperfusion period amounted to 70 ± 32 and 107 ± 87 nmol.g' dry weight for
SPLA2 (+/+) and sPLA? (-/-) hearts, respectively, representing 2.6 ± 0.3 and 3.6 ±
1.7 % of the total post-ischemic tissue FA pool, respectively (Table V).
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Figure 2
Post-ischemic recovery of cardiac output (CO) of isolated ejecting SPLA2 (+/+) (closed
rectangles) and SPLA2 (-/-) hearts (open triangles) following 17.5 min of normothermic
no-flow ischemia. Data are expressed as means - SD (n = 10 and 11 for SPLA2 (+/+) and
SPLA2 (-/-) hearts, respectively). * indicates P < 0.05 vs respective pre-ischemic value of
sPLAj (+/+) hearts, # indicates P < 0.05 vs respective pre-ischemic value of SPLA2 (-/-)
hearts. . .
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Pre-ischemic total cardiac phospholipid (PL) and triacylglycerol (TG) levels
were comparable between both strains (Table VI and VII). Total post-ischemic
phospholipid and triacylglycerol content did not differ between the two groups and
amounted to 170 ± 22 and 174 ± 9 umol.g"' dry weight for total PL content and 34 ±
11 and 38 ± 10 nmol.g"' dry weight for total TG content in sPLA2(+/+) and SPLA2
(-/-) hearts, respectively. The fatty acyl composition of both esterified lipid pools
did not differ between hearts from both strains (Table VI). The total amount of fatty
acids esterified at the glycerol backbone via an ether bond was low in both strains
and amounted to 4.0 ± 3.2 and 4.5 ± 3.6 % of FA present in the PL pool of SPLA2
(+/+) and SPLA2 (-/-) hearts, respectively. Among the most abundant FA species
esterified in the PL pool were palmitic, stearic, linoleic and docosahexaenoic acid,
each representing about 20 % of the total amount of esterified FA. AA accounted
for 6.3 ± 0.7 and 6.5 ± 0.8 % of FA present in the phospholipid pool of SPLA2 (+/+)
and SPLA2 (-/-) hearts, respectively, and did not show a significant difference
between the two mouse strains (Table VI). The triacylglycerol fatty acyl
composition was different from the PL pool, in that stearic acid and
docosahexaenoic acid were much less abundantly esterified in this lipid pool. In
general poly-unsaturated FA species were less abundantly present in the TG pool in
both mouse strains (Table VI). The total amount of AA esterified in the ischemic-
reperfused TG pool was very low in both strains and accounted for only 1.6 ± 0.5
and 1.7 ± 0.3 % of total FA species in SPLA2 (+/+) and SPLA2 (-/-) hearts (N.S.).
Table IV
Ventricular high energy phosphate, (oxy)purine, glycogen and lactate content of reperfused
SPLA2 (+/+) and SPLA2 (-/-) hearts.
/177> . 8.2 ±2.3 10.313.5
3.410.4 3.110.5
0.8 + 0.3 1.011.1
£C 0.7910.04 0.83 ± 0.05
(ar^/jwnmw 0.08 10.10 0.03 10.04
g/ycogew 232 1 50 259199
/ac/a/e 19.519.3 23.6119.8
Data are expressed as means 1 SD in umol.g' dry weight from ventricular tissue freeze
clamped following 17.5 min of ischemia and 60 min of reperfusion (n = 9 and n = 8 for
SPLA2 (+/+) and SPLA2 (-/-) hearts, respectively). EC, energy charge and is defined as
(ATP + 0.5 ADP)/(ATP + ADP + AMP) and is unitless; (oxy)purines are defined as the
sum of adenosine, inosine, hypoxanthine and xanthine.
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Discussion
In the present study the role of type IIA secretory phospholipase A2 (type IIA
SPLA2) in cardiac ischemia/reperfusion-induced loss of function and phospholipid
degradation was explored by using isolated, left ventricular-ejecting mouse hearts
derived from the inbred C57BL/Ks and C57BL/6 mouse strains, the latter mouse
strain being functionally deficient for this SPLA2 (Kennedy e/ a/., 1995, MacPhee e/
o/., 1995).
Table V
Total tissue content and fatty acyl composition of the (unesterified) fatty acid pool of pre-
ischemic and ischemic-reperfused SPLA2 (+/+) and SPLA2 (-/-) hearts.
/V« 7/Ä
Toto/ 198 + 80 2,671 ±1,151* 334 ±127
/<5:0 35 ±25 594 ± 2 4 0 * 59 ±24
76:7 - 29 ±16
75:0 43 + 16 533 ± 2 1 3 * 59 ±22
75:7 35 ±12 459 ± 2 2 6 * 42 ±21
7Ä:2 30 ± 11 554 ± 3 1 5 * 35 ± 11
20:0 - 11 ±10
20:4 3 ± 5 70±32 * 9 ± 1 4
22:4 - 3 ±6
22:6 47 ±29 345 ± 160 * 74 ±26
Data are expressed as means ± SD in nmol.g"' dry weight ventricular tissue (n = 5 and
n = 6 for pre-ischemic SPLA2 (+/+) and SPLA2 (-/-) hearts, respectively; n = 9 and n = 8 for
reperfused SPLA2 (+/+) and SPLA2 (-/-) hearts, respectively). Pre: pre-ischemic, I/R:
ischemic-reperfused. Individual fatty acids are denoted by their chemical notation. —not-
detectable. * indicates P < 0.05 vs corresponding pre-ischemic value.
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2,683
586 ±
±911 *
206*
32 ±15
518 ±
518 ±
520 ±
121*
121 *
2 3 1 *
31 ±40
107 ±
3±5
337 ±
87*
9 3 *
CAqpter 5
Although pre-ischemic values of a number of functional parameters in C57BL/6
hearts were slightly but significantly higher as compared to those in C57BL/K.S
hearts, post-ischemic percentual functional recovery was comparable between the
two strains. Similarly, the amount of irreversibly damaged cardiac muscle cells, as
assessed by the extent of LDH release into the coronary effluent, was comparable
between the two strains. In addition, no significant differences were observed in
metabolic recovery, tissue arachidonic acid (AA) content, total fatty acid (FA)
accumulation, or in the fatty acyl composition of cardiac phospholipids and
triacylglycerols between hearts from both strains. The data in the present study
argue against a major role of type IIA SPLA2 in acute ischemia and reperfusion-
induced AA accumulation, cellular injury and loss of function.Aim of the present
study was to determine whether type IIA SPLA2 plays a significant role in cardiac
membrane phospholipid degradation as reflected by AA accumulation during
experimental ischemia and reperfusion at the intact organ level. Potential
experimental caveats of the present study might be caused by the fact that some
differences in age and pre-ischemic hemodynamic values were observed between
the experimental groups, the latter difference not being easily explainable by the
age factor. However, in the present study we preferred randomization of the
perfusion experiments with the SPLA2 (+/+) and SPLA2 (-/-) mice over age-
matching of the two experimental groups. Although the two mouse strains are
genetically identical for 86 % (Naggert er a/., 1995, Lueders, 1995, Kennedy er a/.,
1997), it can not be excluded that the remaining unidentical 14 % of the genome
might account for undetermined phenotypical differences which might precipitate in
differences in cardiac ischemia tolerance, if any, between the two strains. A more
laborious approach to avoid this potential caveat would involve back-crossing of the
mutation into the wildtype genotype or the creation of a targeted disruption of the
p/a2go gene in a />/a2ga genetic wildtype background (Kennedy er a/., 1997).
Nevertheless, the availability of a type IIA sPLA2-deficient experimental animal
model has enabled a number of groups to demonstrate the specific contribution of
this enzyme in cellular prostaglandin generation (Reddy er a/., 1997, Murakami er
a/., 1997), intestinal tumorigenesis (Cormier er a/., 1997) and the gastric epithelial
response to //e//"co6acrer infection (Wang er a/., 1998). We used a similar
experimental approach and demonstrated that complete absence of functional type
IIA SPLA2 failed to attenuate ischemia and reperfusion-induced AA accumulation,
irreversible cell damage and functional recovery. These findings therefore present
for the first time evidence against a significant role for type IIA SPLA2 in cardiac
membrane phospholipid degradation as observed during ischemia and reperfusion at
the whole organ level.
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Table VI
Total tissue content and fatty acyl composition of the tissue phospholipid pool in pre-
ischemic and ischemic-reperfused SPLA2 (+/+) and SPLA2 (-/-) hearts. f ,* *«-,st;i;tL. •> ••;.«•'!
/ *« Z/R
7b/a/ 180 ±21 170 ±22 171 ±23 174 ±9
7*0
75:0
/tf:0
75:7
7«:0
7«.0p
75:7
22.Ö
0.2 ± 0.0
17.5 ±0.3
1.7 ±0.3
0.5 ±0.1
17.7 ±0.4
1.0 ±0.3
8.9 ±0.4
0.4 ±0.1
17.0 ± 0.1
6.4 ± 0.3
26.4 ± 0.9
0.2 + 0.0
17.8 ±0.6
1.2 ±1.3
0.4 ± 0.0
19.5 ±2.6
0.6 ± 0.6
9.1 ±0.5
0.2 ± 0.2
18.6 ± 0 . 6 *
6.3 ±0.7
24.1 ±0.8
0.2 ± 0.0
17.7 ±0.3
2.1 ±0.3
0.5 + 0.1
17.7 ±0.2
1.3 ±0.2
9.5 ±0.4
0.5 ±0.1
16.3 ± 0 . 3 *
6.5 ±0.3
25.4 ±1.2
0.2 ±0.0
17.7 ±0.7
1.3 ±1.2
0.4 ±0.1
19.2 ±2.4
0.7 ± 0.6
9.6 ±0.6
0.3 ±0.3
18.1 ± 0 . 7 *
6.5 ±0.8
24.1 ±0.9
Total amounts are given in ^imol.g"' dry weight ventricular tissue and fatty acyl
composition is given as relative composition (in %). Data are expressed as means ± SD (n
= 5 and n = 6 for pre-ischemic values for SPLA2 (+/+) and SPLA2 (-/-) hearts, respectively;
n = 8 for both ischemic-reperfused SPLA2 (+/+) and SPLA2 (-/-) hearts). PZ. indicates the
plasmalogen form of the particular fatty acid. Phospholipids are expressed as fatty acyl
equivalents. * indicates P < 0.05 vs corresponding pre-ischemic value, # indicates P < 0.05
corresponding lipid pool of different genotype.
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Type IIA SPLA2 has been implicated as a candidate for cardiac ischemia/reperfusion
induced membrane phopholipid degradation because of its Ca^-dependency and
non-specific hydrolytic action towards phopholipids (Van Bilsen e/ a/., 1995, De
Windt e/ a/., 1998). In accordance with this notion it was found that in the post-
ischemic rat or mouse heart, accumulation of individual FA species is not confined
to AA only, but demonstrates a more general elevation of all major FA species
present in the phospholipid pool (Van Bilsen e? a/., 1989b, Chapter 6). Moreover,
earlier studies have demonstrated that antibodies raised against type IIA SPLA2 and
chemical inhibition resulted in a reduction of both ischemia and reperfusion-
induced membrane degradation and cellular damage of the rat heart (Das ef a/.,
1986, Prasade/a/., 1991).
Table VII
Total tissue content and fatty acyl composition of the tissue triacylglycerol pool in pre-
ischemic and ischemic-reperfused SPLA2 (+/+) and SPLA2 (-/-) hearts.
/Ve //Ä Fre //R
7bta/ 31+7 34+11 36110 38110
76:0
1.410.4
20.112.1
2.010.7
5.010.6
29.5 ±2.1
28.811.8
1.110.3
8.4 ± 3.0
1.210.1
18.212.2
0.8 1 0.2 *
4.010.4 *
24.3 12.9
34.512.1 *
1.610.5
10.914.6
1.210.2
18.710.7
1.410.3
4.610.1
27.211.5
28.61 1.7
1.110.2
12.711.9
1.310.2
18.212.9
0.910.1 *
4.0 1 0.3 *
25.5 12.2
36.211.2*
1.710.3
8.412.4
20:4
22:6
Total amounts are given in umolg"' dry weight ventricular tissue and fatty acyl
composition is given as relative composition (in %). Data are expressed as means 1 SD
(n = 5 and n = 6 for pre-ischemic values for SPLA2 (+/+) and SPLA2 (-/-) hearts,
respectively; n = 8 for both ischemic-reperfused SPLA2 (+/+) and SPLA2 (-/-) hearts),
triacylglycerols are expressed as fatty acyl equivalents. * indicates P < 0.05 vs
corresponding pre-ischemic value.
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Furthermore, since reperfusion is associated with an elevation of intracellular Ca*\
the involvement of this Ca^-dependent, nonspecific hydrolytic enzyme was
anticipated. The present study clearly demonstrates, however, that a complete
functional absence of type IIA SPLA2 neither results in a reduction of membrane
phospholipid degradation as measured by the tissue AA content, nor in a reduction
in the degree of cellular injury or post-ischemic functional recovery.Among the
other candidate cardiac PLA2 enzymes responsible for ischemia/reperfusion-induced
phospholipid hydrolysis are type V SPLA2, type IV CPLA2 and type VI iPLA2, since
all other major mammalian PLA2 species (type IB SPLA2, type IIC SPLA2 and type
X SPLA2) remain to be detected in cardiac tissue (Tischfield er a/., 1997). In light of
the present study, the identification, cloning and characterization of the other low
molecular weight, Ca^*-dependent secretory phospholipase A2 (type V SPLA2)
abundantly present in the heart is of interest (Chen er a/., 1994, Chen er a/., 1998).
Recent characterization of the recombinant human enzyme indicated a limited fatty
acid preference of linoleoyl > palmitoyl > arachidonoyl acyl moieties at the sw-2
position of PE and PC (Chen er a/., 1998). More importantly, it was demonstrated
that both SPLA2S are functionally redundant to each other in terms of AA liberation
(Murakami er a/., 1998). Therefore, It is feasible that type IIA and type V SPLA2
fulfill similar redundant functions in the heart as far as ischemia and reperfusion-
induced AA or FA accumulation, lysophospholipid accumulation and concomitant
cellular damage are concerned. The individual relevance and relationship between
both cardiac SPLA2 enzymes remains subject to future experimental study.
Interestingly, targeted disruption of the intracellularly located type IV
CPLA2 resulted in a significant reduction of post-ischemic brain infarct size in the
mouse (Bonventre er a/., 1997). Because of its intracellular localization and
specificity towards arachidonoyl acyl moieties in diacyl phospholipid species, a role
of this particular enzyme in cardiac ischemia and reperfusion-induced AA liberation
and cellular injury has as yet not been anticipated (Van der Vusse er a/., 1997, De
Windt er a/., 1998). Regarding the promising results obtained in the ischemic brain
(Bonventre er a/., 1997), however, a more thorough investigation of the role of this
enzyme in the ischemic-reperfused heart seems justified and the focus of future
studies.
Finally, Hazen and coworkers have demonstrated that the activity of type
VI iPLA2is greatly enhanced soon after the onset of cardiac ischemia (Hazen er a/.,
1991), making this plasmalogen-specific enzyme another candidate for ischemia
and reperfusion-induced membrane anomalies in the heart. The significance of this
particular PLA2 in ischemia and reperfusion-associated phospholipid degradation
and cardiac muscle cell death is subject of debate, however, since a number of
studies demonstrated that the diacyl form rather than the plasmalogen form of
phospholipids is subject to hydrolysis, while Davis and coworkers demonstrated
that the levels of lysoplasmenylcholine and lysoplasmenylethanolamine did not
increase in the ischemic rat heart (Davies er a/., 1992). Additionally, the time course
of arachidonic acid accumulation during reperfusion does not coincide with that of
type VI iPLA2, since the activity of this enzyme quickly goes down to normal levels
after ischemia, whereas AA continues to accumulate (Van der Vusse er 0/., 1982,
Van Bilsen er a/., 1989, De Windt er a/., 1999). Furthermore, Vesterqvist and
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colleagues reported a marked decrease in type VI iPLA2 activity in isolated rabbit
hearts subjected to a prolonged period of global ischemia, using intact isolated
sarcolemmal membranes as substrate to measure enzyme activity, while Hazen and
colleagues used exogenously added phospholipid substrates (Hazen er a/., 1991,
Vesterqvist er a/., 1996). The conflicting results might, however, be explained in the
light of the different experimental models used. In this way, choline plasmalogen
content in the rat heart represents < 2 % of choline phospholipids compared to 57 %
in canine and 36 % in human myocardium (Davies er a/., 1992). Together with the
findings that over 95 % of phospholipase A2 activity in the human end-staged failed
heart was identified as type VI iPLA2 (Hazen er a/., 1992) and the potent
arrhythmogenic properties and slow clearance of plasmalogen-derived
lysophospholipids (Gross er a/., 1992, Caldwell er a/., 1998), a more throrough
investigation of the role of type VI iPLA2 in the pathophysiological cardiac
phospholipid metabolism in different experimental models is certainly required.
Clearly, the individual role of each cardiac PLA2 in phospholipid hydrolysis
as observed during ischemia and reperfusion will remain subject of future
investigation. In this light, loss-of-function experimental approaches are particularly
efficient in delineating the role of each PLA2 isozyme but does not exclude whether
(PLA2-mediated) membrane phospholipid degradation per se might play a pivotal
role in the transition from reversible to irreversible injury or whether it merely
reflects autolysis of irreversibly damaged cardiac muscle cells (Van der Vusse er
a/., 1994). Gain-of-function experiments with a pre-existing increased type IIA
SPLA2 activity as generated previously (Fox er a/., 1996, Grass er a/., 1996,
Nevelainen er a/., 1997) might therefore provide a more straightforward approach to
study the relevance of membrane phospholipid degradation in the ischemic-
reperfused heart (De Windt er a/., 1998).
In conlusion, the findings in the present study provide evidence against a
decisive role of type IIA SPLA2 in ischemia/reperfusion-induced arachidonic acid
accumulation, cellular injury and cardiac metabolic and functional dysfunction.
Future studies using mouse models with either a cardiac-specific overexpression of
PLA2 activity or a targeted disruption of other cardiac candidate PLA2 enzymes
might delineate whether PLA2-mediated phospholipid degradation contributes to the
development of ischemia/reperfusion-induced cellular death /w v/vo and/or which
type of
 PLA2 is involved in this pathophysiological process.
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Chapter 9
Prelimenary results on
generating transgenic mice with a
cardiac-specific overexpression of
type IIA secretory phospholipase A2.
::' ff; .;T i.Y*
C/rapter 9
Abstract - . .
In the present study transgenic mice were generated to selectively
overexpress type IIA SPLA2 in the myocardium. To this end, the rat
type IIA SPLA2 cDNA was cloned downstream of the 250 bp
ventricular myosin light chain-2 (MLC-2v) promoter. Following
multiple rounds of oocyte micro-injections one founder was obtained
and germline transmission was confirmed by PCR. Additionally, a dot
blot procedure was developed which allowed for determination of the
copy number of transgene integration, amounted to 9 copies per
haploid genome, and identification of heterozygous and homozygous
transgenic animals. However, Northern blot and RT-PCR analysis of
myocardial RNA demonstrated that homozygous transgenic MLC-2v-
SPLA2 mice did not overexpress type IIA SPLA2 in the heart.
Subsequently, the cDNA of rat type IIA SPLA2 was cloned
downstream of the a-myosin heavy chain promoter (a-MHC).
Following one round of micro-injections, multiple founder animals
were identified by using a specific PCR analysis of the genome. The
existence of potential CC-MHC-SPLA2 founder candidates was
confirmed by Southern blot analysis. Interestingly, among these
candidates the founder animal with the highest number of transgene
copies as determined by Southern blot analysis became ill soon after
birth and died a few weeks later. This finding coincidences with the
activation of the a-MHC promoter and might indicate that very high
levels of type IIA SPLA2 in the heart are unreunitable with normal
cardiac function in the mouse.
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Introduction /"
The current technological ability to genetically alter the mouse in combination with
miniaturized physiological /« v/vo and ex v/vo experimental setups offers the
opportunity to study the (patho)physiological role of single genes (Chien er a/.,
1996). To more specifically target a given gene to the myocardium in a gain-in-
function approach, independent laboratories have performed efforts to use promoter
constructs to specifically and exclusively drive transgene expression in the heart m
v/vo (Figure 1). The majority of these promoter constructs were from genes
encoding cardiac proteins expressed abundantly and exclusively in the myocardium.
In this way promoter constructs for a-myosin heavy chain (oc-MyHC), ventricular
myosin light chain-2 (MLC-2v) and cardiac troponin I have been used to drive
transgene expression to the ventricular compartment of the myocardium //i v/vo
(Subramaniam er a/., 1991, Lee er a/., 1992, De Lisi er a/., 1998), while promoters
of the atrial natriuretic peptide (ANF) and atrial myosin light chain-2 (MLC-2A)
drive heterologous expression to the atria (Field er a/., 1988, Doevendans, 1998).
A number of reports provided circumstantial evidence that phospholipase
A2 (PLA2) mediated membrane phospholipid degradation might play a pivotal role
in the transition from reversible to irreversible cellular injury during cardiac
ischemia and reperfusion (Van der Vusse er a/., 1982, Chien er a/., 1984, Das er a/.,
1986, Otani er a/., 1989, Van Bilsen er a/., 1989, Van der Vusse er a/., 1989, Prasad
er a/., 1991,Van der Vusse er a/., 1997). To study the significance of
ischemia/reperfusion-mediated cardiac membrane phospholipid degradation in the
transition of reversible to irreversible cellular injury and, consequently, the extent of
functional recovery, experiments were initiated to generate mice with a cardiac-
specific overexpression of type IIA phospholipase A2 /« v/vo. Subjecting the hearts
from these transgenic animals to ischemia/reperfusion in a recently developed
isolated ejecting mouse heart preparation (De Windt er a/., 1999) will help to
understand the role of this particular type of PLA2 in the development of
irreversible cell damage and loss of cardiac function during ischemia and
reperfusion. To this end, the recently cloned and characterized cDNA coding for
type IIA PLA2 present in the rat heart (De Windt er a/., 1997) was cloned
downstream of a 250 bp fragment of the rat MLC-2v promoter and downstream of
the mouse a-MyHC promoter to specifically target type IIA SPLA2 to the cardiac
ventricles.
Materials and Methods
The MLC-2y-sPLA2 transgenic mouse colony was maintained and bred under
standard housing conditions with an artificial 12 h light cycle and free access to tap
water and standard rodent food (Diet SRM-A, Hope farms, Woerden, the
Netherlands). In all experiments involving surgical procedures, animals were
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anesthetized with a 50 mg.kg' sodium pentobarbital injection i.p. (Nembutal,
Sanofi Sante BV, Maassluis, the Netherlands) prior to surgery. All experimental
protocols were approved by the Institutional Animal Care and Use Committee of
the Maastricht University.
To detect the presence of the transgene in individual MLC-2v-sPLA2 and a-MHC-
SPLA2 mice the genomic DNA was isolated from tail clips using a Qiamp genomic
DNA prep kit (Qiagen, Leusden, the Netherlands) and subjected to PCR
genotyping. In both PCR analyses a 3 -primer designated PLA-R3 [5 -
GAATCATTTGCCCAAACTC-3 ], directed against bp 73 — 91 of the cDNA
coding for rat heart type IIA SPLA2 (De Windt e/ a/., 1997), was used. For the
MLC-2v-sPLA2 transgenic line a 5 -primer designated MLC-F1 [5 -
TCTGCCTACCTACAACTGCC-3 ] specific for the rat MLC-2v promoter was
used, while in the case of <x-MyHC-sPLA2 transgenic mice a 5 -primer designated
MHC-F1 [5 -GGAAACCACTGGGACAC-3 ], specific for the mouse a-MHC
promoter was used. PCR reactions were cycled 35 times at 94 °C for 30 s, at 60
°C for 60 s and at 72°C for 90 s, with an additional amplification cycle of 10 min at
72°C using 100 ng of genomic DNA, 50 pmol of each primer and 1.5 U Taq
polymerase (Gibco BRL). In both MLC-2v-sPLA2 as well as (X-MHC-SPLA2 PCR
genotyping a specific PCR product of about 300 bp is anticipated if the transgene is
present in the genome.
In a subset of FVB/N mice (MLC-2v-sPLA2 mouse strain) the genomic
DNA was used as template in a PCR reaction for genotype the mice in order to
detect the genomic type IIA SPLA2 mutation as described previously (Chapter 8).
The genomic DNA of all the mice tested this way were found to consistent with the
wildtype genome, suggesting that the type IIA SPLA2 mutation is absent in the
genetic background of the transgenic MLC-2y-sPLA2 mice.
A/o/ cfetermmaf/o/i o/copy
Genomic dot blot analysis was used to determine the copy number of the transgene
in the MLC-2y-sPLA2 transgenic line using a modification of a method described
earlier (Hogan e/ a/., 1986, Subramaniam e/ a/., 1991). In short, genomic DNA was
isolated from tail clips using the Qiamp genomic DNA isolation kit according to the
manufacturer s directions (Qiagen) and quantitated spectrophotometrically in triplo.
Subsequently, 5 Uj» of genomic DNA from each individual mouse was digested
overnight with excess EcoRI (5 U/^g). The digested genomic DNA was
resuspended in denaturating buffer (10 mM Tris, 0.2 M NaOH, 1 mM EDTA, 100
mM NaCl), heated to 70 °C for 5 min and spotted in dots in duplo onto nylon filter
(Amersham) in serial 2-fold dilutions using denaturing buffer starting with 1 ng
down to 62.5 ng. As a standard a set of blots was generated using Hind III
linearized pMLCSVOA-sPLAi (see Figure 2) in serial 2-fold dilutions from 100 pg
down to 6.25 pg. After UV crosslinking and baking for 30 min at 80°C, the blots
were prehybridized for 2 h in 6 x SSC, 5 x Denhardt s, 0.5 % sodium dodecyl
sulfate and 100 ng/ml salmon sperm DNA at 58 °C. Subsequently, the blots were
152
Ge«era//«g fype 7Z4
probed overnight with 1.10* cpm.ml"' a-"P-labeled PLA probe (De Windt er a/.,
1997) in the same solution. The probe used was a Xho I/Pst I fragment of part of the
cDNA coding for rat heart type II secretory PLA2 in a pBluescript vector (De Windt
e/ a/., 1997). Following two washes with 2 x SSC, 0.1 % SDS, the blots were
exposed to storage phosphor screens for 24 h and scanned and quantified using a
Phosphorlmager and the ImageQuant software (Molecular Dynamics, Sunnyvale, CA,
USA).
Total RNA from MLC-2v-sPLA2 transgenic hearts (both ventricles and atria), from the
hearts of their corresponding wildtype littermates and from rat ileum was isolated with
the use of TRIzol Reagent (Gibco BRL). The RNA (10 u.g and 5 ug for cardiac tissue
and ileum, respectively) was size-fractionated on a 1% agarose, 18% formaldehyde gel
according to the method described in Sambrook e/ a/. (1989). The RNA was
transferred to a nylon filter (Hybond-N, Amersham) by capillary transfer overnight.
After UV crosslinking and baking at 80 °C for 2 h, the filters were prehybridized for 2
h in 6 x SSC, 5 x Denhardt s solution, 0.5% SDS, 100 u.g/ml salmon sperm DNA at 58
°C and hybridized in the same solution with 10* cpm/ml of ^P-labeled PLA- probe
(Xho I/Pst I fragment of rat heart type IIA SPLA2 cDNA). Final washing conditions
were 1 x SSC with 0.1% SDS at 50 °C for 30 min. To correct for possible differences
in loading and transfer, the immobilized RNA on the filters was visualized by
methylene blue staining prior to hybridization. The Northern blots were exposed to
storage phosphor screens for 90 h and subsequently scanned and quantified using a
Phosphorlmager and the ImageQuant software (Molecular Dynamics, Sunnyvale, CA,
USA).
Total RNA from MLC-2v-sPLA2 mouse hearts and their corresponding
nontransgenic littermates was prepared with the use of TRIzol Reagent (Gibco
BRL). Reverse transcription (RT) was performed with Superscript™-II RNAse H'
reverse transcriptase (Gibco BRL) according to the instructions of the supplier.
Polymerase chain reaction (PCR) was performed on a DNA thermal cycler (Perkin
Elmer Co., Norwark, USA) using Thermus Aquaticus (Taq) polymerase (Gibco
BRL). After an initial incubation of 5 min at 95 °C, the reactions were cycled 15,
20 or 25 times at 94 °C, at 55 °C, and at 72 °C, all for 1 min. An additional
extension reaction at 72 °C for 10 min was included after cycle 25. Samples were
size-fractionated by agarose gel electrophoresis and visualized after staining with
ethidium bromide. RT-PCR was performed using a 5 primer designated PLA-F1
[5'-GAGTTTGGGCAAATGATTC-3'] and a 3 primer designated PLA-R1 [5'-
CAGCTTTATCGCACTGGCA-3']. PLA-F1 and PLA-R1 correspond to bp 73-91
and bp 328-346 of the sequence of type IIA SPLA2 present in the heart (De Windt er
a/., 1997).
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Figure 1. Schematic overview of the generation of transgenic mice. The gene of interest is placed under control
of a promoter sequence (e.g. a cardiac-specific promoter such as the ct-MyHC promoter) to target the expression
of the gene to a specific organ, in this case the heart. The transgene is micro-injected into the male pronucleus
of uncleaved fertilized oocytes. The oocytes are subsequently transferred into the reproductive tract of a
pseudopregnant foster mouse, where the oocytes come to term. Genomic DNA is tested by Southern blot or
PCR procedures to determine whether the transgene has been integrated into the mouse genome. In the different
transgenic lines different numbers of transgenes at different integration sites are usually incorporated. After
confirmation of overexpression of the transgene at the RNA and protein level and documentation of the copy
number of the transgene integration, the phenotype of the transgenic mouse lines is investigated.
(Figure reprinted with permission from De Windt <7 a/., 1998).
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Results
To obtain a MLC-2v-sPLA2 expression vector to drive type IIA SPLA2 specifically
to the heart of mice, a number of subcloning strategies were applied to clone full
length cardiac type IIA SPLA2 cDNA downstream of the 250 bp fragment of the rat
MLC-2v gene promoter. To this end, type IIA SPLA2 was excised from a parental
pBluescript vector (De Windt ef a/., 1997) via an EcoR I/Not I double digest and
inserted into a EcoR I/Not I linearized PCRII vector. Resulting PCRII-SPLA2 was
digested with Spe I to release a ~ 900 bp fragment containing the full length type
IIA SPLA2 cDNA clone (Figure 2). Finally, this Spe I fragment was ligated into the
multiple cloning site of pMLCSVOA, a vector containing the 250 bp trunctated rat
MLC-2v promoter upstream and a luciferase poly adenylation (poly A) signal
downstream of the multiple cloning site, respectively. Resulting transgenic vector
(PMLCSVOA-SPLA2) was subjected to extensive restriction digest and sequencing
analysis to confirm correct orientation and integrity of the open reading frame of
sPLA2.The transgenic vector was digested with Hind III and Kpn I, which cut
immediately 5 of the promoter and 3 of the polyadenylation site, respectively
(Figure 2). In this manner, no contaminating plasmid vector sequences were
included into the microinjected DNA. Subsequent DNA purification and transgene
animal generation was performed as described previously using standard techniques
at the Department of Medicine, University of California - San Diego, CA USA
(Hogan e/ a/., 1986, Lee e/ a/., 1992). Following multiple rounds of micro-
injections only one male founder was obtained and subsequently shipped to the
Maastricht University, The Netherlands, where all further breeding and analysis of
the transgenic line occurred.
Propaga//'o/2 and mor/j/iome/n'c awa/y^w a/ACC^y-sPi/l: m/ce
To confirm integration of the transgenic construct, a genomic DNA PCR strategy
was developed involving a 5 primer specific for the MLC-2y promoter and a 3
primer specifically directed to the type IIA SPLA2 sequence. In Figure 3 a typical
PCR result of a litter from the original male founder with a wildtype female FVB/N
mouse is presented. As demonstrated, a highly specific detection of the transgene
was obtained through this method of screening. In this way, the transgenic line was
propagated until the third generation (F3). Two breeding pairs, both containing one
transgenic and one wildtype parent of the Fl generation, were set up to yield 39
pups in 9 litters, of which 19 were PCR positive. Subsequently, a breeding strategy
was followed involving two (heterozygous) transgenic parents of the F2 generation
to obtain pups with double copies of the transgene (homozygous transgenic) in a
Mendelian fashion. Morphometric analysis, copy number determination, Northern
blot analysis and RT-PCR reactions were performed primarily on the litters derived
from latter homozygous transgenic breeding pair (F3 generation).
Table I depicts the morphometric findings of homozygous transgenic
MLC-2y-sPLA2 transgenic mice compared to their non-transgenic mice. No obvious
differences in health, appearance and body weight were detected between transgenic
and non-transgenic mice. Additionally, gross histological inspection of the heart
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following removal from the thorax demonstrated no obvious abnormalities in
cardiac morphology of transgenic animals, nor significant differences in heart
weight compared to wildtype hearts.
To determine the absolute amount of integrated transgene copies into the haploid
genome of the MLC-2y-sPLA2 transgenic line, a standard curve of serial diluted
plasmid pMLCSVOA-PLA2 containing the transgene was constructed following
hybridization with a 300 bp probe directed against the coding region of type IIA
SPLA2 present in the heart (Xho I/Pst I fragment, see Materials and Methods).
Taking into account that 100 pg of a 4,000 bp plasmid consists of 7.3 x 10*
molecules (first dot) and 6.25 pg contains 4.6 x 10' molecules of the plasmid (last
dot), a standard curve was fitted by plotting the amount of transgene copies against
the signals as quantitated by the Phosphorlmager analysis (Figure 4). In Figure 4A
the triplo serial diluted pMLCSVOA-PLA2 is depicted by numbers 1, 2 and 3. The
genomic DNA derived from two PCR positive MLC-2v-sPLA2 animals (one
homozygous and one heterozygous transgenic mouse) and a wildtype littermate are
also shown. Figure 4B depicts the standard curve obtained by plotting the absolute
amount of arbitrary Phospholmager units against the absolute amount of plasmid
molecules following hybridization with "P-labeled PLA probe. Table II depicts all
arbitrary Phospholmager units calculated from the dot blot analysis as demonstrated
in Figure 4A. Using the equation that follows from the standard curve in Figure 4B,
the absolute amount of SPLA2 copies in the serial diluted genomic DNA are given.
By dividing the absolute transgene copies by the absolute amount of haploid
genome copies spotted in each dot, an estimation of the transgene copy number is
obtained (Table II). Following latter analysis it was found that the wildtype
nontransgenic mouse haploid genome contains only one copy of type IIA SPLA2
(endogenous type IIA SPLA2 gene), while heterozygous transgenic MLC-2v-sPLA2
animals contain 9 copies and homozygous transgenic animals about the double
number of heterozygous transgenic animals, i.e. about 20 copies per haploid
genome (Figure 4A, Table II).
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Figure 2. Cloning strategies to obtain a MLC-2v-sPLAj transgene vector. To obtain a MLC-2v-sPLA2 expression
vector to drive type IIA sPLAj specifically to the heart of mice, a 852 bp fragment containing the 5' and 3' UTF
sequences and open reading frame of rat heart type IIA sPLA; was excised from a parental pBluescript vector and
subcloned into a linearized pCRJI vector. To this end, sPLA> was excised from a parental pBluescript vector (De
Windt <v a/., 1997) via an EcoRI/Notl double digest and ligated into an EcoRI/Notl linearized pCRII vector.
Resulting pCRII-sPLA; was digested with Spel to release a -900 bp fragment containing the open reading frame
of SPLA2. Finally, this Spel fragment was ligated into the multiple cloning site of pMLCSVOA, a vector
containing the 250 bp truncated rat MLC-2v promoter upstream and the luciferase polyadenylation signal
downstream of the multiple cloning site, respectively. A HindlH/Kpnl digest removed the vector sequences from
the transgenic construct for injection into oocytes. * indicates unique restriction site in vector.
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Figure 3. Example of MLC-2„-sPLA2 PCR genotyping. Lane 1 represents positive control as
template (pMLCSVOA-sPLAj plasmid). Lanes 2-8 represent genotyping of 7 individual mice
from a litter of the original founder mouse with a wildtype mate. The molecular weights are
indicated on the left in bp. •.".:'•".'.""".'.•;.':"."•.•'••••'
Following confirmation of germline dependent transmission and copy number
assessment of the transgene it was investigated by RNA blot analysis whether the
MLC-2y-sPLA2 transgenic line demonstrated increased cardiac mRNA levels for
type IIA SPLA2. Figure 5 demonstrates a respresentative result of this analysis,
demonstrating high levels of type IIA SPLA2 mRNA in rat ileum (positive control
tissue). A very weak signal for SPLA2 mRNA was obtained in hearts derived from
wildtype nontransgenic littermates (lane 1, 4 and 6; Figure 5). However, no
difference was found in type IIA SPLA2 mRNA signals in hearts derived from
transgenic MLC-2v-sPLA2 animals (lane 2, 3 and 5; Figure 5). This result
demonstrated that the MLC-2v-sPLA2 transgenic line was not overexpressing type
IIA SPLA2, despite the presence of multiple copies of the transgene.
Table I
Morphometric parameters of homozygous transgenic
MLC-2v-sPLA2 mice and wildtype mice.
30.6 ±4.6 29.9 ±4.1
207 ±22 217 ± 1 2
//W/ßff (>wg.g'; 6 .87±1.16 7.32 ±0.66
/4g<? (Wets ; 28 ± 5 28 ± 5
AT 6 6
Data are expressed as means ± SD. BW, body weight;
HW, heart weight; HW/BW, heart weight-to-body weight
ratio.
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To further investigate this issue, an RT-PCR analysis of SPLA2 transcripts was
performed on total RNA isolated from wildtype and transgenic hearts. To ascertain
linearity of the PCR reaction, PCR products were analyzed following 15, 20, and 25
cycles and subjected to agarose gel electrophoresis. It was found that 20 RT-PCR
cycles were sufficient to detect a weak signal for SPLA2 mRNA and still remain in
the linear phase of PCR product generation (data not shown). No notable
upregulation of mRNA transcripts were observed between wildtype and MLC-2v-
SPLA2 hearts (data not shown). The latter result confirmed the observations
obtained by using Northern blotting procedures that the MLC-2v-sPLA2 transgenic
line did not overexpress type IIA SPLA2 mRNA transcripts in the heart and, hence,
was not suitable for studies to assess the role of PLA2-mediated phospholipid
degradation during cardiac ischemia and reperfusion
C/omng o/
Following the negative result of the MLC-2y-sPLA2 transgenic line, experiments
were undertaken to obtain several transgenic lines of mice with differing amounts of
SPLAT overexpressed and driven to the heart by a 5.5 kb ct-MHC promoter
construct. To this end, the cDNA coding for rat heart type IIA SPLA2 was excised
from the PCRII-SPLA2 vector (Figure 6) by an EcoR I/Xba I double digest and
cloned into EcoR I/Xba I linearized pBluescript vector. This subcloning stategy
allowed excision of the full lenght rat heart type IIA SPLA2 cDNA as an Xho I
fragment, which allowed for cloning into clone 26 (generous gift from Prof. J
Robbins, Children s Hospital Medical Center, Cincinnati OH, USA to Dr. PA
Doevendans, Department of Cardiology, University Hospital Maastricht), a
pBluescript based vector containing the mouse 5.5 kb a-MHC promoter upstream
and the 0.6 kb human growth hormone poly adenylation site (HgH poly A)
downstream of the multiple cloning site. Cloning of the Xho I SPLA2 fragment into
the Sal I site of clone 26 finally resulted in the vector pBluescript-a-MHC-sPLA2.
Resulting transgenic vector (pBluescript-a-MHC-sPLA2) was subjected to
extensive restriction digest and sequencing analysis to confirm correct orientation
and integrity of the open reading frame of SPLA2.
In a collaboration the transgenic vector was sent to Dr. Solito of the
Institute Cochin de Genetique Moleculaire INSERM U-322, Paris, France, where
the ~ 7.0 kb fragment containing the a-MHC promoter, SPLA2 and the HgH poly A
signal were released by Not I restriction digest. Subsequently, the transgenic
construct was purified and injected into fertilized oocytes as described earlier
(Hogane/a/., 1986).
Following one round of injections, three litters with a total of 20 pups were
obtained. Screening of transgenic pups by PCR analysis as described in the
Materials and Methods section demonstrated the presence of 5 PCR positive pups.
The presence of the transgene was further confirmed by Southern blot analysis of
genomic DNA using a probe to detect the HgH poly (A) signal of the transgenic
vector (data not shown). The PCR-positive founder with the highest signal at the
Southern blot level soon became ill between 1-2 weeks after birth and died several
days later. Gross examination of the major organs revealed no apparent
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abnormalities or deviations in organ wet weight and, more importantly, the heart did
not show any morphological abnormalities or signs of hypertrophy (Personal
communications E Solito).
Following overnight fixation in 10 % formalin, the heart of the animal was shipped
to the Netherlands where total RNA was isolated in an attempt to establish whether
transgenic type IIA SPLA2 expression could be detected via Northern blot analysis.
Unfortunately, the quality of the RNA was of such poor quality, probably because
the animal was deceased for some time after detection of the carcass, that the
cardiac RNA had already been degraded upon fixation of the tissues.
Discussion
In the present study two approaches were undertaken to overexpress type IIA SPLA2
levels selectively in the murine myocardium /AJ VIVO. The first approach involved the
generation of transgenic mice where the cDNA of type IIA SPLA2 was placed under
control of the 250 bp MLC-2v promoter. Early studies indicated that this 250 bp
fragment was sufficient to drive exogenous gene products specifically to both
ventricles in the mouse (Lee er a/., 1992, Lee er a/., 1994, Hunter er a/ 1995).
Following multiple rounds of oocyte injections, however, only one founder with 9
copies of the transgene incorporated into the haploid genome was obtained which,
as indicated by Northern blot and RT-PCR analysis of myocardial RNA, did not
show overexpression of the transgene. Hereafter experiments were initiated to
overexpress type IIA sPLAi in a cardiac-restricted fashion under control of the oc-
MyHC promoter. By using this approach, multiple (X-MHC-SPLA2 transgenic
founder mice were identified and await further characterization. Of interest, one
founder with the highest transgene copy number died of unknown cause soon after
birth, which might implicate that driving high type IIA SPLA2 transgene levels in
the heart is unfavorable for correct cardiac function in the adult mouse.
Although the promoter and cis-elements responsible for driving the cardiac-
restricted expression patterns of MLC-2v gene have been identified and
characterized (Henderson er a/., 1989, Lee er a/., 1992, Lee er a/., 1994,
Navankasattusas er a/., 1994, Hunter er a/., 1995, Ross er a/., 1996) only few reports
have documented successful cardiac-restricted overexpression 1/1 v/vo using the
MLC-2v promoter and involved the oncogene //-ras in the murine heart (Hunter er
a/., 1995), two reporter genes, luciferase and ß-galactosidase, in the mouse heart
(Lee er a/., 1992, Lee er a/., 1994, Ross er a/., 1996) and the plasma membrane,
calmodulin-dependent Ca^ ATPase (PMCA) in the rat heart (Hammes er a/.,
1998). One specific advantage of the MLC-2v promoter is based in the ventricular
specificity of the MLC-2y gene in the animal /« v/vo with no detectable expression
in the atria (Lee er a/., 1992, Lee e/ a/., 1994, Ross er a/., 1996). However, major
drawbacks of the promoter are related to the developmental expression pattern of
the MLC-2v gene which itself is one of the earliest markers of cardiac
morphogenesis (O Brien era/., 1993).
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Figure 4. Demonstration of copy number analysis in MLC-2y-sPLA2 transgenic mice. /4, Genomic
DNA isolated from wildtype (-/-), heterozygous (+/-) and homozygous (+/+) transgenic animals was
two-fold serial diluted and spotted in duplicate next to two-fold serial dilutions of the plasmid
containing the transgene (pMLCSVOA-sPLA2; Figure 2). As a radiolabeled probe a 275 bp fragment
of the coding region of rat heart type HA SPLA2 was used (De Windt e/ a/., 1997). B, Taking into
account that 100 pg of a 4,000 bp plasmid consists of 7.3 x 10* molecules (first dot) and 6.25 pg
contains 4.6 x 10* molecules of the plasmid (last dot), a standard curve was fitted by plotting the
number of transgene copies against the signals as quantitated by the Phosphorlmager analysis using
the arbitrary Phospholmager units obtained with the serial diluted plasmid and the absolute number
of nlasmid molecules.
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Table II U
Dol blot procedure for determination of copy number in MLC-2v-sPLA; transgenic mice.
D N A origin
Plasmid
MLC-2.-SPLA, (+/+)
MLC-2,-»PLA, (+/-)
MLC-2.-1PLA, (•/-)
Dot»
1
2
3
4
5
1
2
3
4
5
1
2
3
4
5
1
2
3
4
5
A
478880
198025
105167
55329
31830
454915
264867
121522
43707
23538
161740
80618
49564
28798
12944
19702
9752
4936
2279
-
B
7.3.10*
3.7.10*
1.8.10'
0.9.10'
0.45.10'
-
-
-
-
-
-
-
-
C
-
-
7187657
4184899
1920048
690571
371900
2555492
1273764
783111
455008
204515
311292
154082
77989
36008
-
D
-
340000
170000
85000
42500
21300
340000
170000
85000
42500
21300
340000
170000
85000
42500
21300
Copy number
-
21
25
23
16
17
8
7
9
11
10
1
I
1
1
E
20
9
1
Depicted are the mean arbitrary Phospholmager units (column A) following hybridization with a sPLA2-specific probe.
Data are expressed as means from triplicate (plasmid) or duplicate (MLC-2,-sPLA;) experiments. DNA was spotted in serial
2-fold dilutions starting with 100 pg or I ng (dot 1) and ending with 6.25 pg or 62.5 ng (dot 5) for plasmid and genomic DN/
respectively. Corresponding number of plasmid molecules (B) or number of haploid genomes (D) are indicated. In C the unit
obtained in A are multiplied using the correction factor from the standard curve of Figure 4, i.e. 15.8. Following division of C
by D the copy number of transgene integration into the haploid genome is obtained. Column (E) depicts the mean of the data
presented in column (Copy number) and represents the mean copy number per haploid genome.
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As a consequence, the truncated 250 bp fragment of the MLC-2v promoter drives
not only high transgene expression levels prenatally, but also in a distinct anterior-
posterior gradient, leading to robust expression in the right ventricle and less or no
expression in the left ventricle.This distinct feature, although only once reported
using a MLC-2v-ß-galactosidase fusion gene (Ross e/ a/., 1996), is highly
undesirable for projects where left ventricular ischemic vulnerability is to be tested
in the adult animal using an isolated left ventricular ejecting heart preparation (De
Windt e/ a/., 1999). An additional disadvantage of the MLC-2v promoter is that
relatively large numbers of transgenic founder lines need to be generated and
screened before ventricular overexpression, in the absence of ectopic expression, is
truly achieved (personal communication KR Chien). Regarding latter difficulties,
the MLC-2v promoter is clearly a less apropiate device to generate animal models
with a cardiac-specific gain-of-function. It should be noted that at the time of
generating the MLC-2v-sPLA2 transgenic mice in the present study, this
information (Ross e/ a/., 1996) had not been published about this particular
promoter construct.
Although less restricted in its expression pattern than the MLC-2v promoter,
the a-MHC promoter has been used successfully to drive overexpression of a large
number of transgenes to the myocardium. The a - and ß-MHC genes are a group of
muscle-specific genes which are expressed in both the cardiac and skeletal muscle
compartments. In the mouse, ß-MHC expression is first detected 8 days post-coitum
in the primitive heart tube and as the heart undergoes looping and forms distinct
atrial and ventricular chambers, the expression of ß-MHC becomes restricted to the
ventricular region, whereas a-MHC is restricted to the atrial region. Subsequently,
ß-MHC expression is down-regulated in the ventricular compartment and within 1
week after birth a-MHC transcripts accounts for 95 % of the MHC transcripts in the
heart (Lyons e/ a/., 1990). Similar to the spatio-temporal expression pattern of the
endogenous a-MHC gene in rodents, transgenes under control of the 5.5 kb mouse
a-MHC promoter fragment are expressed atrial-specifically at very low levels
during embryonic development. About one week after birth a copy number
dependent overexpression pattern in both ventricles, both atria and the pulmonary
myocardium is routinely observed (Subramanian era/., 1991). The a -MHC
promoter generally results in a large numbers of founder animals per injection, a
relatively large number of which are likely to demonstrate germline-dependent
overexpression of the transgene (about 35 % of founders). Although the exact
reason for the high successrate of the a-MHC promoter remains to be established,
the size of the transgene (generally over 7 kb), which normally integrates into a
chromosomal locus as a complex of concatemers, and the large number of cardiac
muscle specific enhancers present within the promoter (Molkentin e/ a/., 1996)
probably contribute to the observed efficiency of this promoter. In line with this
notion, it is of interest to note that recent efforts to reconstruct the original MLC-2y
promoter by increasing the size of the construct (up to 5 kb) have resulted in a high
succesrate in obtaining transgenic founders expressing reporter enzymes at very
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high levels in a ventricular-specific fashion without the presence of an anterior-
posterior gradient (personal communications J Robbins).
The observation that the one founder with the highest copy number died
soon after activation of the a-MHC promoter might indicate that high type IIA
SPLA2 expression levels specifically in the heart is incompatible with life, resulting
in selection of transgenic animals with relatively lower levels of the enzyme. This
might also be an alternative explanation for the low successrate of generating MLC-
2v-sPLA2 founders. However, the above considerations are in contrast with the
observation that type IIA SPLA2 transgenic mice have been successfully generated
with overexpression in the heart, albeit not in a cardiac-specific overexpression
pattern (Grass e/ a/., 1996, Nevelainen e/ o/., 1997, Fox e/ a/., 1996).
In summary, it was attempted to create an animal model with a cardiac-
specific overexpression of type IIA SPLA2 by generating mice with rat type IIA
SPLA2 under control of either of the MLC-2v or the a-MHC promoter. Following
multiple rounds of micro-injections, only one transgenic founder line of MLC-2v-
SPLA2 was obtained and propagated. Although germline transmission was observed,
no overexpression of type IIA SPLA2 could be detected in the heart. Subsequently,
type IIA SPLA2 was placed under control of the a-MHC promoter and following
one round of oocyte injections multiple transgenic mice were identified. The
availability of an animal model with a gain-of-function for cardiac PLA2 activity, in
combination with an isolated perfused heart model to perform cardiac
ischemia/reperfusion studies (De Windt e/ a/, 1999), will provide more insight into
the question whether membrane phospholipid degradation is a critical step during
the transition from reversible to irreversible damage.
1 2 3
Figure 5. Northern blot analysis of total RNA isolated from homozygous transgenic MLC-2v-sPLA2
hearts (lane 2, 3, 5) and wildtype non-transgenic littermates (lanes 1, 4, 6) using a P"-labeled type IIA
sPLAi probe (De Windt er a/., 1997). As a positive control and reference for size total RNA derived
from rat ileum was included in the analysis (Lane 7). Arrow indicates size of type IIA SPLA2 mRNA.
To check for equality in loading, the RNA was visualized with methylene blue (data not shown).
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Figure 6. Cloning strategies followed to place the full length cDNA coding for rat heart type IIA sPLAj under
control of the 5.5 kb murine a-MHC promoter. The full length cDNA was excised from the pCRII-sPLA2 vector
(see Figure 2) by an EcoRl/Xbal double digest and subcloned into an EcoRI/Xbal linearized pBluescript vector.
This subcloning strategy allowed excision of the full length rat heart type IIA SPLA2 as an Xho I fragment, which
allowed for ligation into the Sal I site of clone 26, a pBluescript based vector containing the murine 5.5 kb a-MHC
pomoter upstream and the 0.6 kb human growth hormone polyadenylation signal downstream of the multiple
cloning site. Cloning of the Xhol sPLA^ fragment into the Sail site of clone 26 resulted in the vector pBluescript-a-
MHC-sPLA,. A Notl digest subsequently removed the vector sequences from the transgenic construct for injection
into fertilized murine oocvtes.
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General Discussion
CViopter 70
The central hypothesis of this study stated that type IIA secretory phospholipase A2
activity plays a role in ischemia and reperfusion-induced membrane phospholipid
degradation, eventually leading to cardiac muscle cell injury and deterioration of
cardiac function. To address this issue the presence and abundance of type IIA
secretory phospholipase A2 in the heart was established. Secondly, an ex v/vo
perfused, left ventricular ejecting mouse heart model was developed to specifically
study ischemia/reperfusion related phenomena in this organ, puting placing
emphasis on cardiac phospholipid metabolism. Thirdly, phospholipid homeostasis
and cardiac ischemia tolerance were investigated in a mutant inbred mouse strain
that lack type IIA secretory phospholipase A2 to explore whether absence of this
phospholipase isoform would attenuate ischemia and reperfusion-induced cardiac
phospholipid degradation, cellular injury and functional deterioration. In addition,
attempts were made to create transgenic mice overexpressing type IIA
phospholipase A2 in the heart to study the significance of increased phospholipase
A2 activity on cardiac ischemia tolerance in this animal species.
Ischemia/reperfusion-induced damage to the isolated mouse heart
To study ischemia/reperfusion-induced alterations in hemodynamic function,
cardiac energy metabolism and lipid homeostasis in the isolated mouse heart, the
assisted mode perfusion set-up, previously developed for the isolated rat heart,
was downscaled to the level of the mouse heart. It was demonstrated in C/ja/?rer 5
that it is feasible to obtain hemodynamic values of the isolated working mouse heart
that resemble findings of the anesthetized mouse heart /« v/vo (Lembo er a/., 1996,
Lorenz e/ a/., 1997, Milano er a/., 1994). The major improvement of the present
model is that the impedance characteristics of the artificial outflow tract is matched
with the //i v/vo outflow tract of the mouse heart so that physiologically relevent
measurements are obtained. In this experimental model the hemodynamic function
of the mouse heart is quite stable, as evidenced by minor changes in cardiac output
over an extended period of time. The possibility to construct Frank-Starling curves
(at different extracellular Ca~* concentrations) makes this model suitable to properly
evaluate cardiac function in transgenic or gene targeted models with deteriorated
heart function or heart failure.
Isolated Swiss mouse hearts were found to be highly sensitive to an
ischemic insult with a narrow time interval between almost complete hemodynamic
recovery and severe impairment of functional recovery (CTiaprer 6). An ischemic
period of 10 min resulted in hardly any impairment of function and only a limited
degree of cellular injury following reperfusion. These findings indicate that this
mouse heart preparation allows distinction between small differences in
ischemia/reperfusion insults as far as functional and cell injury are concernes. This
notion is substantiated by the finding that the myocardium of the IGF-1
heterozygous knockout mouse is more sensitive to ischemia and reperfusion-
induced damage than the myocardium of wildtype mice following 15 min of global
ischemia. When the ischemic period was extended by 5 min to 20 min, however, the
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function of IGF-1 heterozygous knockout hearts were deteriorated to the same
extent as those of wildtype littermates. Also, subtle differences in cardiac ischemia
tolerance were observed between hearts derived from different mouse strains.
Wildtype C57BL/6 hearts tolerated 15 min of ischemia substantially better (CViapter
S) than Swiss mouse hearts (CAaprer 6). It is doubtful whether such subtle
differences in ischemia tolerance would have been detected in the less physiological
Langendorff perfused heart model, indicating the advantage of the present
ejecting heart model. Collectively, these findings are in line with the notion of a
relative susceptibility of the mouse heart to ischemia/reperfusion damage as
compared to hearts derived from other species such as the rat (Headrick er a/., 1998,
De Groot er a/., 1993).
As indicated by the observations in CAaprer 5, the model is also sufficiently
sensitive to detect subtle differences in murine baseline systolic and diastolic
cardiac function (i.e. before the ischemic insult) as a result of lowered levels of
IGF-1 in a gene targeted mouse model and in different mouse strains. Hearts
derived from Swiss mice (CAaprer 5 a/i^ 6), C57BL/6 mice (C/jap?er S) and 129/Sv
mice (CAaprer 7), mouse strains that are extensively used in cardiovascular studies,
demonstrated some differences in baseline systolic function and contractility. More
specifically, isolated C57BL/6 hearts displayed higher baseline values for systolic
left ventricular pressure and contractility (7ar)/e //, CAaprer 5) than hearts derived
from Swiss (7aft/e /, CAapter 5) and 129/Sv mice (TaA/e //, CAapter 7). Using an
isolated working mouse heart preparation, Hewett and colleagues demonstrated
markedly elevated contractility in BALB/c and DBA mice, as compared to such
strains as Swiss Webster, C57BL/6 and CD-I (Hewett er a/., 1994), resulting from
higher levels of a-skeletal actin in the BALB/c heart due to a duplication event in
the promoter of the gene (Gamer er a/., 1986, Alonso er a/., 1990). It can be
concluded that the isolated ejecting mouse heart preparation may be of value in
future studies to detect differences in cardiac hemodynamic function of various
knockout and transgenic models.
L//7/W cAawges zn rAe zscAemz'c-re/?er/«.yed mowse Aearr
Disruption of the sarcolemma has been proposed as a critical event of
ischemia/reperfusion-induced cellular injury (Jennings er a/., 1986). The initial
weakening of the plasma membrane may be related to several mechanisms.
Impaired anchoring of the plasma membrane to the cytoskeleton and increased
osmotic forces have been postulated to play a role in ischemia/reperfusion-induced
weakening of the sarcolemma (Steenbergen er a/., 1987). In addition, the Ca^-
induced loss of assymmetric bilayer behavior of phospholipid species, such as
phosphatidylserine and phosphatidylethanolamine, leading to phase segregation and
subsequent destabilization of the sarcolemma (Post er a/., 1998, Musters er a/.,
1993, Post er a/., 1995), and enhanced hydrolysis of membrane phospholipids due
to activation of cardiac phospholipases A2 (Van der Vusse er a/., 1982, Chien er a/.,
1984, Prinzen er a/., 1984, Das er a/., 1986, Van Bilsen er a/., 1989, Prasad er a/.,
1991) have also been proposed as alternative mechanisms. Irrespective of the
mechanism, subsequent disruption of the sarcolemma, most probably caused by
physical forces imposed on the cardiac myocyte (Jennings er a/., 1986), leads to
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disruption of the weakened sarcolemma and release of cytoplasmic constituents,
representing a hallmark of irreversible cell injury.
Exposure of Swiss mouse hearts to ischemia either or not followed by
reperfusion did not lead to appreciable changes in the tissue content of
phospholipids or triacylglycerols. However, an initial small but significant decrease
in cardiac unesterified fatty acid content and shifts in the composition of the cardiac
fatty acid pool relative to the pre-ischemic fatty acid pool were observed (C/ja/?rer
6). When the ischemic period was extended (i.e., 20 min) the tissue fatty acid
content started to rise. This increase in fatty acid content was accompanied by a
significant increase in the amount of such (poly)-unsaturated fatty acids as
arachidonic acid. Reperfusion was associated with a substantial rise in the cardiac
fatty acid content, the absolute amount depending on the duration of the ischemic
period. The relatively high contribution of poly-unsaturated fatty acid species, such
as arachidonic acid and docosahexaenoic acid, to the (unesterified) fatty acid pool
indicates a disbalance between the deacylation and reacylation rates of the cardiac
membrane phospholipids during reperfusion. These findings are in line with earlier
observations in the ischemic or reperfused canine heart (Van der Vusse er a/., 1982,
Prinzen er a/., 1984, Chien er a/., 1984) and rat heart (Van Bilsen er a/., 1989) and
support the notion that the underlying mechanisms of disturbances of cardiac
membrane phospholipid homeostasis are similar in the mouse heart.
A linear correlation was found between post-ischemic tissue fatty acid
accumulation on the one hand and the extent of irreversible cell injury, as assessed
by the cumulative release of cytoplasmic enzymes or post-ischemic recovery of
mechanical behavior as determined by the percentage recovery of cardiac output, on
the other (F/gwre S i/i CAaprer 6 aw*/ F/gwre 5 /« Chapter 7). These findings suggest
a close relation between membrane phospholipid degradation and loss of cellular
integrity and, hence, mechanical recovery of the ischemic-reperfused myocardium.
It should be noted that the elevation in post-ischemic fatty acid content, although
substantial, still represents only about 2.5 % of the total murine cardiac
phospholipid content. At first glance this may be a discrepancy between the number
of cells irreversibly damaged (about 10 % following 20 min of global ischemia) and
the amount of (unesterified) fatty acids accumulated. However, if the hydrolysis of
membrane phospholipids is confined to a limited number of cells or only to
phospholipids of the sarcolemma, which represent a small percentage of total
phospholipids, cellular integrity might well be compromised by the observed extent
of phospholipid degradation (Van der Vusse er a/., 1989). It should be noted that the
increased tissue arachidonic acid levels could also be a reflection of reduced
reacylation activity of the post-ischemic heart (Van Bilsen er a/., 1989).
Collectively, these findings lend support to the notion that derangements in cardiac
membrane phospholipid homeostasis, possibly mediated by the activation of cardiac
phospholipases A2, is a causal factor in the transition from reversible to irreversible
cellular damage following ischemia and reperfusion.
Since accumulation of polyunsaturated fatty acids in cardiac tissue reflects
an imbalance between membrane phospholipid hydrolysis and resynthesis, it has
been hypothesized that activation of phospholipase A2 (relative to the activity of
enzymes involved in phospholipid resynthesis) plays a major role in ischemia and
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reperfusion-induced net phospholipid degradation. Circumstantial evidence for the
involvement of cardiac phopholipases A2 in the loss of cellular integrity in the
ischemic-reperfused myocardium is provided by the present findings in the more
ischemia vulnerable, heterozygous IGF-1 knockout mouse. It was demonstrated that
total post-ischemic cardiac arachidonic acid content correlated well with recovery
of cardiac output and cellular viability in this mouse model, suggesting a
relationship between ischemia tolerance and phospholipid homeostasis (F/gwre 5,
C7ia/?rer 7). At present at least three different classes of phospholipase A2 have been
identified in cardiac tissue: (I) the small molecular mass type IIA and V secretory
phospholipases A2; (II) the high molecular mass, type IV cytosolic phospholipase
A2; and (III) the plasmalogen-specific type VI phospholipase A2 (Chen er a/., 1994,
De Windt er a/., 1997, Larsson er a/., 1998, Liu er a/., 1998, Ma er a/., 1999,
Murakami er a/., 1998, Pickard er a/., 1999, Underwood er a/., 1998).
Type IIA secretory phospholipase A2 J V
Type IIA secretory phospholipase A2 was chosen as a likely candidate for cardiac
ischemia and reperfusion-induced phospholipid degradation based on a number of
earlier studies and its enzymatic characteristics. First, in the present study in mice it
was demonstrated (CAapter 6) that like in the ischemic-reperfused rat heart (Van
Bilsen er a/., 1989b) not only arachidonic acid but also other (un)saturated fatty acid
species accumulate during ischemia. This argues in favor of the aspecific type IIA
secretory phospholipase A2. Secondly, the observation that fatty acids continue to
rise in the reperfusion phase points toward a role for type IIA secretory
phospholipase A2 in the process, since reperfusion is known to be accompanied by a
substantial influx of calcium, potentially leading to the activation of the Ca**-
dependent type IIA secretory phospholipase A2. Thirdly, pretreatment of isolated
hearts with antibodies raised against a snake venom type II secretory phospholipase
A2 effectively blocked the degradation of membrane phospholipids and mitigated
the release of cytoplasmic proteins in the acute reperfusion phase (Prasad er a/.,
1991). Anti-type IIA secretory phospholipase A2 antibodies were also found to
decrease phospholipid degradation in homogenates of rat hearts that had been
previously subjected to a period of hypoxia and reoxygenation (Kikuchi-Yanoshita
er a/., 1993). Fourthly, peroxidation of membrane phospholipids due to enhanced
oxygen free radical production occurring during reperfusion (Myers er a/., 1985),
may also play a role, because peroxidation-damaged phospholipids are more
vulnerable to type IIA secretory phospholipase A2 attack (Dan er a/., 1990). Finally,
increased expression levels of type IIA secretory phospholipase A2 have been found
in rat brain after severe forebrain ischemia (Laurtizen er a/., 1994) and in the rat
small intestinal mucosa after ischemia and revascularization (Otamiri er a/., 1987).
On the basis of its Ca^-sensitivity and the profile of fatty acids accumulating in
ischemic/reperfused myocardium, it was proposed that type IIA secretory
phospholipase A2 is involved in phospholipid hydrolysis in the flow-deprived and
reperfused heart.
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3# In this thesis the presence of type IIA secretory phospholipase A2 in the
myocardium was confirmed by cloning of its cDNA from a rat heart cDNA library
and detection of its mRNA in cardiac tissue as well as isolated myocytes. The full
length cDNA predicts a mature protein of 146 amino acids residues, including a
typical N-terminal stretch of 21 amino acid sequence representing a signal peptide
for secretion. As such it resembles mammalian type IIA secretory phospholipases
A2 present in other tissues. Analysis of the tissue distribution of type IIA secretory
phospholipase A2 mRNA (Chapter 5) confirmed its ubiquitous presence (Ishizaki er
a/., 1989, Kennedy e/ a/., 1995). The abundance of the transcript demonstrates large
differences between the tissues examined, with the highest levels in rat ileum and
relatively low levels in the myocardium, spleen and soleus muscle. Using primary
cultures of rat neonatal ventricular cardiomyocytes it was further demonstrated that
type IIA secretory phospholipase A2 was stimulated at the level of gene
transcription by pathophysiologically relevant stimuli such as TNF-oc and
phenylephrine. In this respect, it is of interest to note that in the infarcted human
myocardium high levels of TNF-a have been reported (Maury ef a/., 1989), while
(X|-adrenergic stimulation of cardiomyocytes is associated with hypertrophic growth
(Sadoshima and Izumo, 1997), suggesting a role for type IIA secretory
phospholipase A2 both in myocardial infarction and in the processes leading to
cardiac hypertrophy and failure.
In the present study attempts were made to assess the protein levels of type
IIA secretory phospholipase A2 in various different tissues via Western blotting
techniques. The enzyme was found to be below the detection level in cardiac tissue
via regular immunoblotting techniques, in contrast to rat ileum and rat and human
platelets in which the protein could be readily detected (Chapter 4). The presence of
a N-terminal signal peptide for secretion in the enzyme raises the possibility that
type IIA secretory phospholipase A2 exerts its (patho)physiological functions both
intra- and extracellularly. Recent findings that components of the extracellular
matrix bind to and influence type IIA secretory phospholipase A2 activity are of
interest and support the notion of an extracellular localization of this particular
enzyme (Murakami e/ cr/., 1996, Romano e/ a/., 1998). Whether type IIA secretory
phospholipase A2 is also secreted by cardiac myocytes and/or is localized on the
extracellular side of the sarcolemma and what the physiological consequences
might be of
 this observation remain to be determined.
Ischemia and reperfusion-induced cardiac phospholipid degradation:
involvement of type IIA secretory phospholipase A2
To address the issue whether (increased) phospholipase A2 activity in general is
involved in the transition from reversible to irreversible cardiac cell injury and loss
of cardiac function, attempts were made to create an animal model with a gain-of-
function of type IIA secretory phospholipase A2 in the heart. Unfortunately, one
transgenic line, in which type IIA secretory phospholipase was placed under control
of the ventricular myosin light chain promoter, did not demonstrate transgene
expression in the heart. In a follow-up approach to the latter attempt, a number of
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transgenic founders was produced by placing type IIA secretory phospholipase A2
under control of the a-myosin heavy chain promoter. Interestingly, one founder
animal with a relatively high copy number died at young age, possibly indicating
that high level cardiac overexpression of type IIA secretory phospholipase A2 might
be lethal in the mouse. Future characterization of the remaining founders may result
in transgenic lines with different levels of type IIA secretory phospholipase A2
overexpression.
To more specifically investigate the role of type IIA secretory
phospholipase A2 in cardiac ischemia/reperfusion-induced damage, the ischemia
tolerance of hearts from two closely related inbred mouse strains was investigated.
No significant differences in post-ischemic tissue arachidonic acid or total fatty acid
accumulation, ischemia/reperfusion-induced cellular injury or loss of cardiac
function was observed between two 86 % genetically identical inbred mouse strains,
except for the fact that in one strain no functional type IIA secretory phospholipase
A2 was present (Kennedy e/ a/., 1997). These findings argue against a significant
role for cardiac type IIA secretory phospholipase A2 in sarcolemmal phospholipid
degradation as observed during ischemia and reperfusion in the isolated heart. It
should be noted that these findings do not exclude a role for e.g. circulating type
IIA secretory phospholipase A2 in sarcolemmal phospholipid degradation in the
infarcted heart /« v/vo.
Future directions
It is becoming increasingly clear that ischemia and reperfusion-associated
irreversible cell death is a multifactorial process including free radical generation,
intracellular Ca^ overload and alterations in the sarcolemmal composition. To more
specifically define whether phospolipase A2 mediated hydrolysis of (sarcolemmal)
membrane phospholipids plays a crucial role in the sequence of events leading to
ischemic cardiac cell death, a definition of the individual roles and interplay of the
growing family of cardiac phospholipase A2 is needed. Knowledge about the
significance of ischemia and reperfusion associated phospholipase A2-mediated
cardiac cell damage could be of therapeutic significance, and might lead to
application of specific pharmacological inhibition of ischemia and reperfusion-
induced cellular injury. Regarding the finding that cellular type IIA secretory
phospholipase
 A2 probably does not play a dominant, or rather a redundant, role in
cardiac ischemia/reperfusion-induced cell death (C/iop/er 7), reconsideration of the
pathophysiological roles of the other phospholipase A2 candidates is required.
A major future obstacle in defining the individual roles of cardiac
phospholipases A2 is posed by the identification of novel members and isoforms of
the (cardiac) phospholipase A2 family in recent years. Currently several splice
isoforms of type VI calcium-independent, plasmalogen-specific phospholipase A2
have been detected in cardiac muscle, human pancreatic islets and Chinese hamster
ovary cells (Larsson e/ a/., 1998, Liu e/ a/., 1998, Ma e/ a/., 1999). Calcium-
independent phospholipases A2 have been reasoned to play dominant
pathophysiological roles in cardiac muscle where contractions cause large
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fluctuations in calium concentrations, and, hence, the need exists to regulate
phospholipase A2 activity via calcium-independent processes. Additionally, the
family of calcium-dependent, arachidonoyl-specific type IV cytosolic
phospholipase A2 consists of at least three distinct members, one of which, type IV
CPLA2-Y, was demonstrated to be abundantly present in heart and muscle in a
membrane-bound state (Underwood e/a/., 1998, Pickard er a/., 1999). Finally, the
identification of the novel small molecular mass, Ca^-dependent type V secretory
phospholipase A2 with limited specificity towards fatty acids esterified at the sn-2
position of membrane phospholipids and functions redundant to type ILA secretory
phospholipase A2 remains an attractive candidate for ischemia/reperfusion-
associated membrane phospholipid hydrolysis, especially as this type of
phospholipase A2 is abundantly present in the heart (Chen er a/., 1994, Murakami er
a/., 1998). In this light, the recent findings of Murakami and colleagues
demonstrating cross-talk between type IV cytosolic phospholipase A2, on the one
hand, and type IIA and type V secretory phospholipase A2, on the other, using co-
transfection assays of several phospholipase A2 families, are of interest. It was
observed that (7) type IV cytosolic phospholipase A2 was required for proper action
of both type V and type IIA phospholipases A2, which act in a functionally
redundant manner, and (//) that type IV cytosolic phospholipase A2 and type IIA
and type V secretory phospholipases A2 cooperate in the generation of arachidonic
acid metabolites (Murakami er a/., 1998). Furthermore, studies in mice genetically
deficient of type IV cytosolic phospholipase A2 demonstrated important roles for
this enzyme in such processes as ischemia-induced cell death in the forebrain and
asthmatic processes (Bonventre er a/., 1997, Uozumi er a/., 1997).
Future //i v/rro studies on cultured cardiomyocytes, using adenoviral
overexpression and sense/antisense technologies of the various types of
phospholipase A2 in combination with an /'« v/rro hypoxia-reoxygenation model,
should provide a means to investigate the individual role or potential cross-talk
between the various phospholipase A2 members. An advantage of adenoviral
mediated gene transfer is that the low transfection efficiency of cultured
cardiomyocytes can be circumvented. Such m v/rro technologies provide a
relatively less expensive and time consuming approach than the generation of
genetically altered mouse models to obtain data /« v/rro regarding hypoxia-
reoxygenation-mediated irreversible cell injury. This model, however, would not
provide relevant data on the hemodynamic consequences of ischemia and
reperfusion-induced alterations in the whole organ. Future experimental efforts
should also concentrate on testing the cardiac ischemic vulnerability of mice
genetically engineered to overexpress type IIA or type V secretory phospholipase
A2 in a cardiac-restricted manner (CAaprer 9) using the ex v/vo perfused mouse
heart model as described in the present thesis. In addition, other transgenic mouse
models of type IIA secretory phospholipase A2 overexpression, albeit not in a
cardiac-restricted manner (Grass er a/., 1996, Nevelainen er a/., 1997, Fox er a/.,
1996), and of the type IV cytosolic phospholipase A2 deficient mouse model, could
be tested in the isolated ejecting murine heart model to provide more insight into the
significance of phospholipase A2-mediated membrane phospholipid hydrolysis
during experimental ischemia and reperfusion and to determine the dominant
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phospholipase A2 members) in this particular pathological process. The generation
of mouse models with a gain-of-function and a loss-of-function of each of the
cardiac phospholipase A2 members and testing the ischemic tolerance of their hearts
in e.g. an ex v/vo perfusion setup as described in the present thesis will constitute an
example of molecular physiological approaches that will give more insight into the
pathophysiological processes in the heart. In either way, the mouse as a mammalian
species, complex enough to give relevant information about human
(patho)physiology but still allowing routine genetic manipulations, will be the
future animal model of choice to obtain insight into role of the major players in
ischemia/reperfusion-induced cardiac muscle injury.
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Samenvatting
In Hoofdstuk 1 worden de achtergrond en het doel van de huidige Studie beschreven.
Het hart is een nolle spier die circa 70 maal per minuut samentrekt en daarmee het
lichaam van bloed voorziet. Tijdens iedere contractie voorziet het hart zichzelf van
zuurstof en voedingstoffen via de kransslagaderen. Tijdens een hartinfarct als gevolg
van een vemauwing van een kransslagader of tijdens een kransslagader bypass operatie
lijdt de hartspier onder een periode van zuurstoftekort (ischemie), wat kan leiden tot
afsterving van de hartspiercellen. Herstel van de bloedtoevoer (reperfusie) kan slechts
ten dele de afsterving van hartspiercellen voorkomen en in sommige gevallen zelfs het
proces versterken. Dit fenomeen van ischemie en reperfusie gei'nduceerde
hartspiercelschade wordt ten dele veroorzaakt door veranderingen in de celmembraan,
de natuurlijke barriere van de hartspiercel. Uit experimentele studies is gebleken dat
enzymatische afbraak van de belangrijkste componenten van de celmembraan, namelijk
de fosfolipiden, mogelijk een belangrijke factor speelt in ischemie en reperfusie
geinduceerde celschade. Het lichaam bevat een familie van enzymen, fosfolipases A2
genaamd, die gespecialiseerd zijn in de afbraak van fosfolipiden en die verschillen in
werking en lokalisatie. In het huidige proefschrift werd de rol van het type IIA
secretoire fosfolipase A2 enzym (type IIA sPLA?) nader onderzocht. In hoofdstuk 2
wordt ingegaan op de theoretische overwegingen voor de keuze van dit lid van de
fosfolipase A2 familie. Het type IIA sPLA, werd gekozen op basis van zijn
werkingsprofiel en omdat dit bepaalde enzym gevoelig is voor calcium, een mineraal
dat in verhoogde concentratie voorkomt in het hart tijdens ischemie en reperfusie.
In hoofdstuk 3 werd via moleculair biologische technieken onderzocht of het
type IIA SPLA2 in het hart voorkomt. Daartoe werd het hart van de rat onderzocht op de
aanwezigheid van de moleculaire voorloper van het enzym, het messenger RNA.
Onderzoek wees uit dat het hart inderdaad het type IIA SPLA2 messenger RNA bevat en
dat de genetische code zeer sterk geconserveerd is vergeleken met diverse andere
celtypen en diersoorten. Tevens bleek dat de hoeveelheid van het type IIA SPLA2
messenger RNA in het hart zeer gering zijn.
In hoofdstuk 4 werd de genetische code van het enzym zodanig aangepast dat
het enzym in grote hoeveelheden in de £. Co// bacterie geproduceerd kon worden.
Tegen dit recombinante type IIA SPLA2 enzym werden vervolgens in de konijn
polyclonale antistoffen opgewekt. De mogelijkheid van deze antilichaam fractie om het
type HA SPLA2 enzym aan te tonen werd getest naast andere antilichamen die waren
opgewekt tegen andere typen fosfolipase A2. AI de geteste antilichamen bleken in meer
of minder mate het type IIA SPLA2 enzym te herkennen in diverse celtypen en organen.
Geen van de geteste antilichamen konden het type IIA SPLA2 enzym in het hart echter
aantonen, waaruit geconcludeerd kon worden dat dat dit enzym in geringe hoeveelheden
in het hart voorkomt, aangezien de onderste detectiegrens van het meetsysteem niet
overschreden werd.
Hoofdstuk 5 beschrijft de onrwikkeling van een geisoleerd, met buffer
geperfundeerd muizenhart model om de hemodynamische functie van het intacte hart in
detail te bestuderen. Door speciale aandacht te besteden aan de aorta cannule, de
temperatuur van het geisoleerde hart en de samenstelling van de perfusiebuffer, bleek
het mogelijk te zijn hemodynamische metingen te verrichten die vergelijkbare waarden
opleverden met hartfunctiemetingen in de intacte, levende muis.
Dit model werd verder gebruikt in hoofdstuk 6 om de ischemie tolerantie van
het muizenhart te testen. Door metingen te verichten aan de hoeveelheid intracellulaire
eiwitten die verschijnen in de perfusiebuffer na een periode van ischemie, kon een
schatting gemaakt worden van het percentage hartspiercellen dat onherstelbaar
beschadigd was door de voorafgaande periode van ischemie. Ook werd na afloop van
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het experiment in het hart de stapeling gemeten van o.a. arachidonzuur, een meervoudig
onverzadigd vetzuur dat vrijkomt bij de afbraak van membraanfosfolipiden tengevolge
van fosfolipase A2 activiteit. Het bleek dat de afname in hemodynamische hartfunctie na
een periode van ischemie gecorreleerd kon worden aan enerzijds het percentage
beschadigde hartspiercellen en anderzijds aan de afbraak van membraan fosfolipiden.
Ook wees deze Studie uit dat al na een relatief korte periode van zuurstoftekort (circa 15
minuten) het muizenhart een sterke afhame in hemodynamische functie vertoont,
hetgeen duidt op een grote ischemie gevoeligheid van dit orgaan.
Verder werd in hoofdstuk 7 de ischemie tolerantie gemeten van harten die
afkomstig waren van muizen die zodanig genetische gemodificeerd waren dat ze
verminderde hoeveelheden van de groeifactor insulin-like growth factor-1 (IGF-1)
bevatten. Eerdere experimentele studies hebben uitgewzen dat IGF-1 een protectief
effect heeft op het hart na een periode van zuurstoftekort. De verwachting is dat harten
met een verminderde hoeveelheid IGF-1 gevoeliger zouden zijn voor een periode van
zuurstoftekort. De harten van IGF-1 deficiente muizen bleken inderdaad na een periode
van ischemie en reperfusie slechter hemodynamisch te herstellen, en verhoogde
celschade en grotere stapeling van vrij arachidonzuur in het hart te vertonen. Deze
bevindingen tonen aan dat het model ontwikkeld en beschreven in hoofdstuk 5 en 6
inderdaad gevoelig genoeg is om subtiele verschillen in ischemie tolerantie aan te tonen
van het gei'soleerde, intacte hart. Verder toont deze Studie aan dat fosfolipase Ai-
gemedieerde afbraak van celmembranen van de hartspiercel mogelijk een rol kan spelen
in ischemie en reperfusie geinduceerde harspiercelschade in de IGF-1 deficiente muis.
Om de mogelijke rol van het type IIA SPLA2 te testen in ischemie en reperfusie
geinduceerde afbraak van celmembranen, werd in hoofdstuk 8 de ischemie tolerantie
getest van muizen die een chromosomale mutatie bevatten in de genetische code voor
het type IIA sPLA,. Deze muizenstam bevat als gevolg van deze mutatie geen type IIA
SPLA2 in het hart. De ischemie tolerantie van harten van deze mutante muizenstam werd
vergeleken met die van een nauw verwante muizenstam die normale hoeveelheden type
IIA SPLA2 in het hart bevat. Interessant genoeg werden geen verschillen gevonden in
arachidonzuur stapeling in het hart, de hoeveelheid celschade of de afname in
hemodynamische functie na een periode van ischemie gevolgd door reperfusie. Deze
bevindingen tonen aan dat het type IIA SPLA2 in het geisoleerde muizenhart zeer
waarschijnlijk geen dominante rol speelt in ischemie en reperfusie gemedieerde afbraak
van celmembranen en dat andere leden van de fosfolipase A2 familie mogelijk een
belangrijkere rol in dit fenomeen vervullen.
Om meer inzicht te verkrijgen in de rol van fosfolipase A2 aktiviteit op zieh in
ischemie en reperfusie geassocieerde membraanafbraak in het hart, werden in
hoofdstuk 9 pogingen ondemomen om een transgeen muismodel te creeren, dat
zodanig genetisch gemodificeerd was dat het hart meer fosfolipase A2 bevat. Dit
resulteerde in een transgene muizenstam die weliswaar meer kopien van het gen voor
fosfolipase A2, maar geen aantoonbare hogere hoeveelheden fosfolipase A? in het hart
bevatte. Een vervolgpoging werd gedaan met andere DNA konstrukten en verscheidene
transgene muizen werden gecreerd die meerdere kopieen van het fosfolipase A2 gen
bevatten. Een van de transgene muizen die een groot aantal kopien bevatte srierf snel na
geboorte, wat mogelijk inhoudt dat grote hoeveelheden fosfolipase A2 niet verenigbaar
zijn met normale hartfunctie. De beschikbaarheid van muismodellen met grotere of
verminderde hoeveelheden fosfolipase AT in het hart, in combinatie met een geisoleerd
muizenhartmodel om de ischemie tolerantie van het hart van genetisch gemodifieeerde
muizen te testen, kan in toekomstige studies uitwijzen welk lid van de fosfolipase A2
familie een dominante rol speelt in ischemie en reperfusie geinduceerde hartspierschade.
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Summary
Summary
In chapter 1 the background to the present thesis and the general aim of our study are
presented. The heart is a muscle that contracts approximately 70 times per minute and
supplies the body with blood. During each contraction the heart supplies itself with oxygen
and nutrients through the coronary arteries. During a myocardial infarction as a result of an
occlusion of coronary arteries or during aorta-coronary bypass surgery, the heart is
temporarily devoid of oxygen (ischemia), what eventually leads to cardiac muscle cell
death. Restoration of the cardiac blood supply (reperfusion) is only partially able to reduce
cardiac cell death and may even exacerbate the injuring process. This phenomenon of
ischemia and reperfusion induced cardiac muscle cell death is partially caused by a
disruption of the cellular membrane, which forms the natural barier of the cardiac cell.
Experimental studies have indicated that enzymatic breakdown of the major components of
the cellular membrane, the phospholipids, might play an important role in the transition
from ischemia and reperfusion induced reversible to ireversible cell damage, eventually
leading to cardiac dysfunction. Our body contains a family of enzymes, phospholipases A2,
which are specialized in hydrolyzing membrane phopholipids and differ amongst each other
in their activation profile and subcellular localization. In the present thesis the role of one
particular member of this family, type HA secretory phospholipase A2 (type IIA sPLAj) in
ischemia and reperfusion induced cell damage was investigated in more detail. Chapter 2
presents a review of literature and theoretical background of the rationale behind the choice
for this particular enzyme. In brief, type IIA SPLA2 was chosen on the basis of its activation
profile and its dependency on calcium, a mineral the intracellular level of which is increased
during cardiac ischemia and reperfusion.
In chapter 3 it was investigated whether type IIA sPLAi is present in the heart
using molecular biological techniques. To this end, the rat heart was investigated for the
presence of the messenger RNA of type IIA SPLA2, the molecular precursor of the protein
itself. It was demonstrated that the heart indeed contains this messenger RNA and that the
genetic code of cardiac type IIA SPLA2 was highly conserved amongst different species and
cell types. It was also demonstrated that the amount of type IIA SPLA2 messenger RNA is
very low in the heart.
In chapter 4 high amounts of recombinant type IIA SPLA2 were produced and
purified from the £. Cb/z bacteria. Against this purified enzyme polyclonal antibodies were
produced in the rabbit and used to detect type IIA SPLA2 protein in different tissues. The
ability of the latter antibody to detect type IIA SPLA2 was compared with four other anti-
phospholipase A2 antibodies. It was found that all antibodies were able to detect the enzyme
with different sensitivity. None of the antibodies, however, were able to detect the enzyme
in cardiac tissue, providing further indication that the protein level of type IIA SPLA2 is very
low in cardiac muscle.
Chapter 5 describes the development and characterization of an isolated, buffer
perfused mouse heart model to measure hemodynamic cardiac function devoid of neuro-
humoral stimulation. By paying special attention to the artificial aortic outflow tract, the
temperature of the isolated heart and the composition of the perfusion buffer, it was found
that this model was able to sensitively monitor hemodynamic function, that resembled
cardiac function of the mouse heart <« v/vo.
This model was subsequently used in chapter 6 to study ischemia and reperfusion
phenomena in the mouse heart. By measuring the leakage of intracellular enzymes into the
coronary outflow an estimate could be obtained of the percentage cells irreversibly damaged
during the preceding ischemic period. Biochemical analysis of cardiac tissue after
experimentation allowed measurements of the accumulation of unesterified fatty acids such
as arachidonic acid, which is a sensitive marker for phospholipase A2 activity. A strong
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correlation was found between the tissue accumulation of arachidonic acid on the one hand
and the percentage irreversibly damaged cardiac cells or the post-ischemic recovery of
hemodynamic function on the other. In addition, it was found that the mouse heart shows a
relatively high sensitivity towards global ischemia and reperfusion.
This model was subsequently used in chapter 7 to measure the ischemia tolerance
of hearts derived from mice that were genetically engineered to contain less insulin-like
growth factor-1 (IGF-1) in their bodies. Previous studies provide evidence that IGF-1 has a
potent protective effect on the cardiac muscle during ischemia and reperfusion. As such,
IGF-1 deficient hearts would be expected to be more vulnerable towards ischemia and
reperfusion induced damage. IGF-1 deficient hearts subjected to a period of ischemia
followed by reperfusion indeed demonstrated a significant increase in cellular damage,
lower hemodynamic recovery and increased accumulation of unesterified fatty acids, such
as arachidonic acid. These findings provided further indications that the model described in
chapter 5 and 6 was sensitive enough to detect subtle differences in ischemia tolerance of
isolated mouse hearts. In addition, these observations further point toward a possible role of
phospholipase Ai-mediated hydrolysis of membrane phospholipids in the suequela of events
leading to cardiac ischemia and reperfusion induced cell death.
To study the possible role of type HA SPLA2 in cardiac ischemia and reperfusion-
induced membrane damage and cell death, in chapter 8 the ischemia tolerance was tested of
hearts derived from mice with a chromosomal mutation in the gene of type ILA sPLA?. As a
result of the mutation this mouse strain is unable to produce the type IIA SPLAT enzyme in
the heart. The ischemia tolerance of mutant mouse hearts was compared with hearts derived
from a mouse strain that was closely related but did not contain the mutation, and, hence,
has normal cardiac type IIA sPLAj levels. Interestingly, following ischemia and reperfusion
no differences were found in the accumulation of arachidonic acid, the amount of
irreversible cell damage or recovery of hemodynamic function. These findings indicate that
type IIA SPLA2 activity most probably is not a major factor in cardiac ischemia and
reperfusion-induced membrane damage in the isolated mouse heart and that other members
of the phospholipase A 2 family may have more dominant roles in this phenomenon.
To gain more insight in the role of phospholipase A2 activity during cardiac
ischemia and reperfusion, attempts were made in chapter 9 to create a transgenic mouse
model that was genetically modified to contain increased type IIA secretory phospholipase
A2 activity in the heart. This resulted in a transgenic mouse strain that contained more copies
of the phospholipase A2 gene in its chromosomes, but did not demonstrate a detectable
increase in the amount of the enzym. In a follow up experiment other DNA constructs were
used and multiple transgenic mice were obtained. Interestingly, one mouse that contained a
high number of copies of the phospholipase AT gene died soon after birth, possibly
indicating that large quantities of phospholipase A2 may not be compatible with normal
cardiac function. The availability of genetically engineered mice containing either more or
less of the different members of the phospholipase A2 in the heart, in combination with an
isolated mouse heart model to test the cardiac ischemia tolerance, may indicate in the future
whether or not phospholipase A2 mediated membrane hydrolysis plays a role in the
transition of reversible to irreversible cardiac myocyte injury and which of the members of
the phospholipase A2 family plays a dominant role in this process.
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